ecdc
EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL

SCIENTIFIC ADVICE



Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

2020

www.ecdc.europa.eu

ECDC SCIENTIFIC ADVICE

Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

The content of this guidance was developed by the European Centre for Disease Prevention and Control (ECDC) based on a technical report including grading of the quality of the evidence performed by the Catalan Institute of Oncology (Laia Bruni Coccoz, Beatriz Serrano Carro, Mireia Diaz Sanchis, Claudia Robles, Maria Brotons Agullo, Laia Alemany, Xavier Bosch) and three systematic reviews prepared by ECDC (Edoardo Colzani, Kate Olsson and Silvia Funke); the Robert Koch Institute (Bernhard Ultsch, Thomas Harder and Ole Wichmann) and Santé publique France (Daniel Levy-Bruhl); and the Universities of Parma and of Pisa (Michele Antonelli, Diego Bernini, Alice Canale, Paola Cella, Elisa Filippetti, Pierluigi Lopalco, Anna Odone, Filippo Quattrone, Carlo Signorelli, Marcello Tirani and Alberto Tulipani).

The guidance was coordinated and drafted by Edoardo Colzani with the support of Paloma Carrillo Santisteve, Tarik Derrough, Helen Johnson, Pontus Naucler, Otilia Mårdh, Kate Olsson and Lucia Pastore Celentano from ECDC. All the material in the annexes and the supplementary tables were prepared by the Catalan Institute of Oncology.

The panel of experts was composed of the following members: Prof Margaret Stanley (University of Cambridge), Prof Matti Lehtinen (University of Tampere), Prof Jonathan Ross (Birmingham City University), Prof Arne Vikström (Karolinska Institute), Prof Chris Meijer (University Medical Centre of Amsterdam), Andrew Amato, Helena de Carvalho Gomes, Edoardo Colzani, Tarik Derrough, Kari Johansen, Helen Johnson, Otilia Mårdh, Pontus Naucler, Kate Olsson, Judith Takacs and Andrea Würz (European Centre for Disease Prevention and Control).

In line with ECDC's commitment to openness and transparency and in order to receive comments from the scientific community and stakeholders, ECDC launched a public consultation on the draft guidance in April 2019. This final version of the guidance has taken into account the input provided by the open public consultation.

Suggested citation: European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction, 2020. Stockholm: ECDC; 2020.

Stockholm, March 2020

ISBN 978-92-9498-459-3
doi: 10.2900/71487
Catalogue number TQ-01-20-171-EN-N

Contents

Abbreviations v
Glossary v
Executive summary 1
Scope 1
Guidance development 1
Key conclusions 1
Possible public health implications 2
1. Introduction 3
1.1 Scope and objectives of guidance 3
1.2 Target audience 3
2. Background 4
2.1 Burden of HPV and HPV-related diseases in European countries 4
2.2 Human papillomavirus vaccines 6
2.3 HPV vaccine introduction in Europe 6
2.4 Post-licensure safety and global monitoring of HPV vaccines 9
2.5 Effectiveness and impact of HPV vaccines 10
3. Guidance development 11
3.1 Identification of public health questions for guidance 11
3.2 Collection of evidence 11
3.3 Evidence appraisal and synthesis 11
3.4 Ad hoc scientific panel meeting 13
3.5 External consultations 13
4. Conclusions 14
4.1 Evidence of efficacy of 9-valent HPV vaccine 14
4.2 Evidence of efficacy of quadrivalent and bivalent vaccines for boys/men 16
4.3 Efficacy of HPV vaccination in people living with HIV 18
4.4 Evidence of cost-effectiveness of adding males to current national HPV vaccination programmes 19
5. Implications for public health practice and research 22
5.1 Possible implications for current national HPV immunisation programmes 22
5.1.1 Organisational aspects 23
5.2 Possible implications of vaccinating people living with HIV 24
5.3 Possible implications of HPV vaccine hesitancy 24
5.4 Remaining knowledge gaps 24
6. Next steps 26
6.1 Screening in a post-vaccination era 26
References 27
Annex 1. Supporting tables 36
Efficacy of 9vHPV vaccine in females 16–26 years old 37
Efficacy of 9vHPV vaccine in females 9–15 years old 39
Efficacy of 9vHPV vaccine in males 16–26 years old 41
Efficacy of 9vHPV vaccine in males 9–15 years old 43
Safety of 9vHPV vaccine in females 45
Safety of 9vHPV vaccine in males 46
Efficacy of HPV vaccines in males 16–26 years old 47
Efficacy of HPV vaccines in males 9–15 years old 49
Safety of HPV vaccines in males 51
Efficacy of HPV vaccines in females aged 25 years or above 52
Safety of HPV vaccines in females aged 25 years or above 54
Annex 2. Supplementary material 21

Tables

Table 1. Status of HPV national immunisation programmes in EU/EEA countries, 2019 7
Table 2. Evidence type for benefits: 9vHPV vaccination of females 16–26 years old 14
Table 3. Evidence type for benefits: 9vHPV vaccination of males 16–26 years old 15
Table A1. Numbers of cases and rates (per 100 000) of cancer attributable to HPV in 2012 by country 36
Table A2. Evidence type for benefits: 9vHPV vaccination of females 16–26-years 37
Table A3. Available data for females 16–26 years old from 9vHPV vaccine trials 37

Table A4. 4vHPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in females 16–26 years old 38
Table A5. 9vHPV vaccine trials used for HPV 31, 33, 45, 52 and 58-related outcomes in females 16–26 years old. 38
Table A6. Evidence type for benefits: 9vHPV vaccination of females 9–15 years old 39
Table A7. Available data for females 9–15 years old from 9vHPV vaccine trials 39
Table A8. 4vHPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in females 9–15 years old 40
Table A9. 9vHPV vaccine trials used for HPV 31, 33, 45, 52 and 58-related outcomes in females 9–15 years old .. 40
Table A10. Evidence type for benefits: 9vHPV vaccination of males 16–26 years old 41
Table A11. Available data for males 16–26 years old from 9vHPV vaccine trials 41
Table A12. 4vHPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in males 16–26 years old 42
Table A13. 9vHPV vaccine trials used for HPV 31, 33, 45, 52 and 58-related outcomes in males 16–26 years old.. 42
Table A15. Available data for males 9 to 15 years old from the 9vHPV vaccine trials 43
Table A16. 4vHPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in males 9–15 years old 44
Table A17. 9vHPV vaccine trials used for HPV 31, 33, 45, 52 and 58-related outcomes in males 9–15 years old ... 44
Table A18. Evidence type for harms: 9vHPV vaccination of females 45
Table A19. Available harm data for females from 9vHPV vaccine trials 45
Table A20. Evidence type for harms: 9vHPV vaccination of males 46
Table A21. Available harm data for males from 9vHPV vaccine trials 46
Table A22. Evidence type for benefits: HPV vaccines in males 16–26 years old 47
Table A23. Available data for males 16–26 years old from HPV vaccine trials 47
Table A24. HPV vaccine trials used for HPV vaccine-related outcomes in males 16–26 years old 48
Table A25. Evidence type for benefits: HPV vaccines in males 9–15 years old 49
Table A26. Available data for males 9–15 years old from HPV vaccine trials 49
Table A27. HPV vaccine trials used for HPV vaccine-related outcomes in males 9–15 years old 50
Table A28. Evidence type for harms: HPV vaccination in males 51
Table A29. Available harm data for males from HPV vaccine trials 51
Table A30. Evidence type for benefits: HPV vaccines in females aged 25 years or above 52
Table A31. Available data for females aged 25 years or above from HPV vaccine trials 52
Table A32. HPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in females aged 25 years or above 53
Table A33. Evidence type for harms: HPV vaccines in females aged 25 years or above 54
Table A34. Available harm data for females aged 25 years or above from HPV vaccine trials 54
Table A35. Main characteristics of 21 studies that include cost-effectiveness analysis of universal vaccination 55
Table A36. Incremental cost-effectiveness ratios (ICERs) in local currency from societal perspective and critical parameters 56
Table A37. Incremental cost-effectiveness ratios (ICERs) converted to EUR from societal perspective and critical parameters 60
Table A38. Incremental cost-effectiveness ratios (ICERs) in local currency from third-party payer or healthcare system perspective and critical parameters 64
Table A39. Incremental cost-effectiveness ratios (ICERs) converted to EUR from third-party payer or healthcare system perspective and critical parameters 69

Abbreviations

AIN	Anal intraepithelial neoplasia
2vHPV	Bivalent HPV vaccine
CIN	Cervical intraepithelial neoplasia
CRPS	Complex regional pain syndrome
CI	Confidence interval
CEA	Cost-effectiveness analysis
EMA	European Medicines Agency
4vHPV	Four-valent HPV vaccine
GUM	Genito-urinary medicine
GMT	Geometric mean titre
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HPV	Human papilloma virus
ICER	Incremental cost-effectiveness ratio
ICO	Istituto Catala' d'Oncologia (Spain)
LY	Life years
9vHPV	Nine-valent HPV vaccine
PeIN	Penile intraepithelial neoplasia
PICO	Population Intervention Comparison Outcome
POTS	Postural orthostatic tachycardia syndrome
QALY	Quality-adjusted life years
6MPI	Six-month persistent infection
VaIN	Vaginal intraepithelial neoplasia
VLP	Virus-like particle
VIN	Vulvar intraepithelial neoplasia

Glossary

Cost-effectiveness	The extent to which an intervention or prevention programme is effective in relation to its costs, i.e. euro/life years gained.
Determinant	Factor increasing the probability of occurrence of an event.
Direct evidence	Evidence on relative effects of HPV vaccination derived entirely from direct comparisons.
Impact of vaccination programme	Impact on overall population level effect of a vaccination program. It depends on many factors such as vaccine coverage, herd protection/immunity, effectiveness and efficacy of the vaccine.
Indirect evidence	Evidence of HPV vaccine effectiveness derived entirely from indirect comparisons.
Precancerous lesion	Lesion involving abnormal cells associated with an increased risk of developing into cancer.
Vaccine effectiveness	Real-world reduction of disease in population due to vaccine with evidence coming from observational studies.
Vaccine efficacy	Percentage reduction of disease in vaccinated group of people compared to an unvaccinated group, using the most favorable conditions, e.g. experimental setting.
Vaccine hesitancy	Delay in acceptance or refusal of vaccines despite availability of vaccination services.
Viroprevalence	Prevalence of virus in population.

Executive summary

Scope

This guidance on human papilloma virus (HPV) vaccination in EU countries covers the following areas: efficacy/effectiveness of the 9-valent HPV vaccine, efficacy/effectiveness of HPV vaccination in people living with HIV, efficacy/effectiveness of HPV vaccination in males, and the cost-effectiveness of expanding the HPV vaccination programme to include males.

ECDC previously produced two guidance documents in 2008 and 2012 that addressed questions related to the introduction of HPV immunisation in EU/EEA Member States. This guidance partly complements and updates the information presented in the previous guidance documents. It also covers the efficacy of the 9-valent vaccine, which was not licensed when the last guidance was published.

The document summarises evidence from studies included in the licensing file of HPV vaccines together with post-licensure, peer-reviewed data and analysis where available. This guidance does not address the safety of HPV vaccines observed during the pre- and post-licensing period.

Guidance development

A comprehensive review and appraisal of the evidence concerning the areas mentioned above was conducted using the GRADE methodology whenever applicable. Three new systematic reviews were performed and used alongside an already published one, to collect evidence on each topic. An ad hoc expert panel reviewed the appraised body of evidence, provided information on additional evidence and identified evidence gaps for future research. The panel formulated the conclusions listed below based on the evidence provided.

Key conclusions

- The 9-valent HPV vaccine is efficacious in preventing persistent HPV infection and cervical high-grade or worse lesions caused by the additional HPV types 31, 33, 45, 52 and 58 covered by the vaccine (evidence quality: high) and HPV types 6, 11, 16 and 18 (evidence quality: moderate due to indirectness) in females 16–26 years.
  The 9-valent HPV vaccine is also efficacious in preventing persistent HPV infections, genital warts and high-grade anal intraepithelial lesions caused by HPV types 6, 11, 16 and 18 (evidence quality: moderate due to indirectness) among males 16–26 years.
  Immunogenicity data suggest:
  - non-inferiority of the 9-valent HPV vaccine compared to the quadrivalent HPV vaccine against HPV types 6, 11, 16 and 18;
  - stronger immune response against the additional serotypes 31, 33, 45, 52 and 58 contained in the 9-valent HPV vaccine compared to the quadrivalent HPV vaccine;
  - stronger immunogenicity of the 9-valent HPV vaccine against vaccine serotypes in males and females 9–15-years compared to females 16–26 years.
- The quadrivalent HPV vaccine reduces the risk of persistent HPV infections, genital warts and high-grade anal intraepithelial lesions in males 16–26 years (including men who have sex with men) (evidence quality: high), while data on the efficacy of the bivalent HPV vaccine against HPV infection and HPV-related disease in males were not found.
  Immunogenicity data suggest:
  - non-inferiority of quadrivalent and bivalent HPV vaccines administered to males compared to females;
  - higher immunogenicity of quadrivalent and bivalent HPV vaccines administered to males 9–15 years compared to females aged 16–26 years for specific HPV types contained in each vaccine.
- There was no direct evidence of the efficacy of HPV vaccination on HPV-related clinical outcomes in people living with HIV for the period covered by the systematic review, although low quality evidence of efficacy of the quadrivalent HPV vaccine against HPV persistent infection and against oral HPV infection became available in 2018 and 2019.

- Cost-effectiveness analysis is sensitive to context, and context-specific studies should ideally be done to inform decision-making in this area. According to the cost-effectiveness models reviewed, if the priority is the prevention of cervical disease in women, adding males to current female-only HPV vaccination programmes becomes increasingly cost-effective where there is:
  - persistently lower vaccination coverage among females;
  - lower vaccine cost.

  However, increasing vaccination coverage among girls may still be a more cost-effective primary objective.

  If the objective of the HPV vaccination programme is to prevent HPV-related disease in general, a universal HPV vaccination may be more cost-effective.

Possible public health implications

Greater benefit and protection from the vaccine is thought to come from immunising preadolescent individuals, since HPV vaccination is more efficacious when given to subjects naïve to the HPV types contained in the vaccine, and the immunogenic response has been observed to be stronger in preadolescents than adults.. Subjects at higher risk of HPV infection and illness, including but not limited to people living with HIV and men who have sex with men, may also benefit from the vaccination despite possibly experiencing lower vaccine efficacy due to increased risk of exposure to HPV types included in the vaccines or lower immune response.

As for vaccination programmes, a universal (i.e. gender-neutral) vaccination strategy demands more resources, but will likely provide more resilient herd protection at lower levels of vaccine uptake. It may also lead to a more pronounced decrease of HPV viroprevalence and circulation, and could more effectively protect all risk groups by providing more equitable access to direct protection.

A female-only HPV vaccination of preadolescent girls is probably more cost-effective at current vaccine cost, but does not sufficiently protect men who have sex with men. It is less equitable and less resilient to sudden drops in vaccine uptake.

If vaccination uptake is lower in specific population subgroups (in terms of geographical region, ethnicity, socio-economic status and religion), it may be advisable to channel resources to increasing uptake among these under-vaccinated groups. Different sexual mixing patterns in each population may in fact leave some minority groups excluded from the benefits of the intervention (i.e. when sexual partners are mainly chosen from the same population subgroup). Targeting any such group is an option to consider to ensure equity of access and to improve the effectiveness of the HPV vaccination programme.

Ongoing studies will provide evidence on certain identified research gaps concerning HPV vaccination and allow for additions and updates to this guidance.

1. Introduction

1.1 Scope and objectives of guidance

In 2008, following the first introduction of HPV vaccines in 2006, ECDC produced a document providing guidance on how to identify target populations for HPV vaccination, support the identification of strategy options for HPV vaccine delivery in EU countries, model costs and outcomes of HPV vaccination and monitor and evaluate the impact of HPV vaccination [1]. In 2012, ECDC published an updated guidance addressing, among other aspects, the efficacy and impact of vaccination in males, cost-effectiveness of adding males to the current HPV vaccination programmes and specific aspects related to HPV vaccine hesitancy [2]. The current document aims to systematically look at further updated evidence of effectiveness of HPV vaccination of males and the cost-effectiveness of adding males to the routine HPV vaccination programmes. It also aims, where possible, to provide more solid conclusions based on additional research that has been performed in the last six years. Additionally, it aims to provide guidance concerning the recently licensed 9-valent HPV vaccine (9vHPV) and the efficacy of HPV vaccines in people living with HIV. For information on the topics that are not covered by this guidance document, we refer to the 2012 ECDC guidance on HPV vaccination [2].

Information on the safety of HPV vaccines concerning the topics covered in this guidance has been collected and appraised (see tables in annexes), but will not be discussed in the document as no additional evidence on safety has emerged. Safety of HPV vaccines, and effectiveness and impact of HPV vaccination in women, have been recently assessed by a number of reviews and studies and will not be discussed in this public health guidance. A brief summary of the most recent and comprehensive assessments can be found in 2.4 and 2.5.

1.2 Target audience

The target audience for this document are public authorities, national policymakers, entities responsible for the planning of healthcare and social support systems, national vaccination programmes and professional society organisations with an interest in HPV and/or immunisation programmes.

2. Background

Human papilloma virus is one of the most widespread and common sexually transmitted infections worldwide and is acquired soon after the start of sexual activity. The recognition of the central role of HPV in the etiology of virtually all cervical cancers has radically changed the perspective of diagnosis and prevention of the disease. As other less common genital and non-genital cancers have been shown to be attributable to HPV, not only females, but also males may actually suffer from severe consequences of this viral infection. Moreover, virtually all genital warts (condyloma acuminata) are due to HPV, contributing to the large burden of HPV-related disease in both sexes [3, 4].

Few pathologies other than cervical cancer offer such a wide range of prevention tools and strategies: cervical cytology for screening, HPV vaccines for primary prevention and more recently HPV detection tests for screening. However, no high-quality screening program is currently available for women to prevent HPV-related disease other than cervical cancer, and no organised screening for HPV-related cancers is currently available for men. Nevertheless, despite the unequivocal success of organised population-based cervical screening programs, cervical cancer is still an important cause of morbidity and death among European women. Therefore, vaccination against HPV is expected to provide a significant added benefit for the prevention of all HPV-attributable diseases in both sexes. Evidence of efficacy and effectiveness of HPV vaccines thus needs to be continuously monitored in order to guide public health actions.

Recently, WHO and a number of scientific and public health coalitions have called for the elimination of cervical cancer, while the American Cancer Society and the European Cancer Organisation (ECCO) have passed resolutions for the elimination of all HPV-related cancers [5-8].

2.1 Burden of HPV and HPV-related diseases in European countries

Although most sexually active women acquire a cervical HPV infection during their lifetime, most of these infections clear without any clinical significance [9]. The overall prevalence of a detectable HPV infection in European women from the general population is estimated to be 14%, although it is highly dependent on age. Most European populations show a large peak of HPV incidence in the first years after the start of sexual activity (namely during adolescence and early 20s) [10]. Findings from studies carried out in the USA and in Latin America showed that the prevalence of HPV in males is higher than in females and does not seem to decline with age [11-15].

Only a small fraction of HPV infections persists and eventually progresses to cervical cancer. From the more than 200 HPV types identified, only a few are classified as carcinogenic, namely HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 [16]. Persistent infection with carcinogenic HPV types, also known as high-risk (HR) HPV types, may lead to precancerous lesions and cancer. HR HPV types are not only responsible for virtually all cervical cancer cases, but are also causally related with a variable fraction of other anogenital cancers (vulvar, vaginal, penile and anal cancers) and a subset of head and neck cancers, particularly oropharyngeal cancers [4, 17-19]. Among HR HPV types, HPV16 and HPV18 stand out for their highest carcinogenic capacity [19, 20]. Low-risk (LR) HPV types 6 and 11 are associated with anogenital warts and recurrent respiratory papillomatosis [21, 22]. HPV16, the most carcinogenic type, is consistently the most frequent type detected in HPV-related cancers both in Europe and worldwide [23].

In EU/EEA countries, there are 33 987 newly diagnosed cervical cancer cases and 13 239 deaths each year, with age-standardised incidence rates of 9.6 cases and mortality rates of 2.8 deaths per 100 000 women [24]. Through cervical cancer screening, between 263 227–503 010 cases of precancerous lesions (CIN2 or worse) are diagnosed annually [25]. Incidence rates of other HPV-related anogenital cancers are much lower than those observed for cervical cancer. In Europe, 14 700 annual cases of anogenital cancers other than cervical are attributable to HPV, with 5 400 cases diagnosed in men (about half in the anus and half in the penis) and 9 300 cases diagnosed in women (4 200 in the anus and 5 100 in the vulva and vagina). Regarding precancerous lesions, it is estimated that between 13 997–27 773 cases of vulvar intraepithelial neoplasia 2/3 (VIN2/3), between 2 596–4 751 cases of vaginal intraepithelial neoplasia 2/3 (VaIN2/3), and 1 549 cases in women and 1 097 cases in men of anal intraepithelial neoplasia 2/3 (AIN2/3) are diagnosed each year [25]. Head and neck cancers also constitute a heavy burden, particularly in men, with an estimated 13 800 cases diagnosed annually (11 000 in males and 2 800 in females). Furthermore, increasing trends in the incidence of HPV-positive head and neck cancers have been consistently observed in the last decade in concomitance with the decline in tobacco use. This increase concerned in particular HPV-positive oropharyngeal cancers among young men in northern Europe and North America (26). The seroprevalence of HPV remains significantly higher among females, as does the burden of disease attributable to HPV. However, previous studies showed a different age-distribution of HPV infection between sexes, with males seemingly having a constant HPV prevalence over age, though possibly varying according to context, serotype and type of infection [11].

The Human Papillomavirus Infection in Men (HIM) study reported a different anatomic site-distribution of HPV infections (e.g. higher HPV infection prevalence in the genital region than in the oral cavity) in men. It also reported a different immune response against HPV infection by anatomic site, which seemed weaker in males against re-infections and recurrences as well as low seroconversion rates following natural HPV infection and long-term persistence of oral HPV-16 infection among males. A seemingly more efficient HPV heterosexual transmission from female to male than viceversa was also reported [27-30].

People living with HIV are a specific risk group with a high burden of HPV. In fact, while the proportion of those who are HPV-positive among HIV-uninfected European women with normal cytologic findings is 14%, it is 33% among European women who are infected with HIV [31]. Additionally, HIV-associated immunosuppression may increase the carcinogenicity of HPV and therefore the likelihood of developing a cancer attributable to HPV [32]. A study among men who have sex with men in Hungary identified that 97.5% of HIV-positive and 58.3% of HIV-negative men who have sex with men were positive for any type of HPV (33). In Europe, HPV-16, followed by HPV-18 and HPV-33, is the most common serotype associated with invasive cervical cancer in women living with HIV [31]. Finally, although it is difficult to obtain reliable figures on the incidence of genital warts, it has been estimated that there is an annual incidence of 0.1–0.2% in developed countries, with a peak occurring in teenage years and young adulthood[21, 34].

Figure 1. Age-standardised incidence rates per 100 000 of cancer cases attributable to HPV in 2012

A. Cervical cancer (vulvar, vaginal, anal and penile)



B. Other HPV-attributable anogenital cancers



C. HPV-attributable head and neck cancers (oropharynx, oral cavity and larynx)



Adapted from GLOBOCAN 2012, IARC -27.6.2018, de Martel C, Int J Cancer. 2017

2.2 Human papillomavirus vaccines

There are currently three HPV vaccines licensed in Europe: the bivalent vaccine Cervarix (GlaxoSmithKline Biologicals) that contains virus-like-particles (VLPs) of HPV types 16 and 18, the quadrivalent HPV vaccine Gardasil (Merck Sharp & Dohme – MSD) that includes VLPs of HPV types 6, 11, 16 and 18 and the nonavalent vaccine (MSD), that contains VLPs of HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. All vaccines contain VLPs of HPV types 16 and 18 which are associated with 71% of all cervical cancer cases worldwide (i.e. those attributable to HPV types 16 and 18), while the nonavalent vaccine contains VLPs of additional high-risk HPV types cumulatively responsible for 89% of cervical cancer cases [23, 35].

The bivalent vaccine is licensed for protection against cancer of the cervix (neck of the womb) or anus, and precancerous lesions (abnormal cell growth) in the genital area (cervix, vulva, vagina or anus), caused by certain types of human papillomavirus [36]. The quadrivalent vaccine is licensed for the prevention of premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic human papillomavirus (HPV) types; and for the prevention of genital warts causally related to specific HPV types [37]. The 9-valent vaccine is licensed for protection against precancerous lesions (growths) and cancers in the cervix, vulva or vagina and anus, and genital warts, caused by nine types of the human papillomavirus (HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58) [38]. All vaccines are approved from the age of nine years with a recommended schedule of two doses (0–6 months) up to and including the age of 14 years for the bivalent and nonavalent vaccines, and up to and including the age of 13 years for the quadrivalent vaccine. In individuals older than the above indicated ages (15 years of age for the bivalent and 9-valent vaccines, 14 years of age for the quadrivalent vaccine), the recommended schedule is three doses administered at 0, one (or two) and six months [18, 39-41].

The duration of protection from HPV-related cervical and genital disease attributable to HPV serotypes is reported by the WHO position paper on human papillomavirus vaccines and by the EMA's Summaries of Product Characteristics (SmPC) and European Public Assessment Reports (EPAR) [18, 36-38].

2.3 HPV vaccine introduction in Europe

By 2019, most EU/EEA countries had introduced HPV vaccination in their national immunisation programs [42]. Fifty percent of countries introduced HPV vaccination within the first three years after the European Commisison granted a license for human use of the first HPV vaccines in 2006–2007, and the remaining EU/EEA countries have progressively introduced vaccination in the last five years. Table 1 shows the main characteristics of the programmes. Most current programmes target preadolescent girls within the age range of 9–14 years, either through organised school-based vaccination plans or delivery through primary care services (including family doctors, nurses and gynaecologists). Many countries initially introduced vaccination as multiple age-cohort vaccination, accompanied by temporary catch-up programmes for older ages, and then moved towards catch-up programs for already targeted cohorts that missed vaccination at the recommended ages [43]. In recent years, several countries have also expanded, or will soon expand, vaccination to boys of the same age , namely Austria [44], Belgium [[45], Croatia [46], Czech Republic [47], Denmark [48], Finland [49], Germany [50], Republic of Ireland [51], Italy [52], Liechtenstein, The Netherlands [53], Norway [54-56], Sweden [57, 58] and the United Kingdom (UK) [59, 60]. Other EU/EEA Member States are considering expanding their programmes to include boys as well [61, 62].

Program performance varies considerably across Europe. HPV vaccine uptake varies not only between countries, but also within countries at the regional level. Finland, Hungary, Iceland, Malta, Norway, Portugal, Spain, Sweden and the UK have reported national coverage above 70%. In some countries, including France and Germany, coverage has been consistently below 50%, though recently increasing in France. Other countries such as Denmark and the Republic of Ireland have faced serious HPV vaccination crises resulting in dramatic drops followed by successful recoveries in the last two years thanks to effective HPV vaccination campaigns [63-65]. By 2015, it was estimated that 14 million European females had received the full vaccination course and 17 million at least one dose: this could potentially prevent 76 000 cervical cancer cases in vaccinated girls [43].

Table 1. Status of HPV national immunisation programmes in EU/EEA countries, 2019

Country or territory	Year of introduction	Current age targets for vaccination in years (female, male[a])				Delivery
		Primary		Catch-up		
		Female	Male	Female	Male	
Austria	2014	9	9	10–11 12–15 (PF)	10–11 12–15 (PF)	Sch. (4th grade) Health c. (catch-up)
Since February 2014, the HPV vaccine has been available free of charge for all children living in Austria in the fourth grade (consummate nine year of age). Before 2014, the vaccine was recommended for use but not publicly funded. Children are vaccinated at school and also, in some Länder, in public vaccination centres and by established pediatricians. In addition, the HPV vaccine is offered free of charge from the age of 9–12 years in public vaccination centers. Länder also provide catch-up vaccinations at a reduced cost for children up to the age of 15 years.						
Belgium						
Flanders	2010	12–13	12-13	12–18 (PF)	12-18 (PF)	Sch. (1st year 2ry sch.) Health c. (catch-up)
Wallonia	2011	13–14	13-14	12–18 (PF)	12-18 (PF)	Sch. (2nd year 2ry sch.) Health c. (catch-up)
Flanders: For girls who do not qualify for free vaccination, or opt for a different vaccine than the free vaccine offered, a partial reimbursement is provided through health insurance.						
Bulgaria	2012	12–13				Health c.
In 2007, an expert advisory body, including members from the Ministry of Health and National Center for Infectious and Parasitic Disease Control, issued official recommendations for the use of HPV vaccines in Bulgaria for girls aged 12–18 years before first sexual contact, with catch-up vaccinations up to the age of 26 years. In June 2009, the Ministry of Health included the HPV vaccine in the recommended vaccination list. In 2012, the National Programme for Primary Prevention of Cervical Cancer was approved by the council of ministers. Vaccination of the cohort of girls aged 12 years and reimbursement of the vaccination cost by the National Health Insurance Fund started at the beginning of 2013 in Bulgaria						
Croatia	2016	13	13	-	-	Sch. (8th grade)
Voluntary HPV immunisation with HPV vaccine was available free of charge to all females and males from the age of nine years until the end of 2016.						
Cyprus	2016	12–13	-	-	-	Sch.
Czech Republic	2012	13-14	13–14 (since 2018)	-	-	Health c.
Denmark	2009	12		<18		Health c.
From 1 January 2014–21 December 2015, HPV vaccination was offered to any girl or woman born between 1993–1997. From 1 February–31 December 2018, boys between 15–20 years old who feel attracted to boys could receive HPV vaccination free of charge.. As of 2019, Denmark offers HPV vaccination to boys and girls..						
Estonia	2018	12–14	-	-	-	Sch.
As of January 2020, all 12-year-old girls will be vaccinated within the immunisation programme.						
Finland	2013	11–12	-	-	-	Sch. (6th grade)
During the first two years of the programme, the vaccination was also administered to girls aged 13–15 years (7th–9th grade). From 2020, boys will also be offered the HPV vaccination.						
France	2007	11–14 (PF)	-	<20 (PF)	-	Health c.
Until September 2012, French guidelines recommended the 3-dose vaccine regimen be administered routinely to all girls aged 14 years, and catch-up vaccination to women aged 15–23 without sexual activity or with a start of sexual activity during the year before vaccination. In 2012, the recommendation was expanded to girls aged 11–14 years old with a catch-up vaccination until the age of 20 years. The reimbursement rate for these vaccines is 65% of the price.						
Germany	2007	9–14	9–14	<18	<18	Health c.
On 8 June 2018, the Standing Committee on Vaccination (STIKO) recommended vaccination of boys in Germany. The STIKO recommendation is needed for statutory health insurance companies to cover the costs of vaccination. STIKO published its recommendation in the epidemiological bulletin of the Robert Koch-Institut. Thereafter, the federal joint committee Gemeinsame Bundesausschuss decided to include the vaccination against HPV to all 9–14-year-old girls and boys in the catalogue of statutory health insurance in September 2018. Since 30 November 2018, HPV vaccination for all 9–14-year-old girls and boys and catch-up for 15-17-year old girls and boys is in the catalogue of mandatory benefits of statutory health insurance						
Greece	2008	11–14	-	15–18 18–26 (until December2016)	-	Health c.
Hungary	2014	12	-	-	-	Sch. (7th grade)
Several local governments have decided to pursue their own earlier initiative, thus providing the vaccine to those who are not eligible for the national vaccination programme due to their age.						
Iceland	2011	12	-	-	-	Sch. (7th grade)
Older girls are given the opportunity to receive the vaccine with prescription and by paying for it.						
Rep. Ireland	2010	12–13	12-13	-	-	Sch. (1st year 2ry sch.)

Country or territory	Year of introduction	Current age targets for vaccination in years (female, male[a])				Delivery
In September 2011, a catch-up programme was introduced, targeting all girls 17–18 years of age from 2011–2014. Boys have also been offered the vaccination since September 2019.						
		Primary		Catch-up		
		Female	Male	Female	Male	
Italy	2008	11	11 (since 2015 in certain regions)	Variable by region	-	Health c.
The HPV vaccination is actively offered free of charge to girls up to 12 years of age in all Italian regions. Some regions have extended the offer of vaccination to girls in other age groups. Some regions also offer free of charge HPV vaccination to people living with HIV. Most regions also consider a reduced payment for ages not included in the primary target. In 2015, male vaccination started free of charge in six regions.						
Latvia	2010	12	-	-	-	Sch. and health c.
Liechtenstein	2008	11–14	11–14 (since 2016)	15–26	15–26 (since 2016)	
Liechtenstein follows the recommendations of Switzerland. Vaccination is free of charge for girls and women aged 11–16 years within the framework of the cantonal vaccination programmes. Since 1 July 2016, this was extended to boys and young men aged 11–26 years.						
Lithuania	2016	11	-	-	-	
Luxembourg	2008	9–13	9-13	-	-	Health c.
In Luxembourg, the HPV vaccination programme was introduced in 2008, targeting 12–17-year-old girls, offering a choice of bivalent or quadrivalent vaccine free of charge. In 2015, the programme was changed offering the bivalent vaccine only to 11–13-year-old girls. Since January 2019, the programme has been expanded free of charge to all 9–13-year-old boys and girls.						
Malta	2012	12	-	-	-	Health c.
One of the actions included in the national cancer plan for the Maltese islands 2017–2021 is the consolidation of the HPV vaccination programme. An evaluation of the programme will be performed at the completion of the first five years. This will include an exploration of the impact of expanding the programme to include boys of the same age cohort as girls already invited.						
Netherlands	2009	12–13	-	-	-	Health c.
In 2009, a HPV vaccination catch-up campaign was organised for girls born between 1993–1996 (13–16 years of age at the time). Since 2010, 12-year-old girls are invited to receive the HPV vaccination within the National Immunisation Programme including girls who were born in 1997 or after. All girls receive an invitation when turning 13 years of age. Boys will also be offered the vaccination from 2021. The vaccination is free and not mandatory.						
Norway	2009	12	12	≤25 (2016–2018)	-	Sch. (7th grade)
Since 1 November 2016, and available for two years, women born in 1991 or later are offered HPV vaccination free of charge. In the 2018–2019 school year, the Governmentintroduced HPV vaccine to all 7th-grade boys as part of the childhood immunisation programme.						
Poland						
Since 2008, HPV vaccination has been recommended in the national immunisation programme for girls aged 11–12 years. The expert committee, appointed on the initiative of the Polish Pediatric Society in 2010, also recommended HPV vaccines for girls aged 13–18 years who had not been vaccinated previously. However, Poland did not introduce this vaccination in the mandatory immunisation programme. As there is an extra charge for prophylactic vaccination against HPV in primary healthcare centres, the coverage of Polish teenagers vaccinated against HPV is estimated to be between 7.5%–10%. However, certain districts decided to introduce financed programmes of prophylactic HPV vaccination.						
Portugal	2008	10	-	-	-	Health c.
In October 2008, the HPV vaccination was introduced in the national immunisation programme for 13-year-old girls born after 1995. From 2009–2011, a catch-up vaccination campaign was run for girls ≤17 years (born between 1992–1994). From 2014–2016, girls aged 10–13 years old were covered. Since 2017, only 10-year-old girls are vaccinated.						
Romania	2013	11–14	-	-	-	Health c.
In 2008, the Romanian Ministry of Health rolled out a school-based immunisation campaign providing free HPV vaccination for 10–11-year-old girls. Coverage statistics revealed that only 2.6% of the girls received vaccination and the programme was suspended. In 2009, an information campaign was launched, followed by a second vaccination programme, targeting 12–14-year-old girls. A catch-up programme was also launched, where adult women were given the opportunity to get the vaccine free of charge through their healthcare provider. Despite the availability of the vaccine, uptake remained low and the school-based programme was discontinued at the end of 2011.The programme was launched for the third time in April 2013. HPV vaccination is included in the National Vaccination Program in the category 'Vaccination of Population at Risk' and is targeted at girls aged 11–14 years. The programme is not funded by the National Health System.						

Country or territory	Year of introduction	Current age targets for vaccination in years (female, male[a])				Delivery
Slovakia	2016	13 (PF)	-	-	-	
The recommendation that if a doctor considers a need for the vaccination against infections caused by oncogenic HPV, then the vaccination should be given to girls from the target age group, was implemented into legislation.. The recommendation also targets other age groups, but these have to pay the total price of the vaccine. Neither routine HPV vaccination nor catch-up programmes have begun in Slovakia. From January 2019, the bivalent HPV vaccine is fully reimbursed, while the quadrivalent vaccine is partially reimbursed by the national healthcare system.						
Slovenia	2009	11–12	-	-	-	Sch. (6th grade)
		Primary		Catch-up		
		Female	Male	Female	Male	
Spain	2007-8	12	-	-	-	Sch. and/or health c. (depending on the region)
The Inter-Territorial Council of the National Health System, the coordination body for the different health services from the autonomous communities of Spain, approved a general recommendation to initiate routine HPV vaccination in Spain in 2007. A choice was given at which age to vaccinate in a cohort of girls between 11–14 years of age, but with a preference for age 14, and a deadline for implementation of 2010. Afterwards, each autonomous community designed its own implementation programme starting in three communities in 2007, with the rest following in 2008. Since 2015, as agreed by the Interterritorial Council, HPV is recommended for girls 12 years of age in every region. Since 2018, HPV has been also recommended for the following risk groups: those with warts, hypogammaglobulinemia, immunodeficiency, and myelokathexis (WHIM) syndrome (a primary immunodeficiency); women with solid organ and hematopoietic transplant up to 26 years of age; people living with HIV (with a 3-dose schedule and up to age of 26); sex workers up to the age of 26 (3 dose schedule); and women with excisional treatment of the cervix. Catch-up vaccination in females has been performed up to the age of 18 since 2019.						
Sweden	2012	10–12	-	<18	-	Sch. (5-6th grades)
In 2010, the HPV vaccine was included in the free-of-charge national vaccination programme targeting all girls born in 1999 or later and attending 5th or 6th grade in school. However, the vaccinations did not start until 2012 due to delays in the procurement process. At the same time, all counties additionally introduced free-of-charge catch-up vaccinations targeting girls born between 1993–1998. According to an update of the regulation of child vaccinations (HSLF-FS 2016:51), all girls should now be offered HPV vaccinations up to the age of 18. The vaccination will be also soon offered to boys (starting from those born in 2009).						
United Kingdom	2008-12	11–13	-	<18	-	Sch. (8-10th grades) Health c. (catch-up)
Vaccination programmes and start year of the programme vary slightly by region. Girls who missed HPV vaccination the first time around, can receive a catch up HPV vaccination up to the age of 18. At the start of the programme there was a catch-up for girls born between 1991–1995. The UK has offered HPV vaccination to boys and girls as from 2019.						

a: funded vaccination programmes unless otherwise stated
PF: partially funded
Sch.: school
Health c.: health council
Sources: [43, 66-68].

2.4 Post-licensure safety and global monitoring of HPV vaccines

The three licensed HPV vaccines all showed an excellent safety profile in clinical trials before receiving approval from the European Medicines Agency (EMA). After licensure, the EMA, other regulatory agencies and international bodies continue to monitor the safety of HPV vaccines, and so far, accumulated data regarding the safety profile of the three HPV vaccines are reassuring [69-72]. The Global Advisory Committee for Vaccine Safety (GACVS) of the World Health Organization (WHO) has thoroughly reviewed the evidence on the safety of HPV vaccines on seven occasions, assessing post-licensure surveillance data from the bivalent and the quadrivalent vaccines, data from manufacturers and any safety concerns that have arisen. Since the licensure of HPV vaccines, the committee has assessed concerns on aluminium-containing adjuvants and anaphylaxis, syncope, mass psychogenic illness, autoimmune conditions (including Guillain-Barré syndrome and multiple sclerosis), venous thromboembolism, stroke, pregnancy outcomes, complex regional pain syndrome (CRPS), postural orthostatic tachycardia syndrome (POTS) and premature ovarian failure. It has not found any adverse event of concern to be causally associated with the vaccine besides the risk of anaphylaxis (1.7 cases per million doses) and syncope related to anxiety or stress caused by the injection [69]. The risk of syncope is relatively common in response to any vaccination, especially among adolescents, and its associated complications are potential serious injuries.

Nevertheless, complications of syncope can be prevented by following the established recommendation of 15-minute observation period after administration of the HPV vaccine. The risk of syncope following vaccination with HPV vaccine is not greater compared to other adolescent vaccines, as shown in an analysis of data from the United States [70]. Similarly, reported rates of anaphylaxis after HPV vaccination are not higher than those observed for other vaccines [71]. In the last review of Global Advisory Committee on Vaccine Safety in June 2017, with over 270 million doses of HPV vaccines distributed worldwide and more than a decade of follow-up, the committee considered HPV vaccines to be safe [69]. Furthermore, in 2015, EMA reviewed the evidence regarding CRPS and POTS in young women receiving HPV vaccines, concluding that the evidence does not support a causal association between HPV vaccines and the development of these syndromes [72].

In light of these up-to-date high-quality evaluations not differring from what was previously found (see evidence tables on safety in the annexes), aspects related to the safety of HPV vaccines are not reported in this document. For discussion on safety of HPV vaccines, refer to periodic monitoring by GACVS and Cochrane's recent systematic reviews on HPV vaccine from 2016–2017 [69, 73, 74].

2.5 Effectiveness and impact of HPV vaccines

Since the approval of the first HPV vaccine in 2006, there has been an increasing body of evidence regarding the effectiveness and population impact of HPV vaccines against HPV infection, genital warts and high-grade cervical lesions (CIN2+). In 2019, an update of a meta-analysis published first in 2015, and now including 40 studies from 14 countries, showed a significant impact of HPV vaccination when comparing pre- and post-vaccination periods, with herd protection effects and cross-protection against non-vaccine HPV types demonstrated when high vaccine coverage was achieved [75, 76]. Regarding HPV infection, this meta-analysis documented a 83% reduction in prevalence of HPV types 16 and 18 in girls aged 13–19 years when at least 50% coverage was achieved. Additionally, a 54% reduction in prevalence of HPV types 31, 33 and 45 in same-aged girls and a cross-protective effect in women aged 20–39 years and men under 20 years of age were observed [75, 76]. Reductions in prevalence of HPV vaccine types have so far been documented in vaccinated women in Australia, Belgium, Finland, France, Germany, Japan, the Netherlands, Spain, Sweden, Uganda, and the UK (England and Scotland separately) [66, 77-92], vaccinated women and men in the US [93-95], non-vaccinated women in the UK [82, 84] and non-vaccinated men in Australia [66, 91, 96]. Data from the UK (Scotland) published in 2017 and 2019, and from the Netherlands published in 2018, confirmed high-levels of cross-protection against HPV types 31, 33, and 45 years after vaccination with the bivalent vaccine [80, 84, 97]. Evidence of cross-protection has also been shown in other studies for both bivalent and quadrivalent vaccines [77-82, 98-102]. The reduction of high-grade CIN observed in the meta-analysis was 51% in girls aged 15–19 years [76]. In recent years, a reduction in high-grade cervical precancerous lesions has also been observed in vaccinated populations in several countries such as Australia, Canada, Denmark, Spain, Sweden, the UK (Scotland) and the US [66, 75-77, 85, 97]. Australia has now demonstrated reductions in high-grade cervical precancerous lesions in women up to 30 years of age [66]. Finally, a meta-analysis documented a substantial decrease in genital warts by 67% and 48% in 15–19 years girls and boys, respectively, and by 54% and 32% among 20–24 years old women and men, respectively [76]. The population impact of the quadrivalent HPV vaccine on genital warts has been documented in Australia, Belgium, Canada, Denmark, Germany, Israel, Italy, New Zealand, Spain, Sweden, UK and the US [34, 66, 75, 76, 83, 85, 96, 103-113].

3. Guidance development

The following steps were undertaken in the development of the guidance:

- identification of public health questions for guidance
- collection of evidence
- evidence appraisal and synthesis
- ad hoc scientific panel meeting
- external consultations.

3.1 Identification of public health questions for guidance

In 2016, in order to update and expand on the two previous HPV vaccination guidances, ECDC prepared a short list of proposed topics for its third guidance. ECDC vaccine-preventable disease national focal points[i] were consulted on proposed topics and the following topics were eventually selected:

- efficacy and effectiveness of 9vHPV vaccine in the prevention of HPV-related illness
- efficacy and effectiveness of HPV vaccination in males
- efficacy and effectiveness of HPV vaccination in people living with HIV
- cost-effectiveness of adding males to current HPV vaccination programme.

3.2 Collection of evidence

A systematic review was performed on each of the following topics: efficacy and effectiveness of 9vHPV vaccine (outsourced to the University of Parma), efficacy and effectiveness of HPV vaccination in males (performed internally at ECDC), and cost-effectiveness of adding HPV vaccination in males (performed by the Robert Koch Institut).

For investigating the efficacy of HPV vaccination in people living with HIV, information on people living with HIV was retrieved from the systematic review on efficacy and effectiveness of HPV vaccination in males and from a systematic review performed by Cochrane Response on randomised controlled trials of HPV vaccines [73].

The systematic reviews on the effect of the 9vHPV vaccine and the effect of HPV vaccination in males included data from the main pre-licensure efficacy and immunogenicity clinical trials. The 9vHPV systematic review collected evidence until 30 January 2017. The systematic review of HPV vaccine in males collected evidence until 12 April 2017. These systematic reviews were updated until January 2018. The update was performed via PUBMED using the same search strategy of the original systematic reviews, though with single extraction.

The systematic review on cost-effectiveness of adding males to the vaccination schedule reviewed evidence until 2016.

3.3 Evidence appraisal and synthesis

The appraisal and synthesis of the full body of evidence from the systematic reviews was outsourced to the Catalan Institute of Oncology (ICO), which performed additional data extraction, updated the systematic searches and applied the GRADE methodology to evidence collected where applicable [114].

3.3.1 Methods for evidence synthesis on efficacy and effectiveness of 9-valent HPV vaccine, HPV vaccines in men and in people living with HIV

GRADE methodology was used to evaluate the evidence of effectiveness and efficacy based on the three systematic reviews on the efficacy and effectiveness of the 9vHPV vaccine, HPV vaccination in males and HPV vaccination in people living with HIV [114].

A critical appraisal was performed and additional information from the original articles was extracted where necessary. Data extraction included information on study characteristics such as design, site, period and inclusion/exclusion criteria. Additionally, for 9vHPV vaccine synthesis, data on efficacy of the 4vHPV vaccine were extracted from the main clinical trials.

[i] Nominated representatives of the EU Member States responsible for strategic and operational collaboration on technical and scientific issues for specific diseases areas

The rationale was that the pivotal efficacy trial for the 9vHPV vaccine compared the 9vHPV vaccine to the 4vHPV vaccine [115]. The trial provided direct evidence for the prevention of HPV 31, 33, 45, 52 and 58-related outcomes, but for HPV 6, 11, 16 and 18-related outcomes, the criteria were to determine non-inferior immunogenicity. Consequently, to infer 9vHPV vaccine efficacy for the prevention of HPV 6, 11, 16 and 18-related outcomes, indirect data from 4vHPV vaccine trials were used. Data were extracted by one investigator.

As mentioned above, two sources were used to identify the articles to be included in the evidence synthesis for people living with HIV:

- a Cochrane systematic review of randomised controlled trials of HPV vaccines [73]
- HIV data from the systematic review on HPV vaccine in males performed by ECDC. Data were extracted from the original articles (or the Cochrane systematic review when information was not available in the original article) by one investigator from the ICO group.

The evidence synthesis for the three topics was prepared and structured around a comprehensive subset of PICO (Population Intervention Comparison Outcome) questions on efficacy and immunogenicity (Tables Supp01,02,04,05,07 can be found in separate Excel files on the ECDC website). In addition, a GRADE evidence summary including the main benefits and harms was prepared for each topic.

The evidence synthesis for each PICO question included evidence profile and summary of findings tables. PICO questions on immunogenicity included geometric mean titres (GMTs) and seroconversion outcomes for HPV vaccine types. PICO questions on efficacy included 6-month persistent infection (6MPI) and the main clinical outcomes related to HPV vaccine types. Immunogenicity and efficacy data were extracted from analyses of the per-protocol populations, if not otherwise indicated, for comparability's sake. The EP and SoF tables included quality assessment and summary of results sections (including data on absolute and relative effects). When estimations of relative effect were missing in either the systematic reviews or main articles, estimates were calculated. Calculations included GMT ratios, differences in seroconversion and relative risks.

To prepare the GRADE evidence summaries, the following outcomes were chosen for females: prevention of 6MPI, cervical intraepithelial neoplasia grade 2 or 3 or worse (CIN2/3 or worse), cervical cancer, vulvar intraepithelial neoplasia grade 2 or 3 or worse (VIN2/3 or worse), vulvar cancer, vaginal intraepithelial neoplasia grades 2 or 3 or worse (VaIN2/3 or worse), vaginal cancer and anogenital warts in females. The following outcomes were chosen for males: 6MPI, anal intraepithelial neoplasia grade 2 or 3 or worse (AIN2/3 or worse), anal cancer, penile intraepithelial neoplasia grade 2 or 3 or worse (PeIN2/3 or worse), penile cancer and anogenital warts in males. GRADE evidence summaries were stratified by age group and sex.

GRADE methodology was also applied to evaluate the quality of the evidence for each PICO question and the evidence summaries (i.e. review of the risk of bias, inconsistency, indirectness, imprecision, publication bias and other considerations). Risk of bias assessment was extracted from the systematic reviews whenever possible (ECDC and Cochrane systematic reviews). The criteria used to evaluate imprecision were as follows: downgrade one level if the number of events in the control group were ≤10, or the 95% confidence interval (95% CI) was very wide or not estimable. Indirectness was considered when surrogates were used to assess evidence for other outcomes (i.e. CIN2/3+, VIN2/3+, VaIN2/3+, PeIN2/3+, AIN2/3+ to assess evidence for cervical, vulvar, vaginal, penile or anal cancer, respectively, or immunogenicity data to assess efficacy outcomes).

3.3.2 Methods for evidence synthesis on cost-effectiveness of adding males to the current HPV vaccination protocols

Only those studies from the systematic review that evaluated the cost-effectiveness of universal vaccination were selected for evidence synthesis in this guidance. The systematic review was updated by ICO by adding relevant studies published until 31 December 2017 not included in the original report. The additional articles retrieved were the following: Bresse 2014 [116], Blakely 2014 [117], Haeussler 2015 [118], Jiménez 2015 [56], Damm 2017 [119], Qendri 2017 [120], Largeron 2017 [121] and Mennini 2017 [121].

Twenty-one studies were finally identified for assessing the cost-effectiveness of universal vaccination, of which 12 were published in the last four years [116-135] (Table A36–Table A39).

The variables extracted from the articles were

- author
- country
- year of publication
- year of analysis
- model time horizon
- cost perspective
- health outcomes included in the model
- vaccine type

- currency used in the analysis
- vaccination coverage
- vaccine schedule
- vaccine efficacy
- duration of protection
- vaccine cost (in local currency and converted to EUR using exchange rates)
- base strategy, comparator strategy
- incremental cost-effectiveness ratios (ICER, numerator expressed in local currency and converted to EUR using exchange rates)
- health outcome unit
- CEA threshold used in the article.

The list of multiple registries that identify the different ICERs from each article and the parameters that lead to the specific result are reported in the Annex (Tables A36–39).

ICER is the most common summary measure used to define cost-effectiveness of an intervention. It is defined as the difference in cost between two interventions (e.g. A and B) divided by the difference in health effects: ICER=Cost A–Cost B/Effect A–Effect B, where said change in health effects is usually measured in terms of the number of life years (LYs) saved, or the number of quality-adjusted life years (QALYs) gained. As such, the ICER is frequently expressed as the cost per LY saved or QALY gained. In order to draw conclusions about which strategies are cost-effective, ICERs must be compared to a predetermined reference value or threshold below which an intervention would be considered cost-effective. This threshold serves to signpost policy-makers to which of the possible interventions offer an efficient use of resources. It can also be understood as the upper limit of what society is willing to pay for an additional unit of health effect (e.g. QALY) [136]. There is no consensus as to a universal ICER threshold, with different health technology assessment agencies defining country-specific benchmarks to aid the decision-making process. The most extensive discussion on the use of these values have been held in the UK, where the National Institute for Health and Care Excellence (UK) has defined a range of GBP 20 000–GBP 30 000/QALY gained as the threshold [137]. In the rest of Europe, the thresholds range from EUR 20 000/QALY gained in Spain to EUR 50 000/QALY gained reported in studies in Denmark and Germany [119, 132, 138]. In the US, interventions that cost less than USD 50 000/QALY gained or, occasionally, between USD 50 000–USD 100 000/QALY gained are considered to be good value for the resources invested [139]. A universal threshold was proposed by WHO's Commission on Macroeconomics and Health in its 2002 report on investing in health for economic development. This report recommends that an intervention can be considered highly cost-effective if the ICER is less than the country's per capita gross domestic product (GDP) and cost-effective if the ICER is less than three times the per capita GDP [140].

3.4 Ad hoc scientific panel meeting

An ad hoc panel of experts was set up to review the assessed body of evidence, provide potential additional information on recent evidence that may have been missed, advise on potential research gaps that will need to be filled to better inform HPV vaccination policy and draw conclusions on the main topics of this guidance. The following competences were prioritised in order to choose panel members: vaccine effectiveness/impact, VPD epidemiology, modelling/health economics, evidence-based public health, sexual transmitted infection (STI) epidemiology, cancer epidemiology, STI clinical management, clinical virology, tumour virology, pathology, social sciences, vaccine hesitancy and health communication. In the selection of panel members, priority was given to ECDC internal staff in order to guarantee scientific independence. Additional external experts were included in the panel to cover areas where internal expertise was missing based on their scientific and technical excellence in the areas of HPV and STI research. Of the 16 selected members of the panel, 11 were ECDC staff and five were external experts and researchers in areas related to STI, HPV, clinical and tumour virology, pathology and impact of HPV vaccination. All panel members (internal and external) provided declarations of interests that were assessed in accordance with ECDC's Independence Policy. In order to guarantee full independence of the current guidance, only ECDC members of the panel took part in drawing conclusions on the available evidence, while all panel members contributed to the discussion and identification of additional evidence and research gaps.

3.5 External consultations

The document went through several rounds of consultations before finalisation. Expert panel members had a chance to review the document and contribute additional text as co-authors or with comments. After finalising the first complete draft and passing ECDC'S quality check and internal clearance, the document underwent a round of consultation with the ECDC Advisory Forum composed of appointed representatives of National Institutes of Health from each EU/EEA Member State. Finally, an open consultation was performed with relevant stakeholders (e.g. learned societies, universities, professional societies, patient organisations) invited to provide their input. The received comments can be found in a separate document on the ECDC website.

4. Conclusions

4.1 Evidence of efficacy of 9-valent HPV vaccine

4.1.1 Efficacy of 9vHPV vaccine in females 16–26 years old

Data used to evaluate efficacy on HPV 31, 33, 45, 52, and 58-related clinical outcomes came from a large efficacy trial [115] that compared the 9vHPV vaccine to the 4vHPV vaccine in females 16-26 years. Additional data from trials on immunogenicity of 9vHPV vaccine against these HPV types have also been considered [141, 142]. For HPV 6, 11, 16 and 18-related outcomes, data from trials with 9vHPV vaccine were used to infer non-inferiority with the 4vHPV vaccine [143-145] (Table 2,Table A3–Table A5, supplemental documents Supp04, Supp05).

Table 2. Evidence type for benefits: 9vHPV vaccination of females 16–26 years old

Benefits	Design	Efficacy	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
HPV types 6, 11, 16 and 18							
Compared to 4vHPV vaccine, 9vHPV vaccine showed non-inferior immunogenicity and efficacy for these serotypes (evidence quality for efficacy: moderate).							
HPV types 31, 33, 45, 52 and 58							
6MPI	9vHPV compared to 4vHPV (1RCT)(a)	96.0% (94.6–97.1)	Not serious	Not serious	Not serious	Not serious	High
CIN2/3, VIN2/3, VaIN2/3 or worse		97.4% (85.0–99.9)	Not serious	Not serious	Not serious	Not serious	High
CIN2/3 or worse		97.1% (83.5–99.9)	Not serious	Not serious	Not serious	Not serious	High
VIN2/3, VaIN2/3 or worse		100.0% (71.5–100.0)	Not serious	Not serious	Not serious	Very serious[a]	Low

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
a: downgraded by 1 for imprecision due to very wide 95% confidence interval
a: HPV types 31, 33, 45, 52 and 58 data from protocol 001/NCT00543543 (PICO1 Supp04); supportive data from Protocols 002/NCT00943722 (PICO2 and PICO8 Supp05), 003/NCT01651949 (PICO11 Supp05) (115, 141-145).

Regarding HPV types 31, 33, 45, 52, and 58 in females 16–26 years old, the 9vHPV vaccine prevented 6MPI (efficacy 96.0%; CI 95% 94.6–97.1) and high grade lesions (including CIN2/3 or worse, VIN2/3 or worse and VaIN2/3 or worse; efficacy 97.4%; 85.0–99.9) for at least six years after vaccination (evidence quality: high). In particular, the 9vHPV vaccine resulted in significant decreases in the incidence of CIN2/3 or worse, compared with the 4vHPV vaccine for the additional serotypes (efficacy 97.1%; 83.5–99.9; evidence quality: high). It however showed no significant decrease for VIN2/3 or worse, or for VaIN2/3 or worse, when compared to 4vHPV vaccine for the additional serotypes (evidence quality: low). The modified intention to treat analysis showed that 9vHPV was efficacious in reducing the risk of persistent HPV infection due to additional vaccine types 31, 33, 45, 52 and 58 in individuals who were not HPV infected at study entry. However, it was not more efficacious than 4vHPV in reducing the risk of persistent HPV infection due to the additional vaccine types among individuals who were already infected with HPV at baseline. The 9vHPV vaccine resulted in considerably higher GMTs than the 4vHPV vaccine for HPV types 31, 33, 45, 52 and 58 at months 7 and 42, and seroconversion rates at month 7 in females vaccinated with the 9vHPV for these types were ≥99.6%.

Regarding HPV types 6, 11, 16 and 18, vaccine efficacy studies comparing 9vHPV to placebo were not possible due to ethical issues (the other two previously licensed vaccines protect against HPV 16 and HPV 18 that are the two most carcinogenic types), so only studies comparing the 9vHPV vaccine to 4vHPV vaccine were performed. The 9vHPV vaccine showed non-inferiority at months 7 and 43 compared to the 4vHPV vaccine. Comparable incidence of infection, disease, cytological and abnormalities related to HPV 6, 11, 16, and 18 were reported between the two vaccine groups in the pivotal trial [115]. Seroconversion rates to these HPV types were ≥ 99.8% for both vaccines. Previous vaccine trials have already shown that the 4vHPV vaccine is effective in preventing 6MPI (efficacy 89.0%; 70.0–97.0), CIN2/3 or worse (efficacy 98.2%; 93.3–99.8), VIN2/3 and VaIN2/3 or worse (efficacy 100.0%; 82.6–100.0) and anogenital warts (efficacy 98.9%; 96.1–99.9) related to HPV types 6, 11, 16 and 18 (144). This can be considered indirect evidence of the efficacy of 9vHPV against these outcomes when due to HPV 6, 11, 16 or 18 (evidence quality: moderate).

4.1.2 Efficacy of 9vHPV vaccine in females 9–15 years

In 9–15-year-old females, the 9vHPV vaccine resulted in substantially higher GMTs for HPV types 31, 33, 45, 52 and 58 at month 7, and was non-inferior to the 4vHPV vaccine for GMTs for HPV types 6, 11, 16, and 18 (146, 147). At month 7, seroconversion rates to HPV vaccine types were ≥99.6% following vaccination with the 9vHPV and the 4vHPV vaccines. There was no significant difference between vaccines in the rate of seroconversion for HPV types 6, 11, 16 and 18 and significantly higher seroconversion rates for HPV types 31, 33, 45, 52 and 58.

There were no significant differences in seroconversion rates between females aged 9–15 and 16–26 years following vaccination with the 9vHPV vaccine. GMTs for 9vHPV vaccine types at month 7 were higher, with either two or three doses of 9vHPV vaccine in females 9–15 years old, compared to females 16–26 years old who received three doses of 9vHPV vaccine. There was no significant difference in seroconversion rates between 9–15 and 16–26-year-old females following vaccination with the 9vHPV vaccine (seroconversion rates to HPV vaccine types were ≥99.5% in both groups).

4.1.3 Efficacy of 9vHPV vaccine in males

Direct evidence on efficacy of the 9vHPV vaccine against HPV-related illness due to types 31, 33, 45, 52 and 58-related outcomes could not be assessed due to lack of clinical efficacy data on the 9vHPV vaccine in males.

For HPV types 6, 11, 16 and 18-related health outcomes, , indirect evidence from a 4vHPV vaccine efficacy trial in males 16–26 years old [148, 149], and efficacy and immunogenicity trials comparing 9vHPv and 4vHPV [150] was used to infer non-inferior efficacy of 9vHPV (Tables 3,Table 10–Table 17, supplemental documents Supp04, Supp05), since efficacy studies comparing the 9vHPV vaccine to placebo could not be performed (4.1.1).

Table 3. Evidence type for benefits: 9vHPV vaccination of males 16–26 years old

Benefits	Design	Efficacy	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
HPV types 6, 11, 16 and 18							
6MPI	4vHPV compared to placebo (1RCT)(a)	85.6% (73.4–92.9)	Not serious	Not serious	Serious*	Not serious	Moderate
AIN2/3		74.9% (8.8–95.4)	Not serious	Not serious	Serious*	Not serious	Moderate
PeIN2/3		100.0% (3 788.2–100.0)	Not serious	Not serious	Serious*	Very serious[a]	Very low
Anogenital warts		89.4% (65.5-97.9)	Not serious	Not serious	Serious*	Not serious	Moderate
HPV types 31, 33, 45, 52 and 58							
6MPI	9vHPV compared to 4vHPV (1RCT)(b)	Outcomes not assessable by GRADE methodology due to the lack of clinical efficacy data in males. An efficacy study in males would require a comparison between the investigational 9vHPV vaccine and the licensed 4vHPV vaccine (using a placebo would not be acceptable since the 4vHPV vaccine prevents anal lesions due to HPV types 16 and 18). Consequently, low incidence of HPV 6, 11, 16 and 18-related disease would be expected with both vaccines and a study would require a prohibitively large sample size. As an alternative approach, two immunobridging studies were used to infer efficacy of the 9vHPV vaccine in men 16–26 years old. Studies evaluated immunogenicity of 9vHPV vaccine in males 16–26 years old compared to either 4vHPV or 9vHPV vaccine in females 16–26 years old (population used to establish 9vHPV vaccine efficacy).					
AIN2/3							
PeIN2/3							
Anogenital warts							

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia
**: downgraded by 1 for indirectness due to use of immunobridging to 4vHPV vaccine*
a: downgraded by 1 for imprecision due to very wide 95% confidence interval
a: HPV types 6, 11, 16 and 18 data from Protocol 020/NCT00090285 (PICO1, PICO2 Supp01); supportive data from protocols 003/NCT01651949 (PICO11 Supp05), 020/NCT02114385 (PICO10 Supp05)
b: HPV types 31, 33, 45, 52 and 58 data from Protocol 001/NCT00543543 (PICO1 Supp04); supportive data from protocols 003/NCT01651949 (PICO11 Supp05), 020/NCT02114385 (PICO10 Supp05) (115, 142, 148-151).

Immunogenicity data on the 9vHPV vaccine administered to males 16–26 years old resulted in higher GMTs than the 4vHPV vaccine for HPV types 31, 33, 45, 52 and 58 at month 7 from the first immunisation dose. Seroconversion rates at month 7 in males vaccinated with the 9vHPV for these types were 100.0%. Regarding HPV types 6, 11, 16 and 18, the 9vHPV vaccine showed non-inferior immunogenicity compared to the 4vHPV vaccine at month 7. Seroconversion rates to these HPV types were ≥98.2% following vaccination with any of the two vaccines. The 9vHPV vaccine resulted in higher GMTs in heterosexual males than in females and in men who have sex with men between 16–26 years old at month 7. However, seroconversion rates for HPV vaccine types were ≥99.5% in all groups.

The results from these immunogenicity studies support the extrapolation of 4vHPV vaccine efficacy data for HPV 6, 11, 16, 18- related health outcomes in 16–26-year-old males, to same-aged heterosexual males and men who have sex with men vaccinated with the 9vHPV vaccine.

In 9–15-year-old males, GMTs for the 9vHPV vaccine types at month 7 were higher with either two or three doses of vaccine compared to females 16–26 years old who received three doses of vaccine. There was no significant difference in seroconversion rates between 9–15-year-old males and 16–26-year-old females for seropositivity to the 9vHPV types (seroconversion rates to HPV vaccine types were ≥99.5% in both groups).

4.1.4 Recent evidence not included in systematic review

A recent study from Giuliano et al, using a historical placebo group as comparison, showed efficacy of the 9vHPV vaccine against vulvar and vaginal precancerous lesions [152].

A recently published trial by Ruiz-Sternberg et al showed immunogenicity and efficacy of the 9vHPV vaccine in a multi-country population of Latin American girls, boys and young women. The 9vHPV vaccine prevented high-grade cervical, vulvar and vaginal dysplasia due to HPV serotypes 31, 33, 45, 52 and 58 in this population, with a reported efficacy of 92.3% [153].

The quality of this additional evidence was not formally assessed in this guidance.

4.1.5 Conclusions

- 9vHPV vaccine is efficacious for at least six years in preventing six-month persistent HPV infection and high-grade cervical lesions due to types 31, 33, 45, 52 and 58 in females 16–26 years old not infected with HPV at time of vaccination (evidence quality: high).
- No direct evidence of efficacy of 9vHPV vaccine against HPV-related infection and illness in males was found.
- Immunogenicity data show a non-inferior response of 9vHPV vaccine against the four HPV types included into the 4vHPV vaccine, which was already shown to be effective against HPV-related illness caused by serotypes 6, 11, 16 and 18. This can be considered indirect evidence that the 9vHPV vaccine is effective against HPV-related disease caused by serotypes 6, 11, 16 and 18 in females and males (evidence quality: moderate).
- The 9vHPV vaccine provides stronger immunogenicity against vaccine serotypes in 9–15-year-old males and females compared to 16–26-year-old females.
- Immunogenicity data on 16–26-year-old males and 9–15–year-old females show a stronger immune response from the 9vHPV vaccine compared to the 4vHPV vaccine against the additional 31, 33, 45, 52, and 58 serotypes contained in the 9vHPV vaccine.

4.2 Evidence of efficacy of quadrivalent and bivalent vaccines for boys/men

4.2.1 Efficacy of quadrivalent and bivalent vaccines in males 16–26 years

Evidence on efficacy of HPV vaccination against HPV-related illness was obtained from a 4vHPV vaccine efficacy trial in males [148, 149, 151] comparing the 4vHPV vaccine with placebo. Additional indirect evidence on efficacy was also gathered from immunogenicity studies [142, 150, 154] (Tables 4, Table 22–Table 24, supplemental documents Supp01–02, Supp04 in separate Excel files found on the ECDC website).

Table 4. Evidence type for benefits: 4vHPV vaccination of males 16–26 years old

Benefits	Design	Efficacy	Risk of bias	Inconsistency	Indirectness*	Imprecision	Evidence type (GRADE) 4vHPV vaccine
HPV types 6, 11, 16 and 18							
6MPI	4vHPV compared to placebo (1RCT)(a)	85.6% (73.4–92.9)	Not serious	Not serious	Not serious*	Not serious	High
AIN2/3		74.9% (8.8–95.4)	Not serious	Not serious	Not serious*	Not serious	High
PeIN2/3		100.0% (- 3 788.2–100.0)	Not serious	Not serious	Not serious*	Very serious[o]	Low
Anogenital warts		89.4% (65.5–97.9)	Not serious	Not serious	Not serious*	Not serious	High

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia
**: downgraded by 1 for indirectness due to use of immunobridging to 4vHPV vaccine a: downgraded by 1 for imprecision due to very wide 95% confidence interval*
a: HPV types 6, 11, 16, 18 data from protocol 020/NCT00090285 (PICO1, PICO2 Supp01); supportive data from protocols 020/NCT00090285 (PICO14,PICO15 Supp02), 020/NCT02114385 (PICO3 Supp02), 003/NCT01651949 (PICO4,PICO12,PICO13 Supp02) (142, 148-151, 154).

In the per-protocol analysis, the 4vHPV vaccine prevented 6MPI (efficacy 85.6%; 73.4–92.9), AIN2/3 (74.9%; 8.8–95.5) and anogenital warts (efficacy 89.4%; 65.5–97.9) related to HPV types 6, 11, 16 and 18 (evidence quality: high). Efficacy against PeIN2/3 was not assessable due to lack of statistical power and thus the quality of evidence was considered low because of very serious imprecision. In the intention-to-treat analysis, efficacy with respect to persistent infection with HPV-6, 11, 16, or 18 was 47.8% (95% CI, 36.0–57.6), efficacy against genital warts caused by vaccine types was 65.5% (45.8–78.6), while the rate of grade 2 or 3 anal intraepithelial neoplasia related to infection with HPV-6, 11, 16, or 18 was reduced by 54.2% (95% CI, 18.0–75.3). Differences between per-protocol and intention-to-treat analyses are likely due to the HPV status of the respective populations at time of vaccination (i.e. per-protocol population all HPV-naïve at vaccination).

At month 7, seroconversion rates against HPV-6, 11, 16 and 18 were ≥98.4% following vaccination with 4vHPV vaccine, with GMTs reaching peak values. A gradual decline in GMTs was observed after month 7, although 89.5%, 94.3%, 98.3% and 57.3% of subjects remained seropositive to the four HPV types at month 36. GMTs were generally higher in heterosexual males than men who have sex with men, but seroconversion rates for HPV types 6, 11 and 16 were ≥94.1% at month 7,≥89.4% at month 36 in both groups, ≥80.0% at month 7 and ≥53.3% at month 36 for HPV18 in both groups.

4.2.2 Efficacy of quadrivalent and bivalent HPV vaccination in males 9–15 years old

For this age group, only evidence from immunogenicity trials was available [141, 146, 148, 149, 155-159] (Efficacy of HPV vaccines in males 9–15 years old

Table A25–Table 27 supplemental files Supp01, Supp02, Supp04).

Following vaccination with the 4vHPV vaccine, GMTs for HPV types 6, 11, 16 and 18 at month 7 were non-inferior (or even 1.5-fold higher) than those observed in girls 9–15 years old, and from 1.8–2.7-fold higher than those observed in females 16–23 years old. Seroconversion rates for these types at month 7 in males 9–15 years old vaccinated with the 9vHPV vaccine were ≥99.6%. After month 7, a gradual decline in GMTs was observed, although more than 84.8% of males remained seropositive for HPV types 6, 11 and 16 and 60.8% for HPV18 at month 96.

Following vaccination with the 2vHPV vaccine, all subjects (100.0%) seroconverted for the HPV vaccine types at month 7. After month 7, a gradual decline in GMTs for HPV types 16 and 18 was observed, although all subjects remained seropositive at month 42. GMTs were higher in males aged 10–18 years than in females aged 15–25 years.

4.2.3 Recent evidence not included in the systematic review

A recent updated meta-analysis by Drolet et al concluded that there is compelling evidence of the impact of existing HPV vaccination programmes on anogenital warts diagnoses in boys and men [76].

A recent trial from Japan showed efficacy of 4vHPV vaccine against persistent anal infection in a population of heterosexual and homosexual males [160].

Immunogenicity data from the Mid-Adult Male (MAM) study following administration of 4vHPV vaccine to males 27-45 years old, were considered comparable to those observed in younger age grousps, where clinical efficacy was shown [161, 162].

The quality of this additional evidence was not formally assessed in this guidance.

4.2.4 Conclusions

- The evidence of efficacy of 4vHPV vaccine and 2vHPV vaccine in men is currently limited.
- There is direct evidence that 4vHPV vaccination is efficacious in 16–26-year-old males in preventing six months persistent infections, genital warts and anal intraepithelial neoplasia (i.e. anal cancer precursor lesion) due to HPV types 6, 11, 16 or 18.
- There is no direct evidence on the efficacy of 2vHPV vaccine against HPV-related infection and illness in males.
- 4vHPV and 2vHPV vaccines induce high seroconversion rates and non-inferior immunogenicity in 9–15-year-old males compared to 9–15-year-old females.
- 4vHPV vaccine and 2vHPV vaccine provide stronger immunogenicity in males 9–15 years old compared to females 16–26 years old.

4.3 Efficacy of HPV vaccination in people living with HIV

Direct evidence on the efficacy of HPV vaccination against HPV-related illness for people living with HIV was not found during the time period covered by the systematic review (supplemental file Supp07).

A study on the 4vHPV vaccine in HIV-infected children 7–12 years of age, reported seroconversion rates against HPV types 6, 11, 16 and 18 of ≥97% at month 7, with substantially higher GMTs for HPV types 6, 11, 16 and 18 at months 7 and 24 compared to placebo (evidence quality: moderate) [40, 41]. In a study of HIV infected males older than 18 years of age, the 4vHPV vaccine resulted in seroconversion rates ≥94.9% against the four vaccine types (evidence quality: very low) [163].

In a study of the 2vHPV vaccine in women aged 18–25 years, GMTs were lower among HIV-infected women compared to the GMTs observed in HIV-uninfected women at month 7. Seroconversion rates of 100% against HPV 16 and 18 were observed in both groups at month 7 (evidence quality: low) [164].

In another study comparing the 2vHPV and 4vHPV vaccines in HIV infected adults aged ≥18 years, GMTs for HPV16 did not differ following vaccination with the 2vHPV and 4vHPV vaccines, but they were higher for the 2vHPV vaccine against HPV18 at months 7 and 12 from first immunisation dose (evidence quality: moderate). At month 12 from the first immunisation dose, seroconversion rates following vaccination with 4vHPV and 2vHPV vaccines were 95.7% vs 100.0% respectively against HPV16, and 73.9% vs 97.8% respectively against HPV18 [165, 166].

4.3.1 Recent evidence not included in systematic review

Since the closure of the systematic review, a recent study of moderate size and relatively short follow-up (two years) published in 2018 was identified [167], reporting direct evidence on the efficacy of 4vHPV vaccination against persistent HPV infection in women living with HIV. According to this article, women living with HIV have a higher risk of persistent HPV infection and illness due to HPV serotypes 6, 11, 16 and 18 compared to women not living with HIV despite HPV vaccination. Women living with HIV vaccinated against HPV had lower rates of persistent HPV infection compared to a historical cohort of women living with HIV not vaccinated against HPV. Additionally, after HPV vaccination, women living with HIV with a low CD4 count (<350 cells/μL) showed a higher incidence of HPV-related illness.

Another study on the efficacy of the 4vHPV vaccine, against persistent anal HPV infections and lesions in people living with HIV and older than 27 years, was stopped due to futility by the Data and Safety Monitoring Board [168]. This is probably due to the high baseline prevalence of infections with preventable HPV types among individuals living with HIV and over 27 years old included in the study. However, the trial did still find some evidence of the efficacy of the 4vHPV vaccine against oral HPV infection due to vaccine HPV types.

The quality of this additional evidence was not formally assessed in this guidance.

4.3.2 Conclusions

- There is no current direct evidence on effectiveness of HPV vaccines against HPV-related disease in people living with HIV.
- Immunogenicity data show high seroconversion rates against HPV vaccine types in people living with HIV following 4vHPV and 2vHPV vaccination, but lower antibody titres compared to people not living with HIV vaccinated against HPV.
- New evidence on the efficacy of HPV vaccination in people living with HIV is emerging from ongoing studies.

4.4 Evidence of cost-effectiveness of adding males to current national HPV vaccination programmes

The cost-effectiveness of any HPV vaccination strategy is context specific and depends on both epidemiology and healthcare financing. However, all reviewed studies are consistent in finding the vaccination of preadolescent girls against HPV to be a cost-effective strategy for reducing the health and economic burden of HPV-related disease at the population level. Furthermore, there is evidence to suggest that where there is a high level of vaccination coverage in females, an indirect protective benefit is conferred on males. For example, in heterosexual Australian men under the age of 22 years attending STI clinics, the prevalence of HPV 16/18/6/11 has fallen by 78% since the prevaccination period [91].

In certain settings, universal HPV vaccination programmes have been introduced or proposed, with vaccination offered to both males and females of a certain age. Such programmes may address the following concerns:

- in the context of female-only vaccination, the indirect benefits of herd protection among men who have sex with men are limited [169]
- the degree of herd protection extended to males is associated with vaccination coverage in females, which has been suboptimal in many settings [43]
- on equity grounds, some consider it preferential for both males and females to have access to the direct benefits of vaccination [170].

Whether a universal HPV vaccination programme will be deemed cost-effective in any given setting depends on a number of factors, including:

- health outcomes considered in the analysis (cervical disease, anogenital warts, non-cervical cancers)
- duration of vaccine protection
- baseline coverage rates in females (where appropriate)
- choice of baseline scenario (absence of any HPV vaccination vs. female-only programme)
- costs of vaccine procurement and delivery
- setting specific health economic factors (e.g. ICER threshold, discounting rate and payer perspective).

4.4.1 Evidence of marginal impact of including different health outcomes

Economic evaluations of HPV vaccination vary in the range of disease endpoints considered. In the simplest case, modelling analyses focus on the impact on cervical cancer incidence [134]. In other studies, additional outcomes are included, sometimes progressively [116, 129, 131]. The most comprehensive studies to date include precancerous lesions of the cervix and vagina, genital warts, recurrent respiratory papillomatosis and cancers of the vulva, vagina, anus, penis and head and neck (including oropharyngeal) [116, 131, 133, 135]. A review of the economic evaluations of HPV vaccination from 2017 concluded that across a number of studies, when non-cervical HPV-related diseases are included, the ICER is on average 2.85 times more favourable for female-only vaccination and 3.89 times more favourable for universal vaccination [159]. The additional inclusion of genital warts as an outcome of interest appears to be a significant factor in reducing the ICER, with one study showing a marginal ICER reduction of 41% in the case of 75% vaccination coverage [171].

Tables A36–A39 summarise by study how the ICER is affected by the inclusion of different health outcomes. Additional information is provided in Table A35, where the main characteristics of the studies are included. This table also includes the cost-effectiveness analysis (CEA) threshold used by the authors at the time of the analysis to evaluate the cost-effectiveness of that particular strategy. Of note, these thresholds may vary in time and therefore may not currently be valid.

In broad terms, the ICER decreases when incorporating the potential impact of the vaccine on additional HPV-related health outcomes. The consequence is that cost-effectiveness may be underestimated if the analysis is restricted to a subset of disease endpoints.

4.4.2 Evidence of marginal impact of duration of protection

The duration of protection offered by HPV vaccines is currently unknown and therefore cost-effectiveness studies make assumptions about the rate at which induced immunity wanes.

Duration of protection was assumed to be either lifelong, 20 years, or 10 years post-booster dose in most studies. The assumption significantly affected the ICER estimated by each model. The longer the duration of protection, the lower the marginal impact of the gender-neutral vaccination approach on the ICER compared to the female-only vaccination strategy.

Among the studies included in this review, all but three considered the case where vaccine protection is lifelong.

Eight studies conducted a sensitivity analysis to judge how the ICER would be altered if the duration of protection were shorter (e.g. 10, 20, 25 or 35 years; Table A38). All agreed that findings on cost-effectiveness were sensitive to assumptions on duration of vaccine protection. Notably, five studies concluded that the ICER of the gender-neutral vaccination approach would increase in the case of waning vaccine-induced immunity (since individuals become susceptible again and may be re-infected) [117, 118, 129, 171, 172]. Three studies concluded that the ICER would instead decrease in case of lifelong protection in females, which would reduce virus circulation and would thus lead to less HPV-related disease to be averted in males [121, 127, 133].

4.4.3 Evidence of marginal impact of varying coverage

In the included studies, the ICERs of adding males generally increase with higher baseline vaccination coverage in females. The general view is that increasing female coverage is a more efficient strategy for reducing the burden of HPV-related disease in the population than extending vaccination to males, in particular when priority is given to the prevention of cervical cancer. In fact, as mentioned above, cost-effectiveness models are very sensitive to the inclusion of different health outcomes, the assumed duration of vaccine protection, female coverage rates and the cost of the vaccine. Several studies agree that vaccinating males could be cost-effective where female coverage is low or if vaccine costs were substantially reduced.

Tables A36–A39 summarise the main results, grouped by study, on how ICERs comparing universal vaccination with female vaccination vary by different vaccination coverage rates in females (and in males in certain cases). Certain studies include catch-up vaccination for females only or for both sexes. Additional main characteristics of the studies are included in Table A35.

4.4.4 Evidence of marginal impact of vaccine cost

As the HPV vaccine price decreases, universal vaccination becomes more cost-effective, and some authors have identified the threshold price. For example, a study in New Zealand found that extending vaccination to boys based on a three-dose schedule would only be cost-effective when the price was below NZD 125 per dose (approximately EUR 71 in 2011) [126]. Another recent study from the Netherlands published in 2017 found that the vaccination of boys based on a two-dose regime would be considered cost-effective when the vaccination cost was below EUR 65 per dose, which was the actual cost in the country from 2012–2014 [120].

4.4.5 Evidence of cost-effectiveness of adding men who have sex with men to current national HPV vaccination programmes

Men who have sex with men account for a disproportionately high burden of male HPV-related disease, but benefit less than other males from the herd protection of female-only vaccination [91]. In cases where universal vaccination is found not to be cost-effective, an alternative could be a targeted strategy, e.g. vaccinatingmen who have sex with men.

The potential impact and cost-effectiveness of a focused HPV vaccination programme for men who have sex with men has been modelled in Australia [173, 174], the United Kingdom [169] and the United States [175]. Kim et al. [173] assessed a healthy cohort of men who have sex with men starting at the age of 12 years for lifetime risk of anal cancer and genital warts. Under different scenarios of age at vaccination, duration of vaccine protection, HPV and HIV exposure and anal cancer incidence, cost-effectiveness ratios remained lower than the aforementioned threshold of USD 100 000/QALY gained. Assuming 50% coverage and 90% vaccine efficacy, HPV vaccination of men who have sex with men at age 12 had a cost-effectiveness ratio of USD 15 290/QALY gained compared to no vaccination (assuming 0% HPV exposure prior to vaccination). The cost-effectiveness ratio was USD 19 160/QALY gained if men who have sex with men were vaccinated at age 26 assuming 10% exposure to HPV 6, 11, 16 and 18 prior to vaccination, and USD 37 830/QALY gained when assuming 50% prior exposure to vaccine HPV types 6, 11, 16 and 18.

Using a dynamic model, Lin et al. evaluated the impact of offering vaccination to men who have sex with men who visited genito-urinary medicine clinics (GUM) in the UK [169]. Substantial declines in anogenital warts and male HPV-related cancer incidence were estimated by offering HPV vaccination to men who have sex with men aged 16–40 years. Specifically, anogenital warts incidence was estimated to decrease by 35% within five years (15% where only HIV-positive men who have sex with men were vaccinated), and HPV-related cancer incidence was projected to drop by 55% within 100 years (40% where only HIV-positive men who have sex with men were vaccinated). The authors also indicated that HPV vaccination of this group could be cost-effective if all men who have sex with men up to age 40 were vaccinated at a cost of GBP 48 per dose, or only HIV-positive men who have sex with men were vaccinated at maximum cost of GBP 96.50 per dose. However, they acknowledged that those attending GUM clinics are a subset of the larger population of men who have sex with men. As a consequence of the findings of Lin et al., HPV vaccination has been offered to men who have sex with men aged 45 and under attending GUM clinics in England since April 2018 [176].

In contrast, a compartmental model analysis in Australia concluded that the greatest health benefits for men who have sex with men would only be achieved by targeting 9–15 years old boys. A catch-up vaccination programme for men who have sex with men aged 15–26 years, in addition to the 9-15 years old boys programme, would be cost-effective if implemented soon after the introduction of HPV vaccination of 9-15 years old boys (as the number of unvaccinated men who have sex with men aged 15-26 years would decrease over time) [175].

HPV vaccination as a secondary strategy for the prevention of recurrent high-grade anal intraepithelial lesions and invasive anal cancer was assessed for both HIV-negative and positive men aged 27 years and above in the United States [174, 177, 178]. For both, the risk of recurrence and subsequent progression to invasive anal cancer decreased by around 60% compared to no vaccination. Such an intervention was found to be cost-effective for HIV-negative men and cost-saving for HIV-positive men.

4.4.6 Conclusions

- The cost-effectiveness of adding males to female-only HPV vaccination programmes depends on several factors and model assumptions that may be context-specific, including vaccine price, vaccination coverage rates in females, duration of protection, vaccine efficacy in males and assumed serotype-specific efficacy of the HPV vaccine against different health outcomes.
- Parameters used in cost-effectiveness studies in recent years include lower coverage rates for females, prices well below the original market value and a greater range of potential health benefits due to HPV vaccination.
- If the priority of the HPV vaccination programme is the prevention of cervical disease in women, then adding males to current female-only HPV vaccination programmes becomes more cost-effective with:
  - persistently lower vaccination coverage among females
  - lower cost of the vaccine.

  However, increasing vaccination coverage among girls may still be a more cost-effective primary objective.
- If the objective of the HPV vaccination programme is to prevent HPV-related disease in general, then a universal HPV vaccination may have a more favourable cost-effectiveness.

5. Implications for public health practice and research

This section is based on ECDC's reflections on the potential implications for public health practice of the evidence-based conclusions reported in Section 4.

5.1 Possible implications for current national HPV immunisation programmes

Virtually all countries in the EU/EEA currently have a HPV vaccination programme targeting preadolescent girls (Table 1). A growing number of Member States are considering or have already adopted gender-neutral HPV vaccination [48, 50, 54, 58-60]. Several considerations related to this decision are briefly discussed below.

Sufficiently high HPV vaccination coverage is not only crucial to obtain direct protection of a large number of vaccinated individuals, but also to achieve herd (indirect) protection of those who did or could not get vaccinated [76]. Virtually all cost-effectiveness analyses identify HPV vaccination programmes for preadolescent girls to be cost-effective, even those with relatively low vaccination coverage rates. However, herd effects improve the cost-effectiveness of vaccination and are mainly observed at high vaccination coverage rates [171, 179] and in programmes with multi-cohort vaccination (i.e. vaccinating more than a single age cohort each year) [76]. Routine vaccination of preadolescent girls is still the primary target of HPV vaccination as it provides the greatest health impact, while cost-effectiveness analyses assessing other vaccine target groups (e.g. adding vaccination of males) are less conclusive [171, 180]. The option of vaccinating additional age cohorts advances health benefits to older age groups, although cost-effectiveness becomes less favourable as age at vaccination increases.

The extension of HPV vaccination to preadolescent males can further improve the indirect protection of unvaccinated girls and women through herd immunity and can directly prevent HPV-related conditions in men, including men who have sex with men. Related to this, a Finnish randomised community trial published in 2018 demonstrated that gender-neutral vaccination with the 2vHPV vaccine generates significant herd benefits and cross-protection against a number of HPV non-vaccine types in a low-to-moderate coverage scenario]. The overall cost effectiveness of a gender-neutral vaccination programme will depend on many factors, and balancing of coverage, should there be vaccine supply or resource constraints, may require careful consideration. As the HPV vaccine price decreases, the cost-effectiveness of universal vaccination can increase. Aside from the vaccine price, other previously discussed factors that influence the cost-effectiveness of adding males to HPV vaccination programmes include coverage among girls, number of doses, duration of protection and number of HPV-related health outcomes considered primary objectives of the immunisation programme [180].

Evidence of duration of protection was not assessed in the current guidance, but it is an important factor in determining the overall impact of the vaccination. Cost-effectiveness models show that the longer the duration of protection, the less the marginal impact of the gender-neutral vaccination approach is compared to the female-only vaccination strategy (Annex 1). Ongoing studies suggest that currently licensed vaccines administered to preadolescent girls provide at least 10 years of protection [18]. Age at vaccination and vaccination schedule (i.e. number of doses) influence the strength of the immunogenic response to the vaccine and may also possibly affect duration of protection, though no correlate of protection for HPV vaccination has been identified yet. Large population-based studies will produce more data on some of these aspects in the future [83, 182-184].

The current evidence of HPV vaccine efficacy in males is limited and refers to the prevention of persistent HPV infections, genital warts and anal cancer precursor lesions (anal intraepithelial neoplasia). No meaningful vaccine efficacy estimate is available for penile intraepithelial lesions and there is no direct evidence of efficacy against anal, penile and oropharyngeal cancers. Compared to females, males seems to have a constant HPV prevalence over age [11]. Importantly, vaccine efficacy is significantly higher for individuals who are HPV-naïve, so vaccinating before the beginning of sexual activity (i.e. before exposure to HPV infection) is generally preferable.

The demonstrated efficacy of HPV vaccination on different HPV-related health outcomes also needs to be considered when modelling the cost-effectiveness of HPV vaccination. It is biologically plausible that HPV vaccination is effective against all HPV vaccine type-attributable cancers and illnesses, even though some of these effects are not yet supported by currently available evidence.

The introduction of the 9vHPV vaccine will likely have an impact on the new additional HPV vaccine types contained in the 9vHPV vaccine [75]. The 9vHPV vaccine could thus be potentially more beneficial for adults already infected with a HPV type (e.g. people living with HIV, men who have sex with men and women older than 25 years), as these individuals would be protected against at least some of the additional HPV types contained in the 9vHPV vaccine.

However, the effectiveness of the 9vHPV vaccine should also be compared to the effectiveness of all other available HPV vaccines in order to evaluate options for an optimal immunisation strategy [172, 185]. Potential changes in the cost-effectiveness of interventions following introduction of the 9vHPV vaccine should also be considered. A recent modelling study published in 2016, assuming 95% vaccine-type efficacy and lifelong protection, predicted that administering 9vHPV to girls could already provide the majority of the benefits achievable with a gender-neutral vaccination strategy [186].

5.1.1 Organisational aspects

The cost of the vaccine is one of the main determinants of the cost of intervention and a key determinant in estimates of cost-effectiveness. The choice of which type of HPV vaccine to use should be linked to the evidence of its effectiveness and impact, which may vary between countries and regions due to different epidemiological situations, HPV type distribution and HPV vaccination programme objectives (e.g. prevention of cervical cancer and HPV-related diseases). In 2018, the centre d'expertise et de référence en santé publique from Quebec (Canada) recommended a mixed vaccination schedule based on some of these considerations [187].

In virtually all studies considered, evidence shows that girls-only vaccination programme is a cost-effective strategy. However, achieving and maintaining high vaccine uptake over time may be challenging in practice. Recent experiences in certain EU/EEA Member States suggest that sudden drops in vaccination coverage are possible [63]. In such events, a female-only vaccination programme could also suffer from important drops in indirect protection of unvaccinated groups, possibly causing significant HPV-associated harm in the population over time. A gender-neutral vaccination programme would be more resilient against sudden drops of vaccination coverage as it would provide more robust and stronger indirect protection, as emerged from literature published in 2016 and 2018 [90, 181, 188].

Gender-neutral vaccination requires the administration of about twice as many doses and this comes with a financial cost for society. Nevertheless, returns on investment can be anticipated due to increased direct and indirect (herd) protection that may prevent the cost of treating excess cases of genital warts and cancer attributable to HPV in both sexes. Among other factors, this once again will be dependent on the local epidemiology of HPV-related illnesses, their current and future trends and the HPV serotypes mainly involved and circulating. The number of doses administered to each person will affect the resources and supply needed for the intervention, and this will also depend on age at HPV vaccination, on the presence of a multi-cohort vaccination programme, and on the distance between the first and the second vaccination dose. Currently, WHO recommendations indicate that two doses of HPV vaccine are enough when given to preadolescents and adolescents under 15 years of age, while three doses are recommended in individuals above 15 years of age [18]. Dose and cost sparing options are under investigation and may provide alternatives in the future [189, 190].

Adding groups at risk like people living with HIV and men who have sex with men to the routine girls-only vaccination policy may be considered an alternative option in case of limited resources or supply. In fact, despite lower vaccine efficacy due to the higher prevalence of HPV infection in these groups, the overall impact of the intervention could still be high due to the high absolute risk among these people [191].

5.1.2 Social aspects

Cervical cancer disproportionally affects women with lower socio-economic status and socio-economic differences have been observed in attendance to cervical screening [192-194]. In certain European settings, HPV vaccination has been observed to be associated with more equal access across all socio-economic strata of the population [195]. If this were not the case, special attention should be paid to reaching all socio-economic strata and groups in the population in order to increase the benefits of HPV vaccination without causing health inequalities.

Since HPV is an STI, sexual mixing patterns and HPV viral circulation may vary across countries and groups. For this reason, additional resources may be best invested in certain settings to reach girls belonging to unvaccinated subgroups of the population rather than starting a universal HPV immunisation programme that may still not protect these under-vaccinated communities (e.g. specific geographical, ethnic, cultural, socio-economic or religious groups). A HPV vaccination strategy should ideally take into account evidence on sexual mixing patterns and on circulation of HPV viral types within the population. If vaccination uptake is lower in specific population subgroups, it may be advisable to channel resources to increasing uptake among the unvaccinated.

5.1.3 Ethical considerations

Men who have sex with men are at increased risk of HPV infection and transmission. They have limited to no protection from a female-only vaccination strategy and thus do not directly benefit from it. Adding men who have sex with men to a female-only vaccination strategy may pose certain challenges. The best immunogenic response against HPV is achieved by vaccinating preadolescent individuals, while it may turn out unfeasible and questionable to identify men who have sex with men at such an early age. Moreover, from the evidence that was reviewed in the guidance, men who have sex with men appear to have lower immunogenic responses to HPV vaccination

compared with heterosexual men from the same age group which could be possibly due to more exposure to HPV. It may be difficult in practice to deliver a programme targeted at men who have sex with men, as it may not reach a sufficient proportion of that community for herd protection to be achieved. However, gender-neutral vaccination of all preadolescents would directly (and indirectly for the unvaccinated) protect men who have sex with men without posing any of these challenges.

A universal vaccination strategy would also be more equal in giving both sexes the opportunity to be directly protected against HPV-related disease. Additionally, achieving through universal vaccination the highest possible indirect (herd) protection, and obtaining sustained reduction of HPV circulation in the population, may also positively affect people who cannot directly benefit from HPV vaccination, such as those with immunocompromised conditions.

Regardless of the HPV vaccination strategy chosen, different countries may optionally consider offering HPV vaccination to men who have sex with men who are no longer in the target (age) groups for routine HPV vaccination, in order to provide them with some direct protection against HPV-related disease.

In case of limited supply of HPV vaccine, vaccination of girls might be preferred over universal vaccination. The WHO's Strategic Advisory Group of Experts (SAGE) on immunisation has recently called for temporary suspension of implementation of gender neutral vaccination strategies due to global HPV vaccines shortages currently foreseen for the next four years [196, 197].

5.2 Possible implications of vaccinating people living with HIV

In the presence of limited direct evidence, immunogenicity data suggest that seroconversion is achieved following HPV vaccination by most people living with HIV and no safety signals for HPV vaccine have emerged in this group from previous literature reviews [73]. Although the studies reviewed in the guidance did not discriminate between different levels of immunosuppression of people living with HIV, it is known that the immunogenic response to a vaccine of people living with HIV may depend on their immunocompetence status (e.g. CD4 count), which also depends on whether they are on HIV treatment [198]. The general principle that earlier vaccination causes better immune response should theoretically also be valid for people living with HIV (given sufficient level of immunity).

People living with HIV are also at increased risk of HPV infection. This may decrease the benefits of the vaccination as they may be less likely to be HPV-naïve. This once again underscores the need to vaccinate against HPV as early as possible in order to obtain greater benefits from immunisation.

5.3 Possible implications of HPV vaccine hesitancy

Despite the high number of girls successfully vaccinated in Europe every year, many still miss the opportunity to be vaccinated. Vaccine hesitancy refers to 'delay in acceptance or refusal of vaccination despite availability of vaccination services' [22], thus mainly addressing perceptions and opinions of the population that is offered or eligible for vaccination. Understanding knowledge, attitudes and decision patterns regarding HPV vaccination at all levels (decision makers, healthcare workers, parents, target populations) could be relevant for increasing and maintaining high uptake. It is important to mention the role of healthcare workers, as they are among the most trusted advisors and influencers of vaccination decisions [199] as they may administer the vaccine, inform the population on their eligibility for HPV vaccination, address concerns regarding the safety and efficacy of the vaccine and provide recommendations when requested. Healthcare workers' perceptions and opinions regarding HPV vaccination may influence their behaviour and consequently patient vaccine hesitancy, as well as vaccine acceptability in general.

Identifying effective interventions and communication strategies, tailored to different target groups (including parents when appropriate) and adapted to the local context is also an important aspect to consider.

5.4 Remaining knowledge gaps

Most of the evidence reviewed and appraised in this guidance referred to vaccines efficacy data, while little data on HPV vaccines effectiveness and impact were captured by the systematic reviews for the topics covered in the document. The knowledge gaps concerning real-life evidence of effectiveness and impact of the 9vHPV vaccine, of HPV vaccination in males, and of HPV vaccination in people living with HIV, will be filled by ongoing studies and could confirm the positive findings observed in the efficacy and immunogenicity trials.

After reviewing and discussing the evidence, the expert panel identified the following specific knowledge gaps and areas in need of further evidence:

- more data on efficacy and effectiveness of all available HPV vaccines in males
- additional evidence of cross-protection of all available HPV vaccines
- additional and updated evidence on strength and duration of protection of HPV vaccines
- context-specific HPV transmission patterns between and within sexes, and by age
- effect of HPV vaccination according to sexual transmission patterns (e.g. number of sexual partners, subgroups of the population with different viral mixing patterns and vaccination uptake)
- efficacy of a single dose of HPV vaccine for those who do not complete the full cycle
- additional benefit of 9vHPV vaccination for women and men older than 25 years
- data on efficacy/effectiveness of 2vHPV vaccine in males
- data on HPV vaccine efficacy and kinetics of anti-HPV antibodies in people living with HIV
- additional evidence on HPV vaccine efficacy against genital warts and anal intraepithelial neoplasia in men who have sex with men;
- age-specific prevalence of HPV infection of the oral cavity;
- efficacy of HPV vaccines on oral HPV infection in males
- efficacy of HPV vaccines in immunosuppressed individuals (including people living with HIV)
- identification of immune-correlates of protection and potential use in public health surveillance
- immune/vaccine responses of different HPV serotype variants
- effectiveness of adjuvant HPV vaccination (using prophylactic HPV vaccines)
- impact of HPV vaccination on screening uptake behaviour
- possible additional causative associations between HPV infection and other diseases
- continuous vigilance on possible HPV serotype replacement
- vigilance on HPV vaccine failures and their characterisation
- factors affecting HPV vaccine uptake (including reasons for lower uptake in males in several settings) and sudden drops in the vaccination rate.

6. Next steps

Research is ongoing in several of the areas covered by the guidance. Large cohort studies are being carried out and will provide data on the real-life effectiveness of the vaccine on HPV-related illness [83, 182-184], while new impact assessements of current HPV vaccination programmes are being performed [96]. As more countries recommend universal HPV vaccination, it is possible that more evidence on the impact of HPV vaccination will become available in the coming years. Studies on HPV infection of the oral cavity may shed more light on the impact of HPV vaccination on oropharyngeal cancers attributable to HPV, as they have increased in certain developed countries [26, 168]. Ongoing studies on the efficacy of a single dose of HPV vaccine may be informative in many respects, including kinetics of anti-HPV antibodies, duration of protection, best possible HPV vaccination schedule and cost-effectiveness [200]. More head-to-head comparisons of existing vaccines and experiences from the use of mixed HPV vaccination schedules may also produce additional insight on how to maximise effectiveness of intervention and improve efficiency [190]. Some data may be incorporated into future modelling studies to inform decision-making while taking into account possible changes in costs of intervention (including screening), and evidence about anticipated desirable effects of the vaccination.

6.1 Screening in a post-vaccination era

The first routine HPV vaccination cohorts are starting to reach the age where they are being invited for cervical screening for the first time. Recent research published in 2016–2017 suggests that in a (partially) vaccinated population, less intensive screening programmes, characterised by a later start age, longer time interval and less invasive primary test, may provide similar or higher benefits at lower cost (and lower harm as measured by colposcopy rate) than maintaining current screening guidelines [201, 202].

However, Kim et al. [135] note that a universal screening policy that aims to target the average risk profile in a population, not taking into account vaccination status, may lead to inefficiencies and foregone health benefits. Therefore, it is essential to assess the unfolding impact of a less frequent screening programme on the unvaccinated as to whether they will be at a heightened risk as they lose some of the direct benefit of screening or being adequately protected by herd immunity. In a modelling study predicting cervical cancer incidence in England up to 2040, Castanon et al. emphasise that focus should be placed on increasing screening coverage among unvaccinated women [203].

Furthermore, the advent of primary HPV testing [201, 204], together with the development of new technologies for triage [205], will alter the general approach to the prevention of HPV-related disease over the coming years [179].

The guidance will need to be further updated within the next five years with new evidence that emerges from research and implementation of the intervention.

References

1. European Centre for Disease Prevention and Control. Guidance for the introduction of HPV vaccines in EU countries: ECDC; 2008 [Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0801_GUI_Introduction_of_HPV_Vaccines_in_EU.pdf.
2. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in European Union countries – an update: ECDC; 2012 [Available from: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/20120905_GUI_HPV_vaccine_update.pdf.
3. International Agency for Research on Cancer. Human Papillomaviruses 2018 [Available from: https://monographs.iarc.fr/wp-content/uploads/2018/06/mono100B-11.pdf.
4. IARC. Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. a review of human carcinogens. . IARC Monogr Eval Carcinog Risks. 2012;100(Pt B):1-441.
5. World Health Organisation. Cervical Cancer 2019 [Available from: https://www.who.int/cancer/cervical-cancer.
6. International Papillomavirus Society. The critical role of stakeholder collaborations: Aiming for the elimination of HPV-related disease in Europe 2019 [cited 2019. Available from: https://ipvsoc.org/news/stakeholder-collaborations-elimination-hpv-related-disease/.
7. American Cancer Society. American Cancer Society Launches Campaign to Eliminate Cervical Cancer 2018 [Available from: http://pressroom.cancer.org/HPVcancerfreelaunch.
8. Summit; EEC. Resolution on HPV cancer elimination passed 2019 [Available from: https://www.ecco-org.eu/Global/News/Latest-News/2019/09/NEWS-ECCO-2019-Summit-Resolution-on-HPV.
9. Schiffman M, Doorbar J, Wentzensen N, de Sanjose S, Fakhry C, Monk BJ, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.
10. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010;202(12):1789-99.
11. Giuliano AR, Lazcano-Ponce E, Villa LL, Flores R, Salmeron J, Lee JH, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2036-43.
12. Han JJ, Beltran TH, Song JW, Klaric J, Choi YS. Prevalence of Genital Human Papillomavirus Infection and Human Papillomavirus Vaccination Rates Among US Adult Men: National Health and Nutrition Examination Survey (NHANES) 2013-2014. JAMA Oncol. 2017;3(6):810-6.
13. Lewis RM, Markowitz LE, Gargano JW, Steinau M, Unger ER. Prevalence of Genital Human Papillomavirus Among Sexually Experienced Males and Females Aged 14-59 Years, United States, 2013-2014. J Infect Dis. 2018;217(6):869-77.
14. Daugherty M, Byler T. Genital Wart and Human Papillomavirus Prevalence in Men in the United States From Penile Swabs: Results From National Health and Nutrition Examination Surveys. Sex Transm Dis. 2018;45(6):412-6.
15. Gargano JW, Unger ER, Liu G, Steinau M, Meites E, Dunne E, et al. Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014. J Infect Dis. 2017;215(7):1070-9.
16. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009;10(4):321-2.
17. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9.
18. WHO. Human papillomavirus vaccines: WHO position paper, May 2017. Wkly Epidemiol Rec. 2017;92(19):241-68.
19. Serrano B, de Sanjose S, Tous S, Quiros B, Munoz N, Bosch X, et al. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions. Eur J Cancer. 2015;51(13):1732-41.
20. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97(14):1072-9.
21. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:F12-23.
22. Patel H, Jeve YB, Sherman SM, Moss EL. Knowledge of human papillomavirus and the human papillomavirus vaccine in European adolescents: a systematic review. Sex Transm Infect. 2016;92(6):474-9.
23. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56.

24. Ervik M, Lam F, Ferlay J, Mery L, Soerjomataram I, Bray F. Cancer Today 2016 [Available from: http://gco.iarc.fr/today.

25. Hartwig S, Baldauf JJ, Dominiak-Felden G, Simondon F, Alemany L, de Sanjose S. Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Res. 2015;1:90-100.

26. Castellsague X, Alemany L, Quer M, Halec G, Quiros B, Tous S, et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst. 2016;108(6):djv403.

27. Giuliano AR, Viscidi R, Torres BN, Ingles DJ, Sudenga SL, Villa LL, et al. Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study. Papillomavirus Res. 2015;1:109-15.

28. Nyitray AG, Lin HY, Fulp WJ, Chang M, Menezes L, Lu B, et al. The role of monogamy and duration of heterosexual relationships in human papillomavirus transmission. J Infect Dis. 2014;209(7):1007-15.

29. Pierce Campbell CM, Kreimer AR, Lin HY, Fulp W, O'Keefe MT, Ingles DJ, et al. Long-term persistence of oral human papillomavirus type 16: the HPV Infection in Men (HIM) study. Cancer Prev Res (Phila). 2015;8(3):190-6.

30. Giuliano AR, Nyitray AG, Kreimer AR, Pierce Campbell CM, Goodman MT, Sudenga SL, et al. EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection. Int J Cancer. 2015;136(12):2752-60.

31. Clifford GM, Tully S, Franceschi S. Carcinogenicity of Human Papillomavirus (HPV) Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer. Clin Infect Dis. 2017;64(9):1228-35.

32. Clifford GM, de Vuyst H, Tenet V, Plummer M, Tully S, Franceschi S. Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa. J Acquir Immune Defic Syndr. 2016;73(3):332-9.

33. Szabo E, Kosa C, Babarczi E, Sulyok M, Ujhelyi E, Banhegyi D, et al. Prevalence of Anal Human Papillomavirus Infection in Hungarian Men Who Have Sex with Men. Pathol Oncol Res. 2018;24(3):671-7.

34. Leval A, Herweijer E, Arnheim-Dahlstrom L, Walum H, Frans E, Sparen P, et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 2012;206(6):860-6.

35. Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.

36. European Medicines Agency. EPAR Cervarix. London: European Medicines Agency; 2019.

37. European Medicines Agency. EPAR Gardasil. London: European Medicines Agency; 2019 30 April 2019.

38. European Medicines Agency. EPAR Gardasil 9. European Medicines Agency; 2019 13 March 2019.

39. Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents - Full Text View - ClinicalTrials.gov [cited 2018 4 July 2018]. Available from: https://clinicaltrials.gov/ct2/show/NCT00534638.

40. Levin MJ, Moscicki AB, Song LY, Fenton T, Meyer WA, 3rd, Read JS, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr. 2010;55(2):197-204.

41. Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA, 3rd, et al. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis. 2012;206(8):1309-18.

42. European Centre for Disease Prevention and Control. ECDC Vaccine Scheduler. Human Papillomavirus Infection: Recommended vaccinations [cited 2018 4 July 2018]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=38&SelectedCountryIdByDisease=-1.

43. Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453-63.

44. Paul KT. "Saving lives": Adapting and adopting Human Papilloma Virus (HPV) vaccination in Austria. Soc Sci Med. 2016;153:193-200.

45. Nancy T, Gerkens S, Cornelis J, Jespers V, Hanquet G. Cost-effectiveness analysis of HPV vaccination of boys in Belgium. Belgian Health Care Knowledge Centre; 2019 15 July 2019.

46. Health; CIoP. Immunisation against Human Papillomavirus 2016 [

47. Republic; C-CCSPitC. Vaccinating girls and boys against human papillomavirus (HPV) prevents the development of several serious cancers and protects human lives [Available from: https://www.cervix.cz/index-en.php?pg=news&aid=289.

48. Aeldreministeriet S-o. Regeringen vil tilbyde gratis HPV-vaccine til drenge 2018 [29 August 2018]. Available from: http://www.sum.dk/Aktuelt/Nyheder/Forebyggelse/2018/August/Regeringen-vil-tilbyde-gratis-HPV-vaccine-til-drenge.aspx?utm_source=POLITICO.EU&utm_campaign=97056a6bad-EMAIL_CAMPAIGN_2018_08_29_02_38&utm_medium=email&utm_term=0_10959edeb5-97056a6bad-190032977.

49. The National Institute for Health and Welfare recommends including the HPV vaccine in the boys' vaccination programme [press release]. Helsinki, 25 January 2019 2019.

50. Takla A, Wiese-Posselt M, Harder T, Meerpohl JJ, Robl-Mathieu M, Terhardt M, et al. Background paper for the recommendation of HPV vaccination for boys in Germany. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2018;61(9):1170-86.

51. Health Information and Quality Authority. Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys. Dublin: Health Information and Quality Authority; 2018 4 December 2018.

52. salute; Md. Piano Nazionale Prevenzione Vaccinale 2017-2019 2017 [Available from: http://www.salute.gov.it/imgs/C_17_pubblicazioni_2571_allegato.pdf.

53. Netherlands; HCot. Vaccination against HPV. 2019 19 June 2019. Report No.: 2019/09.

54. Norwegian Ministry of Health and Care Services. Free HPV vaccine to boys 2017 [Available from: https://www.regjeringen.no/en/aktuelt/free-hpv-vaccine-to-boys/id2552726/.

55. Juvet LK, Saeterdal I, Couto E, Harboe I, Klemp M. Effect of HPV-vaccination of boys: Norwegian Institute of Public Health; 2015 [Available from: https://www.fhi.no/en/publ/2015/effect-of-hpv-vaccination-of-boys/.

56. Jimenez E, Torkilseng EB, Klemp M. Cost-effectiveness of HPVvaccination of boys aged 12 in a Norwegian setting. Kunnskapssenteret (Norwegian Knowledge Centre for the Health Services),; 2015. Report No.: 1890-1298.

57. HPV-vaccin införs för pojkar [press release]. 18 September 2019 2019.

58. Folkhalsomnyndigheten- Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme 2017 [Available from: https://www.folkhalsomyndigheten.se/contentassets/6adf7b5f24b54399a5b42ef47c50b275/human-papilloma-virus-vaccination-boys-swedish-national-vaccination-programme.pdf.

59. Joint Committee on Vaccination and Immunisation. Statement on HPV vaccination 2018 [Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/726319/JCVI_Statement_on_HPV_vaccination_2018.pdf.

60. Kmietowicz Z. Boys in England to get HPV vaccine from next year. BMJ. 2018;362:k3237.

61. Lei n.71/2018 de 31 de dezembro. Orçamento de Estado para 2019, 71/2018 (2018).

62. Martin JG. La Comunidad de Madrid amplía la vacuna del virus del papiloma humano a los primeros grupos de hombres 20 minutos2019 [Available from: https://www.20minutos.es/noticia/3614752/0/vacuna-madrid-papiloma-humano-virus/.

63. Soborg B. Addressing HPV vaccine hesitancy in Denmark. Eur J Public Health. 2017;27(Suppl 3).

64. Lynge E, Skorstengaard M, Lubker CL, Thamsborg L. HPV-vaccination impact in Denmark: is the vaccine working? Expert Rev Vaccines. 2018;17(9):765-7.

65. Corcoran B, Clarke A, Barrett T. Rapid response to HPV vaccination crisis in Ireland. Lancet. 2018;391(10135):2103.

66. Brotherton JML, Bloem PN. Population-based HPV vaccination programmes are safe and effective: 2017 update and the impetus for achieving better global coverage. Best Pract Res Clin Obstet Gynaecol. 2018;47:42-58.

67. ICO/WHO HPV Information Centre [cited 2018 20 February 2018]. Available from: http://www.hpvcentre.net/.

68. European Centre for Disease Prevention and Control. Vaccine Scheduler - Human Papillomavirus Infection: Recommended vaccinations 2019 [cited 2019. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=38&SelectedCountryIdByDisease=-1.

69. Organization WH. Global Advisory Committee on Vaccine Safety meeting report, 7-8 June 2017. Wkly Epidemiol Rec. 2017;92(28):393-404.

70. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279-84.

71. Phillips A, Patel C, Pillsbury A, Brotherton JML, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2017;2017.

72. Agency EM. HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS 2016 [Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/European_Commission_final_decision/WC500196773.pdf.

73. Cochrane. Randomized controlled trials of human papillomavirus vaccines: Systematic reviews. World Health Organization; 2016.

74. Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:CD009069.

75. Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-80.

76. Drolet M, Benard E, Perez N, Brisson M, Group HPVVIS. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394(10197):497-509.

77. Purrinos-Hermida MJ, Santiago-Perez MI, Trevino M, Dopazo R, Canizares A, Bonacho I, et al. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. PLoS One. 2018;13(8):e0201653.

78. Kumakech E, Berggren V, Wabinga H, Lillsunde-Larsson G, Helenius G, Kaliff M, et al. Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix(R)) Pilot Project in Uganda. PLoS One. 2016;11(8):e0160099.

79. Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, et al. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection. J Infect Dis. 2019;219(3):382-90.

80. Donken R, King AJ, Bogaards JA, Woestenberg PJ, Meijer C, de Melker HE. High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years After Vaccination in Young Dutch Women. J Infect Dis. 2018;217(10):1579-89.

81. Woestenberg PJ, King AJ, van Benthem BHB, Donken R, Leussink S, van der Klis FRM, et al. Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors. J Infect Dis. 2018;217(2):213-22.

82. Mesher D, Panwar K, Thomas SL, Edmundson C, Choi YH, Beddows S, et al. The Impact of the National HPV Vaccination Program in England Using the Bivalent HPV Vaccine: Surveillance of Type-Specific HPV in Young Females, 2010-2016. J Infect Dis. 2018;218(6):911-21.

83. Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013;105(7):469-74.

84. Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. Lancet Infect Dis. 2017;17(12):1293-302.

85. Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016;63(4):519-27.

86. Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, et al. Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC Infect Dis. 2014;14:87.

87. Judlin P, Jacquard AC, Carcopino X, Aubin F, Dahlab A, Mistretta F, et al. Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study. Sex Health. 2016;13(1):49-54.

88. Merckx M, Vanden Broeck D, Benoy I, Depuydt C, Weyers S, Arbyn M. Early effects of human papillomavirus vaccination in Belgium. Eur J Cancer Prev. 2015;24(4):340-2.

89. Dillner J, Nygard M, Munk C, Hortlund M, Hansen BT, Lagheden C, et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 2018;36(26):3820-9.

90. Lehtinen M, Soderlund-Strand A, Vanska S, Luostarinen T, Eriksson T, Natunen K, et al. Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I). Int J Cancer. 2018;142(5):949-58.

91. Chow EPF, Machalek DA, Tabrizi SN, Danielewski JA, Fehler G, Bradshaw CS, et al. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. The Lancet Infectious Diseases. 2017;17(1):68-77.

92. Lehtinen T, Soderlund-Strand A, Petaja T, Eriksson T, Jokiranta S, Natunen K, et al. Human Papillomavirus (HPV) Prevalence in Male Adolescents 4 Years After HPV-16/18 Vaccination. J Infect Dis. 2017;216(8):966-8.

93. Markowitz LE, Gee J, Chesson H, Stokley S. Ten Years of Human Papillomavirus Vaccination in the United States. Acad Pediatr. 2018;18(2S):S3-S10.

94. Swedish KA, Factor SH, Goldstone SE. Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clin Infect Dis. 2012;54(7):891-8.

95. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016;137(3):e20151968.

96. Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, et al. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Eurosurveillance. 2018;23(41).

97. Palmer T, Wallace L, Pollock KG, Cuschieri K, Robertson C, Kavanagh K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;365:l1161.

98. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(10):958-66.

99. Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100-10.

100. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781-9.

101. Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926-35.

102. Bogaards JA, van der Weele P, Woestenberg PJ, van Benthem BHB, King AJ. Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18. J Infect Dis. 2019;220(7):1141-6.

103. Checchi M, Mesher D, Mohammed H, Soldan K. Declines in anogenital warts diagnoses since the change in 2012 to use the quadrivalent HPV vaccine in England: data to end 2017. Sex Transm Infect. 2019;95(5):368-73.

104. Guerra FM, Rosella LC, Dunn S, Wilson SE, Chen C, Deeks SL. Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): A population-based assessment. Vaccine. 2016;34(39):4678-83.

105. Dominiak-Felden G, Gobbo C, Simondon F. Correction: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study. PLoS One. 2016;11(1):e0148665.

106. Flagg EW, Torrone EA. Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014. Am J Public Health. 2018;108(1):112-9.

107. Herweijer E, Ploner A, Sparen P. Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine. 2018;36(15):1917-20.

108. Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E. Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sex Transm Dis. 2013;40(1):28-31.

109. Oliphant J, Stewart J, Saxton P, Lo M, Perkins N, Ward D. Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction. N Z Med J. 2017;130(1452):9-16.

110. Sando N, Kofoed K, Zachariae C, Fouchard J. A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women--an ecological study. Acta Derm Venereol. 2014;94(3):288-92.

111. Bollerup S, Baldur-Felskov B, Blomberg M, Baandrup L, Dehlendorff C, Kjaer SK. Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years into the Danish Human Papillomavirus Vaccination Program for Girls and Women. Sex Transm Dis. 2016;43(4):238-42.

112. Cocchio S, Baldovin T, Bertoncello C, Buja A, Furlan P, Saia M, et al. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis. 2017;17(1):249.

113. Chow EP, Read TR, Wigan R, Donovan B, Chen MY, Bradshaw CS, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2015;91(3):214-9.

114. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94.

115. Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial. Lancet. 2017;390(10108):2143-59.

116. Bresse X, Goergen C, Prager B, Joura E. Universal vaccination with the quadrivalent HPV vaccine in Austria: impact on virus circulation, public health and cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):269-81.

117. Blakely T, Kvizhinadze G, Karvonen T, Pearson AL, Smith M, Wilson N. Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand. Vaccine. 2014;32(22):2645-56.

118. Haeussler K, Marcellusi A, Mennini FS, Favato G, Picardo M, Garganese G, et al. Cost-Effectiveness Analysis of Universal Human Papillomavirus Vaccination Using a Dynamic Bayesian Methodology: The BEST II Study. Value Health. 2015;18(8):956-68.

119. Damm O, Horn J, Mikolajczyk RT, Kretzschmar MEE, Kaufmann AM, Delere Y, et al. Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Eff Resour Alloc. 2017;15:18.

120. Qendri V, Bogaards JA, Berkhof J. Health and Economic Impact of a Tender-Based, Sex-Neutral Human Papillomavirus 16/18 Vaccination Program in the Netherlands. J Infect Dis. 2017;216(2):210-9.

121. Mennini FS, Bonanni P, Bianic F, de Waure C, Baio G, Plazzotta G, et al. Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy. Cost Eff Resour Alloc. 2017;15:11.

122. E J, EB T, M K. Cost-Effectiveness of HPV-Vaccination of Boys Aged 12 in a Norwegian Setting Oslo: Norwegian Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015 [Available from: http://www.ncbi.nlm.nih.gov/books/NBK390581/.

123. Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health. 2007;4(3):165-75.

124. Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, Franco EL, et al. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine. 2014;32(44):5845-53.

125. Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care. 2010;26(2):183-91.

126. Pearson AL, Kvizhinadze G, Wilson N, Smith M, Canfell K, Blakely T. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program. BMC Infect Dis. 2014;14:351.

127. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ. 2008;337:a769.

128. Zechmeister I, Blasio BF, Garnett G, Neilson AR, Siebert U. Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine. 2009;27(37):5133-41.

129. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858-67.

130. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28-41.

131. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, Markowitz LE. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443-50.

132. Olsen J, Jorgensen TR. Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females. Cost Eff Resour Alloc. 2015;13:4.

133. Burger EA, Sy S, Nygard M, Kristiansen IS, Kim JJ. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One. 2014;9(3):e89974.

134. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10(11):1915-23.

135. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.

136. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118-24.

137. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013 London: National Institute for Health and Care Excellence. ; 2013 [cited 2017 28 November 2017]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK395867/.

138. Vallejo-Torres L, Garcia-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746-61.

139. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood). 2000;19(2):92-109.

140. Commission WMaH. Macroeconomics and Health: Investing in Health for Economic Development.: World Health Organization; 2002.

141. Van Damme P, Olsson SE, Block S, Castellsague X, Gray GE, Herrera T, et al. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Pediatrics. 2015;136(1):e28-39.

142. Castellsague X, Giuliano AR, Goldstone S, Guevara A, Mogensen O, Palefsky JM, et al. Immunogenicity and safety of the 9-valent HPV vaccine in men. Vaccine. 2015;33(48):6892-901.

143. Group FIIS, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.

144. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2(10):868-78.

145. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-8.

146. Iversen OE, Miranda MJ, Ulied A, Soerdal T, Lazarus E, Chokephaibulkit K, et al. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. JAMA. 2016;316(22):2411-21.

147. Vesikari T, Brodszki N, van Damme P, Diez-Domingo J, Icardi G, Petersen LK, et al. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil(R) in 9-15-Year-Old Girls. Pediatr Infect Dis J. 2015;34(9):992-8.

148. Goldstone SE, Jessen H, Palefsky JM, Giuliano AR, Moreira ED, Jr., Vardas E, et al. Quadrivalent HPV vaccine efficacy against disease related to vaccine and non-vaccine HPV types in males. Vaccine. 2013;31(37):3849-55.

149. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr., Penny ME, Aranda C, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364(5):401-11.

150. Van Damme P, Meijer C, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, et al. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. Vaccine. 2016;34(35):4205-12.

151. Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Jr., Aranda C, Jessen H, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576-85.

152. Giuliano AR, Joura EA, Garland SM, Huh WK, Iversen OE, Kjaer SK, et al. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population. Gynecol Oncol. 2019;154(1):110-7.

153. Ruiz-Sternberg AM, Moreira ED, Jr., Restrepo JA, Lazcano-Ponce E, Cabello R, Silva A, et al. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Papillomavirus Res. 2018;5:63-74.

154. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Jr., Vardas E, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol. 2012;19(2):261-7.

155. Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26(3):201-9.

156. Petaja T, Keranen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44(1):33-40.

157. Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657-65.

158. Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135-45.

159. Suijkerbuijk AW, Donken R, Lugner AK, de Wit GA, Meijer CJ, de Melker HE, et al. The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases. Expert Rev Vaccines. 2017;16(4):361-75.

160. Mikamo H, Yamagishi Y, Murata S, Yokokawa R, Han SR, Wakana A, et al. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study. Vaccine. 2019;37(12):1651-8.

161. Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA, et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33(42):5640-6.

162. Pinto LA, Kemp TJ, Torres BN, Isaacs-Soriano K, Ingles D, Abrahamsen M, et al. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. J Infect Dis. 2016;214(8):1276-83.

163. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis. 2010;202(8):1246-53.

164. Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine. 2013;31(48):5745-53.

165. Faust H, Toft L, Sehr P, Muller M, Bonde J, Forslund O, et al. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559-65.

166. Toft L, Storgaard M, Muller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis. 2014;209(8):1165-73.

167. McClymont E, Lee M, Raboud J, Coutlee F, Walmsley S, Lipsky N, et al. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living with HIV. Clin Infect Dis. 2018.

168. Wilkin TJ, Chen H, Cespedes MS, Leon-Cruz JT, Godfrey C, Chiao EY, et al. A randomized, placebo-controlled trial of the quadrivalent HPV vaccine in HIV-infected adults age 27 years or older: AIDS Clinical Trials Group protocol A5298. Clin Infect Dis. 2018.

169. Lin A, Ong KJ, Hobbelen P, King E, Mesher D, Edmunds WJ, et al. Impact and Cost-effectiveness of Selective Human Papillomavirus Vaccination of Men Who Have Sex With Men. Clin Infect Dis. 2017;64(5):580-8.

170. Malmqvist E, Natunen K, Lehtinen M, Helgesson G. Just implementation of human papillomavirus vaccination. J Med Ethics. 2012;38(4):247-9.

171. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30 Suppl 5:F157-67.

172. Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine. 2013;31(37):3863-71.

173. Kim JJ. Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis. 2010;10(12):845-52.

174. Deshmukh AA, Chiao EY, Das P, Cantor SB. Clinical effectiveness and cost-effectiveness of quadrivalent human papillomavirus vaccination in HIV-negative men who have sex with men to prevent recurrent high-grade anal intraepithelial neoplasia. Vaccine. 2014;32(51):6941-7.

175. Zhang L, Regan DG, Ong JJ, Gambhir M, Chow EPF, Zou H, et al. Targeted human papillomavirus vaccination for young men who have sex with men in Australia yields significant population benefits and is cost-effective. Vaccine. 2017;35(37):4923-9.

176. Public Health England. HPV vaccination for Men who have Sex with Men 2018 [Available from: https://www.gov.uk/government/collections/hpv-vaccination-for-men-who-have-sex-with-men-msm-programme.

177. Deshmukh AA, Chhatwal J, Chiao EY, Nyitray AG, Das P, Cantor SB. Long-Term Outcomes of Adding HPV Vaccine to the Anal Intraepithelial Neoplasia Treatment Regimen in HIV-Positive Men Who Have Sex With Men. Clin Infect Dis. 2015;61(10):1527-35.

178. Deshmukh AA, Cantor SB, Fenwick E, Chiao EY, Nyitray AG, Stier EA, et al. Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: The time is now. Vaccine. 2017;35(38):5102-9.

179. Malagon T, Laurie C, Franco EL. Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review. Expert Rev Vaccines. 2018;17(5):395-409.

180. Diaz M, de Sanjose' S, Bosch FX, Bruni L. Present challenges in cervical cancer prevention: Answers from cost-effectiveness analyses. Rep Pract Oncol Radiother. 2018.

181. Lehtinen M, Luostarinen T, Vanska S, Soderlund-Strand A, Eriksson T, Natunen K, et al. Gender-neutral vaccination provides improved control of human papillomavirus types 18/31/33/35 through herd immunity: Results of a community randomized trial (III). Int J Cancer. 2018.

182. Skufca J, Ollgren J, Artama M, Ruokokoski E, Nohynek H, Palmu AA. The association of adverse events with bivalent human papilloma virus vaccination: A nationwide register-based cohort study in Finland. Vaccine. 2018;36(39):5926-33.

183. Scheller NM, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA. 2015;313(1):54-61.

184. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.

185. Drolet M, Boily MC, Van de Velde N, Franco EL, Brisson M. Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness? PLoS One. 2013;8(6):e67072.

186. Brisson M, Laprise JF, Chesson HW, Drolet M, Malagon T, Boily MC, et al. Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States. J Natl Cancer Inst. 2016;108(1).

187. INSPQ. Public health expertise and reference centre Quebec: Institut National de Sante' Publique Quebec; 2018 [cited 2018 16 October 2018]. Available from: https://www.inspq.qc.ca/en/publications/2458.

188. Elfstrom KM, Lazzarato F, Franceschi S, Dillner J, Baussano I. Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs. J Infect Dis. 2016;213(2):199-205.

189. Brotherton JM, Budd A, Rompotis C, Bartlett N, Malloy MJ, Andersen RL, et al. Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. Papillomavirus Res. 2019;8:100177.

190. Gilca V, Sauvageau C, Panicker G, De Serres G, Ouakki M, Unger ER. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Vaccine. 2018.

191. Harder T, Wichmann O, Klug SJ, van der Sande MAB, Wiese-Posselt M. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med. 2018;16(1):110.

192. Saghari S, Ghamsary M, Marie-Mitchell A, Oda K, Morgan JW. Sociodemographic predictors of delayed- versus early-stage cervical cancer in California. Ann Epidemiol. 2015;25(4):250-5.

193. Gauri A, Messiah SE, Bouzoubaa LA, Moore KJ, Koru-Sengul T. Cervical cancer sociodemographic and diagnostic disparities in Florida: a population-based study (1981-2013) by stage at presentation. Ethn Health. 2018:1-9.

194. Akinyemiju T, Ogunsina K, Sakhuja S, Ogbhodo V, Braithwaite D. Life-course socioeconomic status and breast and cervical cancer screening: analysis of the WHO's Study on Global Ageing and Adult Health (SAGE). BMJ Open. 2016;6(11):e012753.

195. Cameron RL, Kavanagh K, Cameron Watt D, Robertson C, Cuschieri K, Ahmed S, et al. The impact of bivalent HPV vaccine on cervical intraepithelial neoplasia by deprivation in Scotland: reducing the gap. J Epidemiol Community Health. 2017;71(10):954-60.

196. Arie S. HPV: WHO calls for countries to suspend vaccination of boys. BMJ. 2019;367:l6765.

197. (WHO); WHO. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2019: conclusions and recommendations. Weekly epidemiological record. 2019;47(94):541-60.

198. Crum-Cianflone NF, Wallace MR. Vaccination in HIV-infected adults. AIDS Patient Care STDS. 2014;28(8):397-410.

199. Coles VA, Patel AS, Allen FL, Keeping ST, Carroll SM. The association of human papillomavirus vaccination with sexual behaviours and human papillomavirus knowledge: a systematic review. Int J STD AIDS. 2015;26(11):777-88.

200. Stanley M, Dull P. HPV single-dose vaccination: Impact potential, evidence base and further evaluation. Vaccine. 2018;36(32 Pt A):4759-60.

201. El-Zein M, Richardson L, Franco EL. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. J Clin Virol. 2016;76 Suppl 1:S62-S8.

202. Simms KT, Hall M, Smith MA, Lew JB, Hughes S, Yuill S, et al. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia. PLoS One. 2017;12(1):e0163509.

203. Castanon A, Landy R, Pesola F, Windridge P, Sasieni P. Prediction of cervical cancer incidence in England, UK, up to 2040, under four scenarios: a modelling study. Lancet Public Health. 2018;3(1):e34-e43.

204. Ronco G, Giorgi Rossi P, Giubilato P, Del Mistro A, Zappa M, Carozzi F, et al. A first survey of HPV-based screening in routine cervical cancer screening in Italy. Epidemiol Prev. 2015;39(3 Suppl 1):77-83.

205. Verhoef VM, Bosgraaf RP, van Kemenade FJ, Rozendaal L, Heideman DA, Hesselink AT, et al. Triage by methylation-marker testing versus cytology in women who test HPV-positive on self-collected cervicovaginal specimens (PROHTECT-3): a randomised controlled non-inferiority trial. Lancet Oncol. 2014;15(3):315-22.

Annex 1. Supporting tables

Table A1. Numbers of cases and rates (per 100 000) of cancer attributable to HPV in 2012 by country

Cervical cancer					Other anogenital	Head and neck
	Annual number new cases	Incidence ASR (W)	Annual number of deaths	Mortality ASR (W)	Incidence ASR (W)	Incidence ASR (W)
Austria	363	5.8	178	2.0	1.19	1.27
Belgium	639	8.6	219	1.9	1.54	1.68
Bulgaria	1 254	24.5	437	7.0	0.97	1.01
Croatia	325	10	140	3.2	1.14	0.84
Cyprus	31	4.1	17	1.5	0.92	0.18
Czech Republic	1 016	14.1	315	3.2	0.99	1.44
Denmark	363	10.6	97	1.9	2.16	1.48
Estonia	186	19.9	80	5.9	1.05	0.86
Finland	143	4.3	53	1.0	1.02	0.65
France	2 862	6.8	1167	1.9	1.76	1.88
Germany	4 995	8.2	1 566	1.7	1.27	1.79
Greece	421	5.2	208	1.8	0.82	0.27
Hungary	1 178	18	461	5.3	0.93	3.04
Iceland	14	7.9	2	0.4	1.49	0.54
Rep. Ireland	357	13.6	101	3.3	1.40	0.9
Italy	2 918	6.7	1 016	1.5	1.07	0.46
Latvia	284	17.3	135	6.3	0.99	0.92
Lithuania	615	26.1	221	7.5	1.08	1.16
Luxembourg	24	4.9	13	2.4	1.29	1.31
Malta	12	3.8	3	0.8	0.98	0.48
Netherlands	750	6.8	242	1.6	1.66	0.95
Norway	294	9.8	101	2.3	1.67	0.8
Poland	3 513	12.2	1 858	5.4	0.72	1.27
Portugal	720	9	390	3.7	0.92	1.02
Romania	4 343	28.6	1 909	10.8	0.77	2.02
Slovakia	607	16.1	232	5.2	0.94	2.08
Slovenia	139	10.5	64	3.0	1.20	0.84
Spain	2 511	7.8	848	2.1	1.00	0.65
Sweden	451	7.4	187	1.9	1.28	0.72
United Kingdom	659	7.1	979	1.8	1.35	0.99

Age-standardised (world) incidence rate (per 100 000) of cancer cases attributable to HPV in 2012 by country in Europe.
GLOBOCAN 2012, IARC -27.6.2018
de Martel C, Int J Cancer. 2017
ASR (W): age-standardised rate (women)

Efficacy of 9vHPV vaccine in females 16–26 years old

Table A2. Evidence type for benefits: 9vHPV vaccination of females 16–26-years

Outcome-related HPV type	Benefits	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
HPV types 6, 11, 16 and 18	6MPI	4vHPV (3RCT) (a)	Not serious	Not serious	Serious*	Not serious	Moderate
	CIN2/3 or worse		Not serious	Not serious	Serious*	Not serious	Moderate
	Cervical cancer		Not serious	Not serious	Very serious*,γ	Not serious	Low
	VIN2/3, VaIN2/3 or worse		Not serious	Not serious	Serious*	Not serious	Moderate
	Vulvar or vaginal cancer		Not serious	Not serious	Very serious*,γ	Not serious	Low
	Anogenital warts		Not serious	Not serious	Serious*	Not serious	Moderate
HPV types 31, 33, 45, 52 and 58	6MPI	9vHPV (1RCT) (b)	Not serious	Not serious	Not serious	Not serious	High
	CIN2/3, VIN2/3, VaIN2/3 or worse		Not serious	Not serious	Not serious	Not serious	High
	CIN2/3 or worse		Not serious	Not serious	Not serious	Not serious	High
	Cervical cancer		Not serious	Not serious	Seriousγ	Not serious	Moderate
	VIN2/3, VaIN2/3 or worse		Not serious	Not serious	Not serious	Very seriousαβ	Low
	Vulvar or vaginal cancer		Not serious	Not serious	Seriousγ	Very seriousαβ	Very low

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
**: Downgraded by 1 for indirectness due to use of immunobridging to 4vHPV vaccine.*
γ: Downgraded by 1 for indirectness due to use of ≥CIN2, ≥VIN2 or ≥VaIN2 as surrogate markers for cervical, vulvar or vaginal cancer.
α: Downgraded by 1 for imprecision due to low event rate.
β: Downgraded by 1 for imprecision due to very wide 95% confidence interval.
a: HPV types 6, 11, 16 and 18 data from protocols 007/NCT00365716 and NCT00365378, 013/NCT00092521, 015/NCT00092534 [4-6] (PICO2 Supp04); supportive data from protocols 001/NCT00543543 [1] (PICO5 and PICO6 Supp05), 002/NCT00943722 [2] (PICO2 and PICO8 Supp05), 003/NCT01651949 [3] (PICO11 Supp05)
b: HPV types 31, 33, 45, 52 and 58 data from protocol 001/NCT00543543 [1] (PICO1 Supp04); supportive data from protocols 002/NCT00943722 [2] (PICO2 and PICO8 Supp05), 003/NCT01651949 [3] (PICO11 Supp05).
Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159; 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39; 3. Castellsagué, et al. Vaccine. 2015;33:6892-901; 4. Kjær SK, et al. Cancer Prev Res. 2009;2:868-78; 5. Dillner J, et al. BMJ. 2010;341:c3493; 6. Villa LL, et al. Lancet Oncol. 2005;6:271-8.2

Table A3. Available data for females 16–26 years old from 9vHPV vaccine trials

Outcomes	HPV 6, 11, 16 and 18-related		HPV 31, 33, 45, 52 and 58-related	
	Direct	Indirect	Direct	Indirect
6MPI	No(a)	Immunogenicity(b)[1-3]	Yes [1]	Immunogenicity [1–3]
CIN2/3, VIN2/3, VaIN2/3 or worse	No(a)	Immunogenicity(b)[1-3]	Yes [1]	Immunogenicity [1–3]
CIN2/3 or worse	No(a)	Immunogenicity(b)[1-3]	Yes [1]	Immunogenicity [1–3]
Cervical cancer	No	Immunogenicity(b)[1-3]	No	≥CIN2, immunogenicity [1–3]
VIN2/3, VaIN2/3 or worse	No(a)	Immunogenicity(b)[1-3]	Yes [1]	Immunogenicity [1–3]
Anogenital warts	No(a)	Immunogenicity(b)[1-3]	--	--

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
a: 9vHPV vaccine clinical used 4vHPV vacine as a comparator. This trial did not have enough power to assess vaccine efficacy for clinical endpoints related to HPV types 6, 11, 16 and 18.
b: Immunogenicity of 9vHPV compared with 4vHPV vaccine was used to infer efficacy.
Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159; 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39; 3. Castellsagué X, et al. Vaccine. 2015;33:6892-901.

Table A4. 4vHPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in females 16–26 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy
007/NCT00365716 and NCT00365378, 013/NCT00092521, 015/NCT00092534 [4-6]	4vHPV in females 16–26 years (per protocol population)	Placebo in females 16–26 years old	551	6MPI	89.0% (70.0–97.0) – PICO2 Supp04
			15 729	CIN2/3 or worse	98.2% (93.3–99.8) – PICO2 Supp04
			15 802	VIN2/3, VaIN2/3 or worse	100.0% (82.6–100.0) – PICO2 Supp04
			15 334	Anogenital warts	98.9% (96.1–99.9) – PICO2 Supp04

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; vVaIN: vaginal intraepithelial neoplasia.
Sources: 4. Villa LL, et al. Lancet Oncol. 2005;6:271-8; 5. Kjær SK, et al. Cancer Prev Res. 2009;2:868-78; 6 .Dillner J, et al. BMJ. 2010;341:c3493.

Table A5. 9vHPV vaccine trials used for HPV 31, 33, 45, 52 and 58-related outcomes in females 16–26 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy
001/NCT00543543 [1]	9vHPV in females 16–26 years old (per protocol population)	4vHPV in females 16–26 years old	11 896	6MPI	96.0% (94.6–97.1) – PICO1 Supp04
			12 033	CIN2/3, VIN2/3, VaIN2/3 or worse	97.4% (85.0–99.9) – PICO1 Supp04
			11 892	CIN2/3 or worse	97.1% (83.5–99.9) – PICO1 Supp04
			12 021	VIN2/3, VaIN2/3 or worse	100.0% (–71.5–100.0) – PICO1 Supp04
			14 215	Seroconversion and geometric mean titres (by HPV)	PICO5, PICO6 Supp05
002/NCT00943722 [2]	9vHPV in females and males 9–15 years old (per protocol population)	9vHPV in females 16–26 years old (immunobridging)	3 074	Seroconversion and geometric mean titres (by HPV)	PICO2, PICO8 Supp05
003/NCT01651949 [3]	9vHPV in females 16–26 years old (per protocol population)	9vHPV in males 16–26 years old (immunobridging)	2 520	Seroconversion and geometric mean titres (by HPV)	PICO11 Supp05

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159; 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39; 3. Castellsagué X, et al. Vaccine. 2015;33:6892-901.

Efficacy of 9vHPV vaccine in females 9–15 years old

Table A6. Evidence type for benefits: 9vHPV vaccination of females 9–15 years old

Outcome-related HPV type	Benefits	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
HPV types 6, 11, 16, 18	6MPI	4vHPV (3RCT)(a)	Not serious	Not serious	Very serious[*¥]	Not serious	Low
	CIN2/3 or worse		Not serious	Not serious	Very serious[*¥]	Not serious	Low
	Cervical cancer		Not serious	Not serious	Very serious[*γ¥]	Not serious	Low
	VIN2/3, VaIN2/3 or worse		Not serious	Not serious	Very serious[*¥]	Not serious	Low
	Vulvar or vaginal cancer		Not serious	Not serious	Very serious[*γ¥]	Not serious	Low
	Anogenital warts		Not serious	Not serious	Very serious[*¥]	Not serious	Low
HPV types 31, 33, 45, 52 and 58	6MPI	9vHPV (1RCT)(b)	Not serious	Not serious	Serious[¥]	Not serious	Moderate
	CIN2/3, VIN2/3, VaIN2/3 or worse		Not serious	Not serious	Serious[¥]	Not serious	Moderate
	CIN2/3 or worse		Not serious	Not serious	Serious[¥]	Not serious	Moderate
	Cervical cancer		Not serious	Not serious	Very serious[γ¥]	Not serious	Low
	VIN2/3, VaIN2/3 or worse		Not serious	Not serious	Serious[¥]	Very serious[αβ]	Very low
	Vulvar or vaginal cancer		Not serious	Not serious	Very serious[γ¥]	Very serious[αβ]	Very low

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia
[*]: Downgraded by 1 for indirectness due to use of immunobridging to 4vHPV vaccine.
[¥]: Downgraded by 1 for indirectness due to use of immunobridging to females 16–26 years old.
[γ]: Downgraded by 1 for indirectness due to use of ≥CIN2, ≥VIN2 or ≥VaIN2 as surrogate markers for cervical, vulvar or vaginal cancer.
[α]: Downgraded by 1 for imprecision due to low event rate.
[β]: Downgraded by 1 for imprecision due to very wide 95% confidence interval.
a:HPV types 6, 11, 16, 18 data from protocol 007/NCT00365716 and NCT00365378, 013/NCT00092521, 015/NCT00092534 [5–7] (PICO2 Supp04); supportive data from protocols 001/NCT00543543 [1] (PICO5 and PICO6 Supp05), 002/NCT00943722 [2] (PICO2 and PICO8 Supp05), 009/NCT01304498 [3] (PICO1 Supp05), 010/NCT01984697 [4] (PICO3 Supp05)
b: HPV31, 33, 45, 52 and 58 data from protocol 001/NCT00543543 [1] (PICO1 Supp04); supportive data from protocols 002/NCT00943722 [2] (PICO2 and PICO8 Supp05), 009/NCT01304498 [3] (PICO1 Supp05), 010/NCT01984697 [4] (PICO3 Supp05). Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159; 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39; 3. Vesikari T, et al. Pediatr Infect Dis J. 2015;34:992-8; 4. Iversen OE, et al. JAMA. 2016;316:2411-2421; 5. Kjær SK, et al. Cancer Prev Res. 2009;2:868-78; 6. Dillner J, et al. BMJ. 2010;341:c3493; 7. Villa LL, et al. Lancet Oncol. 2005;6:271-8.2.

Table A7. Available data for females 9–15 years old from 9vHPV vaccine trials

Outcomes	HPV 6, 11, 16 and 18-related		HPV 31, 33, 45, 52 and 58-related	
	Direct	Indirect	Direct	Indirect
6MPI	No	Immunogenicity(a)[2-4]	No	Immunogenicity [2-4]
CIN2/3 or worse	No	Immunogenicity(a)[2-4]	No	Immunogenicity [2-4]
Cervical cancer	No	Immunogenicity(a)[2-4]	No	≥CIN2, immunogenicity [2-4]
VIN2/3, VaIN2/3 or worse	No	Immunogenicity(a)[2-4]	No	Immunogenicity [2-4]
Anogenital warts	No	Immunogenicity(a)[2-4]	--	--

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
a: Immunogenicity of two clinical trials comparing 3 doses of the 9vHPV vaccine in females aged 9–15 years old with females aged 16–26 years and comparing 3 doses 9vHPV with 4vHPV vaccine in females aged 9–15 years old was used to infer efficacy. Sources: 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39; 3. Vesikari T et al. Pediatr Infect Dis J. 2015;34:992-8; 4. Iversen OE, et al. JAMA. 2016;316:2411-2421.

Table A8. 4vHPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in females 9–15 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy
007/NCT00365716 and NCT00365378, 013/NCT00092521, 015/NCT00092534 [5-7]	4vHPV in females 16–26 years old (per protocol population)	Placebo in females 16– 26 years old	551	6MPI	89.0% (70.0-97.0) – PICO2 Supp04
			15 729	CIN2/3 or worse	98.2% (93.3-99.8) – PICO2 Supp04
			15 802	VIN2/3, VaIN2/3 or worse	100.0% (82.6-100.0) – PICO2 Supp04
			15 334	Anogenital warts	98.9% (96.1–99.9) – PICO2 Supp04

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
Sources: 5. Villa LL, et al. Lancet Oncol. 2005;6:271-8; 6 Kjær SK, et al. Cancer Prev Res 2009;2:868-78; 7 Dillner J, et al. BMJ. 2010;341:c3493.

Table A9. 9vHPV vaccine trials used for HPV 31, 33, 45, 52 and 58-related outcomes in females 9–15 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy
001/NCT00543543 [1]	9vHPV in females 16–26 years old (per protocol population)	4vHPV in females 16–26 years old	11 896	6MPI	96.0% (94.6-97.1) - PICO1 Supp04
			12 033	CIN2/3, VIN2/3, VaIN2/3 or worse	97.4% (85.0-99.9) - PICO1 Supp04
			11 892	CIN2/3 or worse	97.1% (83.5-99.9) - PICO1 Supp04
			12 021	VIN2/3, VaIN2/3 or worse	100.0% (–71.5-100.0) - PICO1 Supp04
			14 215	Seroconversion and geometric mean titres (by HPV)	PICO5, PICO6 Supp05
002/NCT00943722 [2]	9vHPV in females 9–15 years old (per protocol population)	9vHPV in females 16–26 years old (immunobridging)	2 405	Seroconversion and geometric mean titres (by HPV)	PICO2, Supp05
009/NCT01304498 [3]	9vHPV in females 9–15 years old (per protocol population)	4vHPV in females 9–15 years old (immunobridging)	600	Seroconversion and geometric mean titres (by HPV)	PICO1 Supp05
010/NCT01984697 [4]	9vHPV (2 doses) in females 9–14 years old (per protocol population)	9vHPV (3 doses) in females 16–26 years old (immunobridging)	554	Seroconversion and geometric mean titres (by HPV)	PICO3 Supp05

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159; 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39; 3. Vesikari T et al. Pediatr Infect Dis J. 2015;34:992-8; 4. Iversen OE, et al. JAMA. 2016;316:2411-2421.

Efficacy of 9vHPV vaccine in males 16–26 years old

Table A10. Evidence type for benefits: 9vHPV vaccination of males 16–26 years old

Outcome-related HPV type	Benefits	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
HPV types 6, 11, 16 and 18	6MPI	4vHPV (1RCT) (a)	Not serious	Not serious	Serious*	Not serious	Moderate
	AIN2/3		Not serious	Not serious	Serious*	Not serious	Moderate
	Anal cancer		Not serious	Not serious	Very serious*γ	Very seriousαβ	Very low
	PeIN2/3		Not serious	Not serious	Serious*	Very seriousαβ	Very low
	Penile cancer		Not serious	Not serious	Very serious*γ	Very seriousαβ	Very low
	Anogenital warts		Not serious	Not serious	Serious*	Not serious	Moderate
HPV types 31, 33, 45, 52 and 58	6MPI	9vHPV (1RCT) (b)	These outcomes are not assessable by GRADE methodology due to the lack of clinical efficacy data in males. Efficacy study in males would require a comparison between the investigational 9vHPV vaccine and the licensed 4vHPV vaccine (using a placebo would not be acceptable since the 4vHPV vaccine prevents anal lesions due to HPV types 16 and 18). Consequently, low incidence of HPV 6, 11, 16 and 18-associated disease would be expected with both vaccines, and the study would require a prohibitively large sample size. As an alternative approach, two immunobridging studies were used to infer efficacy of 9vHPV vaccine in men 16–26 years. These studies evaluate the immunogenicity of the 9vHPV vaccine in males 16–26 years old compared to either 4vHPV or 9vHPV vaccine in females 16–26 years old (the population used to establish 9vHPV vaccine efficacy).				
	AIN2/3						
	Anal cancer						
	PeIN2/3						
	Penile cancer						

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
**: Downgraded by 1 for indirectness due to use of immunobridging to 4vHPV vaccine.*
γ: Downgraded by 1 for indirectness due to use of AIN2/3 or PeIN2/3 as surrogate markers for anal cancer or penile cancer.
α: Downgraded by 1 for imprecision due to low event rate.
β: Downgraded by 1 for imprecision due to very wide 95% confidence interval.
a: HPV types 6, 11, 16, 18 data from protocol 020/NCT00090285 [4–6] (PICO1, PICO2 Supp01); supportive data from protocols 003/NCT01651949 [2] (PICO11 Supp05), 020/NCT02114385 [3] (PICO10 Supp05)
b: HPV types 31, 33, 45, 52 and 58 data from protocol 001/NCT00543543 [1] (PICO1 Supp04); supportive data from protocols 003/NCT01651949 [2] (PICO11 Supp05), 020/NCT02114385 [3] (PICO10 Supp05).
Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159; 2. Castellsagué, et al. Vaccine. 2015;33:6892-901; 3. Van Damme P, et al. Vaccine. 2016;34:4205-4212; 4. Palefsky J, et al. N Engl J Med 2011;365:1576-85; 5. Giuliano AR, et al. N Engl J Med. 2011;364:401-11; 6. Goldstone SE, et al. Vaccine. 2013;31:3849-55.

Table A11. Available data for males 16–26 years old from 9vHPV vaccine trials

Outcomes	HPV 6, 11, 16 and 18-related		HPV 31, 33, 45, 52 and 58-related	
	Direct	Indirect	Direct	Indirect
6MPI	No	Immunogenicity(b) [2,3]	No	Immunogenicity [2,3]
AIN2/3	No	Immunogenicity(b) [2,3]	No	Immunogenicity [2,3]
Anal cancer	No	Immunogenicity(b) [2,3]	No	Immunogenicity [2,3]
PeIN2/3	No	Immunogenicity(b) [2,3]	No	Immunogenicity [2,3]
Penile cancer	No	Immunogenicity(b) [2,3]	No	Immunogenicity [2,3]
Anogenital warts	No	Immunogenicity(b) [2,3]	--	--

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
a: Immunogenicity from the pivotal clinical trial (in females 16– 26 years old) and from two immunobridging clinical trials (comparing 3 doses of the 9vHPV vaccine in heterosexual males aged 16–26 years old with females aged 16–26 years and comparing 3 doses 9vHPV with 4vHPV vaccine in males aged 16–26 years) were used to infer efficacy.
Sources: 2. Castellsagué X, et al. Vaccine. 2015;33:6892-901; 3. Van Damme P, et al. Vaccine. 2016;34:4205-4212.

Table A12. 4vHPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in males 16–26 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy
020/NCT00090285 [4-6]	4vHPV in males 16–26 years (per protocol population)	Placebo in males 16–26 years	2 790	6MPI	85.6% (73.4–92.9) – PICO1 Supp01
			402	AIN2/3*	74.9% (8.8–95.4) – PICO2 Supp01
			402	Anal cancer	--
			2 805	PeIN2/3	100.0% (−3788.2–100.0) – Supp01
			2 805	Penile cancer	--
			2 805	Anogenital warts	89.4% (65.5–97.9) – PICO1 Supp01

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
** population: men who have sex with men (MSM)*
Sources: 4 Palefsky J, et al. N Engl J Med 2011;365:1576-85; 5 Giuliano AR, et al. N Engl J Med. 2011;364:401-11; 6 Goldstone SE, et al. Vaccine. 2013;31:3849-55.

Table A13. 9vHPV vaccine trials used for HPV 31, 33, 45, 52 and 58-related outcomes in males 16–26 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy
001/NCT00543543 [1]	9vHPV in females 16–26 years old (per protocol population)	4vHPV in females 16–26 years old	14 215	Efficacy outcomes	PICO1 Supp04
				Seroconversion and geometric mean titres (by HPV)	PICO5, PICO6 Supp05
003/NCT01651949 [2]	9vHPV in heterosexual males 16–26 years old (per protocol population)	9vHPV in females 16–26 years old (immunobridging)	2 520	Seroconversion and geometric mean titres (by HPV)	PICO11 Supp05
020/NCT02114385 [3]	9vHPV in males 16–26 years old (per protocol population)	4vHPV in males 16–26 years old (immunobridging)	500	Seroconversion and geometric mean titres (by HPV)	PICO10 Supp05

HPV: human papillomavirus.
Sources: 1 Huh WK, et al. Lancet. 2017;390:2143-2159; 2. Castellsagué X, et al. Vaccine. 2015;33:6892-901; 3 Van Damme P, et al. Vaccine. 2016;34:4205-4212.

Efficacy of 9vHPV vaccine in males 9–15 years old

Table A14. Evidence type for benefits: 9vHPV vaccination of males 9– 15years old

Outcome -related HPV type	Benefits	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
HPV6, 11, 16 and 18	4vHPV (1RCT)(a)		Not serious	Not serious	Very serious*¥	Not serious	Low
	AIN2/3		Not serious	Not serious	Very serious*¥	Not serious	Low
	Anal cancer		Not serious	Not serious	Very serious*γ¥	Very seriousαβ	Very low
	PeIN2/3		Not serious	Not serious	Very serious*¥	Very seriousαβ	Very low
	Penile cancer		Not serious	Not serious	Very serious*γ¥	Very seriousαβ	Very low
	Anogenital warts		Not serious	Not serious	Very serious*¥	Not serious	Low
HPV31, 33, 45, 52 and 58	6MPI	9vHPV (1RCT) (b)	Outcomes not assessable by GRADE methodology due to lack of clinical efficacy data in males. Efficacy study in males would require comparison between investigational 9vHPV vaccine and licensed 4vHPV vaccine (using a placebo would not be acceptable since 4vHPV vaccine prevents anal lesions due to HPV types 16 and 18). Consequently, low incidence of HPV types 6, 11, 16 and 18-associated disease would be expected with both vaccines and the study would require a prohibitively large sample size. Two immunobridging studies used to infer efficacy of 9vHPV vaccine in men 9–15 years old. Studies evaluate immunogenicity of 3 doses or 2 doses of 9vHPV vaccine compared 9vHPV vaccine in females 16–26 years old (population used to establish 9vHPV vaccine efficacy).				
	AIN2/3						
	Anal cancer						
	PeIN2/3						
	Penile cancer						

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
**: Downgraded by 1 for indirectness due to use of immunobridging to 4vHPV vaccine.*
¥: Downgraded by 1 for indirectness due to use of immunobridging to males 16–26-year old.
γ: Downgraded by 1 for indirectness due to use of AIN2/3 or PeIN2/3 as surrogate markers for anal cancer or penile cancer.
α: Downgraded by 1 for imprecision due to low event rate.
β: Downgraded by 1 for imprecision due to very wide 95% confidence interval.
a: HPV types 6, 11, 16, 18 data from protocol 020/NCT00365716 [4-6] (PICO1, PICO2 Supp01); supportive data from protocols 002//NCT00943722 [2] (PICO 8 Supp05), 010/NCT01984697 [3] (PICO9 Supp05)
b: HPV 31, 33, 45, 52 and 58 data from protocol 001/NCT00543543 [1] (PICO1 Supp04); supportive data from protocols 002//NCT00943722 (PICO 8 Supp05) [2], 010/NCT01984697 [3] (PICO9 Supp05).
Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159; 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39; 3. Iversen OE, et al. JAMA. 2016;316:2411-2421; 4. Palefsky J, et al. N Engl J Med 2011;365:1576-85; 5. Giuliano AR, et al. N Engl J Med. 2011;364:401-11; 6. Goldstone SE, et al. Vaccine. 2013;31:3849-55.

Table A15. Available data for males 9 to 15 years old from the 9vHPV vaccine trials

Outcomes	HPV 6, 11, 16 and 18-related		HPV 31, 33, 45, 52 and 58-related	
	Direct	Indirect	Direct	Indirect
6MPI	No	Immunogenicity(b)[2-3]	No	Immunogenicity [2-3]
AIN2/3	No	Immunogenicity(b)[2-3]	No	Immunogenicity [2-3]
Anal cancer	No	Immunogenicity(b)[2-3]	No	Immunogenicity [2-3]
PeIN2/3	No	Immunogenicity(b)[2-3]	No	Immunogenicity [2-3]
Penile cancer	No	Immunogenicity(b)[2-3]	No	Immunogenicity [2-3]
Anogenital warts	No	Immunogenicity(b)[2-3]	--	--

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
a: Immunogenicity from the pivotal clinical trial (in females 16–26 years old) and from two immunobridging clinical trials (comparing 3 doses of the 9vHPV vaccine in heterosexual males aged 16–26 years old with females aged 16–26 years and comparing 3 doses 9vHPV with 4vHPV vaccine in males aged 16–26 years old) were used to infer efficacy.
Sources: 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39; 3. Iversen OE, et al. JAMA. 2016;316:2411-2421.

Table A16. 4vHPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in males 9–15 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy
020/NCT00365716 [4–6]	46vHPV in males 16–26 years old (per protocol population)	Placebo in males 16–26 years old	2 790	6MPI	85.6% (73.4–92.9) – PICO1 Supp01
			402	AIN2/3*	74.9% (8.8–95.4) – PICO2 Supp01
			402	Anal cancer	--
			2 805	PeIN2/3	100.0% (-3 788.2–100.0) – PICO1 Supp01
			2 805	Penile cancer	--
			2 805	Anogenital warts	89.4% (65.5–97.9) – PICO1 Supp01

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
** population: men who have sex with men (MSM).*
Sources: 4 Palefsky J, et al. N Engl J Med 2011;365:1576-85; 5 Giuliano AR, et al. N Engl J Med. 2011;364:401-11; 6 Goldstone SE, et al. Vaccine. 2013;31:3849-55.

Table A17. 9vHPV vaccine trials used for HPV 31, 33, 45, 52 and 58-related outcomes in males 9–15 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy
001/NCT00543543 [1]	9vHPV in females 16–26 years old (per protocol population)	4vHPV in females 16–26 years old	14 215	Efficacy outcomes	PICO1 Supp04
				Seroconversion and geometric mean titres (by HPV)	PICO5, PICO6 Supp05
002/NCT00943722 [2]	9vHPV in males 9–15 years old (per protocol population)	9vHPV in females 16–26 years old (immunobridging)	2 405	Seroconversion and geometric mean titres (by HPV)	PICO8, Supp05
010/NCT01984697 [3]	9vHPV (2 doses) in males 9–14 years old (per protocol population)	9vHPV (3 doses) in females 16–26 years old	554	Seroconversion and geometric mean titres (by HPV)	PICO9 Supp05

HPV: human papillomavirus.
Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159. 2. Van Damme P, et al. Pediatrics. 2015;136:e28-39. 3. Iversen OE, et al. JAMA. 2016;316:2411-2421.

Safety of 9vHPV vaccine in females

Table A18. Evidence type for harms: 9vHPV vaccination of females

Harms	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
Any adverse events	2RCT (a)	Not serious	Not serious	Not serious	Not serious	High
Injection site events (day 1 to 15)[α]		Not serious	Not serious	Not serious	Not serious	High
Systemic adverse events (day 1 to 15)[β]		Not serious	Not serious	Not serious	Not serious	High
Serious adverse events any time[δ]		Not serious	Not serious	Not serious	Not serious	High
Discontinuation due to adverse events		Not serious	Not serious	Not serious	Not serious	High

HPV: human papillomavirus; RCT: randomised clinical trial.
Analysis in participants who received at least 1 study vaccine dose and for whom safety follow-up data were available.
Outcomes are recorded regardless of causality.
[α]: Injection site adverse events include pain, swelling, erythema and pruritus.
[β]: Systemic events are defined as all events that are not correlated to the injection site and are not serious (they include principally headache, pyrexia and dizziness).
[δ]: Serious events were defined as side effects that results in death, life-threatening, or requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity or in congenital anomaly/birth defect.
a: data from protocols 001/NCT00543543 [1] (PICO5 Supp06) and 009/NCT01304498 [2] (PICO1 Supp06); supportive data from protocols 002/NCT00943722 [3] (PICO2-Supp06), 010/NCT01984697 [4] (PICO3 Supp06) and 006/NCT01047345 [5] (PICO6 Supp06).
Sources: 1 Huh WK, et al. Lancet. 2017;390:2143-2159. 2 Van Damme P, et al. Vaccine. 2016;34:4205-4212. 3 Van Damme P, et al. Pediatrics. 2015;136:e28-39. 4 Iversen OE, et al. JAMA. 2016;316:2411-2421. 5 Garland SM, et al. Vaccine. 2015;33:6855-64.

Table A19. Available harm data for females from 9vHPV vaccine trials

Harms	Females 16–26 years old			Females 9–15 years old		
	Protocol (design)	Incidence in 9vHPV % (n/N)	Incidence in 4vHPV % (n/N)	Protocol (design)	Incidence in 9vHPV % (n/N)	Incidence in 4vHPV % (n/N)
Any adverse events	001/NCT00543543 (1RCT) (a)	6 660/7 071 (94.2%)	6 448/7 078 (91.1%)	009/NCT01304498 (1RCT)(b)	287/299 (96.0%)	281/300 (93.7%)
Injection site events (days 1–15)[α]		6 416/7 071 (90.7%)	6 012/7 078 (84.9%)		274/299 (91.6%)	265/300 (88.3%)
Systemic adverse events (days 1–15)[β]		3 948/7 071 (55.8%)	3 883/7 078 (54.9%)		142/299 (47.5%)	156/300 (52.0%)
Serious adverse events any time[δ]		233/7 071 (3.3%)	184/7 078 (2.6%)		1/299 (0.3%)	2/300 (0.7%)
Discontinuation due to adverse events		<8/7 071 (0.1%)	4/7 078 (0.1%)		1/299 (0.3%)	1/300 (0.3%)

HPV: human papillomavirus; RCT: randomised clinical trial
Analysis in participants who received at least 1 study vaccine dose and for whom safety follow-up data were available.
Outcomes are recorded regardless of causality.
[α]: Injection site adverse events include pain, swelling, erythema and pruritus.
[β]: Systemic events are defined as all events that are not correlated to the injection site and are not serious (they include principally headache, pyrexia and dizziness).
[δ]: Serious events were defined as side effects that results in death, life-threatening, or requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or in congenital anomaly/birth defect.
a: data from protocol 001/NCT00543543 [1] (PICO5 Supp06); supportive data from protocols 002/NCT00943722 [3] (PICO2-Supp06), 010/NCT01984697 [4] (PICO3 Supp06) and 006/NCT01047345 [5] (PICO6 Supp06).
b: data from protocol 009/NCT01304498 [2] (PICO1 Supp06); supportive data from protocols 002/NCT00943722 [3] (PICO2-Supp06) and 010/NCT01984697 [4] (PICO3 Supp06).
Sources: 1. Huh WK, et al. Lancet. 2017;390:2143-2159. 2. Van Damme P, et al. Vaccine. 2016;34:4205-4212. 3. Van Damme P, et al. Pediatrics. 2015;136:e28-39. 4. Iversen OE, et al. JAMA. 2016;316:2411-2421. 5. Garland SM, et al. Vaccine. 2015;33:6855-64.

Safety of 9vHPV vaccine in males

Table A20. Evidence type for harms: 9vHPV vaccination of males

Harms	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
Any adverse events	1RCT (a)	Not serious	Not serious	Not serious	Not serious	High
Injection site events (days 1–15)[α]		Not serious	Not serious	Not serious	Not serious	High
Systemic adverse events (days 1–15)[β]		Not serious	Not serious	Not serious	Not serious	High
Serious adverse events any time[δ]		Not serious	Not serious	Not serious	Not serious	High
Discontinuation due to adverse events		Not serious	Not serious	Not serious	Serious[*]	Moderate

HPV: human papillomavirus; RCT: randomised clinical trial
Analysis in participants who received at least 1 study vaccine dose and for whom safety follow-up data were available. Outcomes are recorded regardless of causality.
[α]: Injection site adverse events include pain, swelling, erythema and pruritus.
[β]: Systemic events are defined as all events that are not correlated to the injection site and are not serious (they include principally headache, pyrexia and dizziness).
[δ]: Serious events were defined as side effects that results in death, life-threatening, or requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or in congenital anomaly/birth defect.
[*]: Downgraded by 1 for imprecision due to wide 95% confidence interval
a: data from protocol 020/NCT02114385 [1] (PICO9 Supp06); supportive data from protocol 003/NCT01651949 [2] (PICO10-Supp06), 002/NCT00943722 [3] (PICO7-Supp06), 010/NCT01984697 [4] (PICO8 Supp06).
Sources: 1. Van Damme P, et al. Vaccine. 2016;34:4205-4212. 2. Castellsagué, et al. Vaccine. 2015;33:6892-901. 3. Van Damme P, et al. Pediatrics. 2015;136:e28-39. 4. Iversen OE, et al. JAMA. 2016;316:2411-2421.

Table A21. Available harm data for males from 9vHPV vaccine trials

Harms	Males 16–26 years old			Males 9–15 years old		
	Protocol (design)	Incidence in 9vHPV % (n/N)	Incidence in 4vHPV % (n/N)	Protocol (design)	Incidence in 9vHPV % (n/N)	Incidence in 4vHPV % (n/N)
Any adverse events	020/NCT02114385 (1RCT) (a)	204/248 (82.3%)	203/248 (81.9%)	002/NCT00943722 and 010/NCT01984697 (2 Not RCT) (b)	584/958 (61.0%)	--
Injection site events (days 1–15)[α]		196/248 (79.0%)	179/248 (72.2%)		506/958 (52.8%)	--
Systemic adverse events (days 1–15)[β]		101/248 (40.7%)	100/248 (40.3%		289/958 (30.2%)	--
Serious adverse events any time[δ]		0/248 (0.0%)	6/248 (2.4%)		16/958 (1.6%)	--
Discontinuation due to adverse events		0/248 (0.0%)	0/248 (0.0%)		0/958 (0.0%)	--

HPV: human papillomavirus; RCT: randomised clinical trial
Analysis in participants who received at least 1 study vaccine dose and for whom safety follow-up data were available. Outcomes are recorded regardless of causality.
[α]: Injection site adverse events include pain, swelling, erythema and pruritus.
[β]: Systemic events are defined as all events that are not correlated to the injection site and are not serious (they include principally headache, pyrexia and dizziness).
[δ]: Serious events were defined as side effects that results in death, life-threatening, or requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity, or in congenital anomaly/birth defect.
a: data from protocol 020/NCT02114385 [1] (PICO9 Supp06); supportive data from protocol 003/NCT01651949 [2] (PICO10-Supp06)
b: data from protocols 002/NCT00943722 [3] (PICO7-Supp06), 010/NCT01984697 [4] (PICO8 Supp06).
Sources: 1. Van Damme P, et al. Vaccine. 2016;34:4205-4212. 2. Castellsagué, et al. Vaccine. 2015;33:6892-901. 3. Van Damme P, et al. Pediatrics. 2015;136:e28-39. 4. Iversen OE, et al. JAMA. 2016;316:2411-2421.

Efficacy of HPV vaccines in males 16–26 years old

Table A22. Evidence type for benefits: HPV vaccines in males 16–26 years old

Outcome-related HPV type	Benefits	Design	Risk of bias	Inconsistency	Indirectness*	Imprecision	Evidence type (GRADE) 4vHPV vaccine (a)	Evidence type (GRADE) 9vHPV vaccine* (b)
HPV types 6, 11, 16 and 18	6MPI	4vHPV (1RCT) (a)	Not serious	Not serious	Not serious	Not serious	High	Moderate
	AIN2/3		Not serious	Not serious	Not serious	Not serious	High	Moderate
	Anal cancer		Not serious	Not serious	Serious[γ]	Very serious[αβ]	Low	Very low
	PeIN2/3		Not serious	Not serious	Not serious	Very serious[αβ]	Low	Very low
	Penile cancer		Not serious	Not serious	Serious[γ]	Very serious[αβ]	Low	Very low
	Anogenital warts		Not serious	Not serious	Not serious	Not serious	High	Moderate

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
γ: Downgraded by 1 for indirectness due to use of AIN2/3 or PeIN2/3 as surrogate marker for anal cancer or penile cancer.
α: Downgraded by 1 for imprecision due to low event rate.
β: Downgraded by 1 for imprecision due to very wide 95% confidence interval.
**: Evidence quality for efficacy of the 9vHPV vaccine downgraded 1 level due use of immunobridging studies to extrapolate efficacy (indirectness for the 9vHPV vaccine changes from 'Not serious' to 'Serious' and from 'Serious' to 'Very serious').*
a: HPV types 6, 11, 16, 18 data from protocol 020/NCT00090285 [1-3] (PICO1, PICO2 Supp01); supportive data from protocols 020/NCT00090285 [4] (PICO14,PICO15 Supp02)
b: HPV types 6, 11, 16, 18 data from protocol 020/NCT00090285 [1-3] (PICO1, PICO2 Supp01); supportive data from protocols 020/NCT02114385 [5] (PICO3 Supp02), 003/NCT01651949 [6] (PICO4,PICO12,PICO13 Supp02), 001/NCT00543543 [7] (PICO1 Supp04).
Sources: 1. Palefsky J, et al. N Engl J Med 2011;365:1576-85. 2. Giuliano AR, et al. N Engl J Med. 2011;364:401-11. 3.Goldstone SE, et al. Vaccine. 2013;31:3849-55. 4. Hillman RJ, et al. Clin Vaccine Immunol. 2012;19:261-7. 5. Van Damme P, et al. Vaccine. 2016;34:4205-4212. 6. Castellsagué, et al. Vaccine. 2015;33:6892-901. 7. Huh WK, et al. Lancet. 2017;390:2143-2159.

Table A23. Available data for males 16–26 years old from HPV vaccine trials

Outcomes	HPV 6, 11, 16 and 18-related	
	Direct	Indirect
6MPI	Yes (a) [2–3]	Immunogenicity (b) [4–6]
AIN2/3	Yes (a) [1]	Immunogenicity (b) [4–6]
Anal cancer	No	Immunogenicity (b) [4–6]
PeIN2/3	Yes (a) [2–3]	Immunogenicity (b) [4–6]
Penile cancer	No	Immunogenicity (b) [4–6]
Anogenital warts	Yes (a) [1–3]	Immunogenicity (b) [4-6]

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: snal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
a: Efficacy from 4vHPV vaccine trials in males 16–26 years.
b: Immunogenicity from two immunobridging clinical trials with 9vHPV vaccine (comparing the 9vHPV vaccine in heterosexual males 16–26 years old with females 16–26 years and comparing 9vHPV vaccine with 4vHPV vaccine in malesaged 16–26 years) and from clinical trials with the 4vHPV vaccine (comparing 4vHPV in 16–26-year-old men who have sex with men with heterosexual males 16–23 years old) were used to infer efficacy.
Sources: 1. Palefsky J, et al. N Engl J Med 2011;365:1576-85. 2. Giuliano AR, et al. N Engl J Med. 2011;364:401-11. 3. Goldstone SE, et al. Vaccine. 2013;31:3849-55. 4. Hillman RJ, et al. Clin Vaccine Immunol. 2012;19:261-7. 5. Van Damme P, et al. Vaccine. 2016;34:4205-4212. 6. Castellsagué X, et al. Vaccine. 2015;33:6892-901.

Table A24. HPV vaccine trials used for HPV vaccine-related outcomes in males 16–26 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy	Comments
020/NCT00090285 [1-4]	4vHPV in males 16–26 years old (per protocol population)	Placebo in males 16–26 years old	2 790	6MPI	85.6% (73.4-92.9) – PICO1 Supp01	
			402	AIN2/3	74.9% (8.8-95.4) – PICO2 Supp01	Efficacy in MSM
			402	Anal cancer	--	
			2 805	PeIN2/3	100.0% (-3 788.2-100.0) – PICO1 Supp01	
			2 805	Penile cancer	--	
			2 805	Anogenital warts	89.4% (65.5-97.9) – PICO1 Supp01	Efficacy in subgroup 402 MSM (100.0% (8.2-100)) - PICO2 Supp01
	4vHPV in MSM heterosexual males 16–26 yearsold (per protocol population)	4-valent in heterosexual males 16–23 years old	4 065	Seroconversion and geometric mean titres (by HPV)	PICO14, PICO15 Supp02	
020/NCT02114385 [5]	9vHPV in males 16–26 years old (per protocol population)	4vHPV in males 16–26 years old (immunobridging)	500	Seroconversion and geometric mean titres (by HPV)	PICO3 Supp02	
003/NCT01651949 [6]	9vHPV in heterosexual males 16–26 years old (per protocol population)	9vHPV in females 16–26 years old (immunobridging)	2207	Seroconversion and geometric mean titres (by HPV)	PICO4 Supp02	
	9vHPV in MSM 16–26 years (per protocol population)	9vHPV in females/males 16–26 years old (immunobridging)	2520	Seroconversion and geometric mean titres (by HPV)	PICO12, PICO13 Supp02	
001/NCT00543543 [7]	9vHPV in females 16–26 years old (per protocol population)	4vHPV in females 16–26 years old	14215	Efficacy outcomes	PICO1 Supp04	

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia; MSM: men who have sex with men.
Sources: 1. Palefsky J, et al. N Engl J Med 2011;365:1576-85. 2. Giuliano AR, et al. N Engl J Med. 2011;364:401-11. 3. Goldstone SE, et al. Vaccine. 2013;31:3849-55. 4. Hillman RJ, et al. Clin Vaccine Immunol. 2012;19:261-7. 5. Van Damme P, et al. Vaccine. 2016;34:4205-4212. 6. Castellsagué X, et al. Vaccine. 2015;33:6892-901. 7. Huh WK, et al. Lancet. 2017;390:2143-2159.

Efficacy of HPV vaccines in males 9–15 years old

Table A25. Evidence type for benefits: HPV vaccines in males 9–15 years old

Outcome-related HPV type	Benefits	Design	Risk of bias	Inconsistency	Indirectness*	Imprecision	Evidence type (GRADE) 4vHPV vaccine (a)	Evidence type (GRADE) 9vHPV/2vHPV vaccines* (b)
HPV types 6, 11, 16 and 18	6MPI	4vHPV (1RCT)(a)	Not serious	Not serious	Serious¥	Not serious	Moderate	Low
	AIN2/3		Not serious	Not serious	Serious¥	Not serious	Moderate	Low
	Anal cancer		Not serious	Not serious	Very serious¥·	Very seriousαβ	Very low	Very low
	PeIN2/3		Not serious	Not serious	Serious¥	Very seriousαβ	Very low	Very low
	Penile cancer		Not serious	Not serious	Very serious¥·	Very seriousαβ	Very low	Very low
	Anogenital warts		Not serious	Not serious	Serious¥	Not serious	Moderate	Low

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
¥: Downgraded by 1 for indirectness due to use of immunobridging to males 16 to 26-year old
γ: Downgraded by 1 for indirectness due to use of AIN2/3 or PeIN2/3 as surrogate marker for anal cancer or penile cancer.
α: Downgraded by 1 for imprecision due to low event rate.
β: Downgraded by 1 for imprecision due to very wide 95% confidence interval.
**: Evidence quality for efficacy of 9vHPV and the 2vHPV vaccines downgraded 1 level due to use of immunobridging to extrapolate efficacy (indirectness for the 9vHPV vaccine changes from 'Serious' to 'Very serious').*
a: HPV types 6, 11, 16, 18 data from protocol 020/NCT00090285 [1-3] (PICO1, PICO2 Supp01); supportive data from protocols 020/NCT00090285 [4] (PICO14,PICO15 Supp02), NCT00092495 [5] (PICO5 Supp02), NCT00092547 [6,7] (PICO6, PICO7, PICO8 Supp02).
b: HPV types 6, 11, 16, 18 data from protocol 020/NCT00090285 [1-3] (PICO1, PICO2 Supp01); supportive data from protocols NCT00534638 [8] (PICO11 Supp02), NCT00309166 [9] (PICO16 Supp02), 002/NCT00943722 [10] (PICO1 Supp02), 010/NCT01984697 [11] (PICO2 Supp02), 001/NCT00543543 [12] (PICO1 Supp04).
Sources: 1. Palefsky J, et al. N Engl J Med 2011;365:1576-85. 2. Giuliano AR, et al. N Engl J Med. 2011;364:401-11. 3. Goldstone SE, et al. Vaccine. 2013;31:3849-55. 4. Hillman RJ, et al. Clin Vaccine Immunol. 2012;19:261-7. 5. Block SL, et al. Pediatrics. 2006;118:2135-45. 6. Reisinger KS, et al. Pediatr Infect Dis J. 2007;26:201-9. 7. Ferris D, et al. Pediatrics. 2014;134:e657-65. 8. http://clinicaltrials.gov/ct2/show/NCT00534638?cond=NCT00534638&rank=1 9. Petäjä T, et al. J Adolesc Health. 2009;44:33-40. 10. Van Dame P, et al. Pediatrics. 2015;136:e28-39. 11. Iversen OE, et al. JAMA. 2016;316:2411-2421. 12. Huh WK, et al. Lancet. 2017;390:2143-2159.

Table A26. Available data for males 9–15 years old from HPV vaccine trials

Outcomes	HPV types 6, 11, 16 and 18-related	
	Direct	Indirect
6MPI	No	Immunogenicity(a)[5-11]
AIN2/3	No	Immunogenicity(a)[5-11]
Anal cancer	No	Immunogenicity(a)[5-11]
PeIN2/3	No	Immunogenicity(a)[5-11]
Penile cancer	No	Immunogenicity(a)[5-11]
Anogenital warts	No	Immunogenicity(a)[5-11]

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia.
a: Immunogenicity from immunobridging clinical trials with the HPV vaccines in males aged 9–5 years compared to females aged 16–26 years, were used to infer efficacy.
Sources: 5. Block SL, et al. Pediatrics. 2006;118:2135-45. 6. Reisinger KS, et al. Pediatr Infect Dis J. 2007;26:201-9. 7. Ferris D, et al. Pediatrics. 2014;134:e657-65. 8. http://www.clinicaltrials.gov/ct2/show/NCT00534638?cond=NCT00534638 9. Petäjä T, et al. J Adolesc Health. 2009;44:33-40. 10. Van Dame P, et al. Pediatrics. 2015;136:e28-39. 11 Iversen OE, et al. JAMA. 2016;316:2411-2421.

Table A27. HPV vaccine trials used for HPV vaccine-related outcomes in males 9–15 years old

Protocol	Intervention	Comparator	Number	Outcome	Efficacy	Comments
020/NCT00090285 [1-4]	4vHPV in males 16–26 years old (per protocol population)	Placebo in males 16–26 years old	2790	6MPI	85.6% (73.4–92.9) – PICO1 Supp01	
			402	AIN2/3	74.9% (8.8-95.4) – PICO2 Supp01	Efficacy in MSM
			402	Anal cancer	--	
			2805	PeIN2/3	100.0% (–3788.2-100.0) – PICO1 Supp01	
			2805	Penile cancer	--	
			2805	Anogenital warts	89.4% (65.5-97.9) – PICO1 Supp01	Efficacy in subgroup 402 MSM (100.0% (8.2-100)) – PICO2 Supp01
	4vHPV in MSM heterosexual males 16–26 years old (per protocol population)	4-valent in heterosexual males 16–23 years old	4065	Seroconversion and geometric mean titres (by HPV)	PICO12, PICO15 Supp02	
NCT00092495 [5]	4vHPV in males 10–15 years old (per protocol population)	4vHPV in females 16–23 years old (immunobridging)	769	Seroconversion and geometric mean titres (by HPV)	PICO5 Supp02	
018/NCT00092547 [6,7]	4vHPV in males 9–15 years old (per protocol population)	4vHPV in females 9–15 years old (immunobridging)	952	Seroconversion and geometric mean titres (by HPV)	PICO6, PICO7, PICO8 Supp02	
NCT00534638 [8]	2-valent HPV in males 12–15 years old (per protocol population)	None	536	Seroconversion and geometric mean titres (by HPV)	PICO11 Supp02	
NCT00309166 [9]	2-valent HPV in males 10–18 years old (per protocol population)	4vHPV in females 15–25 years old (immunobridging)	522	Seroconversion and geometric mean titres (by HPV)	PICO16 Supp02	
002/NCT00943722 [10]	9vHPV in males 9–15 years old	9vHPV in females 16–26 years old (immunobridging)	938	Seroconversion and geometric mean titres (by HPV)	PICO1 Supp02	
010/NCT01984697 [11]	9vHPV in males 9–14 years old (2 doses)	9vHPV in females 16–26 years old	553	Seroconversion and geometric mean titres (by HPV)	PICO2 Supp02	
001/NCT00543543 [12]	9vHPV in females 16–26 years old (per protocol population)	4vHPV in females 16–26 years old	14215	Efficacy outcomes	PICO1 Supp04	

HPV: human papillomavirus; 6MPI: 6-month persistent infection; AIN: anal intraepithelial neoplasia; PeIN: penile intraepithelial neoplasia; MSM: men who have sex with men.
Sources: 1. Palefsky J, et al. N Engl J Med 2011;365:1576-85. 2. Giuliano AR, et al. N Engl J Med. 2011;364:401-11. 3. Goldstone SE, et al. Vaccine. 2013;31:3849-55. 4. Hillman RJ, et al. Clin Vaccine Immunol. 2012;19:261-7. 5. Block SL, et al. Pediatrics. 2006;118:2135-45. 6. Reisinger KS, et al. Pediatr Infect Dis J. 2007;26:201-9. 7 .Ferris D, et al. Pediatrics. 2014;134:e657-65. 8. http://www.clinicaltrials.gov/ct2/show/NCT00534638?cond=NCT00534638 9. Petäjä T, et al. J Adolesc Health. 2009;44:33-40. 10. Van Dame P, et al. Pediatrics. 2015;136:e28-39. 11. Iversen OE, et al. JAMA. 2016;316:2411-2421. 12. Huh WK, et al. Lancet. 2017;390:2143-2159.

Safety of HPV vaccines in males

Table A28. Evidence type for harms: HPV vaccination in males

Harms	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
Any adverse events	5RCT (a)	Not serious	Not serious	Not serious	Not serious	High
Injection site events (days 1–15)		Not serious	Not serious	Not serious	Not serious	High
Systemic adverse events (days 1–15)		Not serious	Not serious	Not serious	Not serious	High
Serious adverse events any time		Not serious	Not serious	Not serious	Not serious	High
Discontinuation due to adverse events		Not serious	Not serious	Not serious	Serious*	Moderate

HPV: human papillomavirus; RCT: randomised clinical trial
Analysis in participants who received at least 1 study vaccine dose and for whom safety follow-up data were available.
Outcomes are recorded regardless of causality.
**: Downgraded by 1 for imprecision due to wide 95% confidence interval.*
a: data from protocol 020/NCT00090285 [1] (PICO7 Supp03), 020/NCT02114385 [2] (PICO3 Supp03), 018/NCT00092547 [3] (PICO6 Supp03), NCT00534638 [4] (PICO9 Supp03), NCT00309166 [5] (PICO11 Supp03); supportive data from protocol 020/NCT00090285 [6] (PICO10 Supp03), 003/NCT01651949 [7] (PICO4 Supp03), NCT00092495 [8] (PICO5 Supp03), NCT00943722 [9] (PICO1 Supp03), NCT01984697 [10] (PICO2 Supp03).
Sources: 1. Moreira ED, et al. Hum Vaccin. 2011;7:768-75. 2. Van Damme P, et al. Vaccine. 2016;34:4205-4212. 3. Reisinger KS, et al. Pediatr Infect Dis J. 2007;26:201-9. 4. Lehtinen M, et al. Hum Vaccin Immunother. 2016;12:3177-3185. 5. Petäjä T, et al. J Adolesc Health. 2009;44:33-40. 6. PalefskyJ M, et al. N Engl J Med. 2011;365:1576-85. 7. Castellsagué X, et al. Vaccine. 2015;33:6892-901. 8. Block SL, et al. Pediatrics. 2006;118:2135-45. 9. Van Damme P, et al. Pediatrics. 2015;136:e28-39. 10. Iversen OE, et al. JAMA. 2016;316:2411-2421.

Table A29. Available harm data for males from HPV vaccine trials

Harms	Males 16–26 years old			Males 9–15 years old		
	Protocol (design)	Incidence in vaccinated % (n/N)	Incidence in controls (placebo group) n/N (%)[α]	Protocol (design)	Incidence in vaccinated % (n/N)	Incidence in controls (placebo group) n/N (%)[¥]
Any adverse events	020/NCT00090285 and 020/NCT02114385 (2RCT) (a)	1 446/2 193 (65.9%)	1 134/1 950 (58.2%)	018/NCT00092547, NCT00534638 and NCT00309166 (3RCT) (b)[γφ]	956/1 128 (84.8%)	812/1 050 (77.3%)
Injection site events (days 1–15)		1 365/2 193 (62.2%)	1046/1 950 (53.6%)		880/1 128 (78.0%)	690/1 050 (65.7%)
Systemic adverse events (days 1–15)		376/2 193 (17.1%)	283/1 950 (14.5%)		543/1 128 (48.1%)	526/1 050 (50.1%)
Serious adverse events any time		8/2 193 (0.4%)	11/1 950 (0.6%)		27/1 128 (2.4%)	16/1 050 (1.5%)
Discontinuation due to adverse events		0/248 (0.0%)	--		0/1 128 (0.0%)	0/1 050 (0.0%)

HPV: human papillomavirus; RCT: randomised clinical trial
Analysis in participants who received at least 1 study vaccine dose and for whom safety follow-up data were available.
Outcomes are recorded regardless of causality.
a: data from Protocol 020/NCT00090285 [1] (PICO7 Supp03), 020/NCT02114385 [2] (PICO3 Supp03); supportive data from Protocol 020/NCT00090285 [6] (PICO10 Supp03), 003/NCT01651949 [7] (PICO4 Supp03)
b: data from protocol 018/NCT00092547 [3] (PICO6 Supp03), NCT00534638 [4] (PICO9 Supp03), NCT00309166 [5] (PICO11 Supp03); supportive data from protocols NCT00092495 [8] (PICO5 Supp03), NCT00943722 [9] (PICO1 Supp03), NCT01984697 [10] (PICO2 Supp03)
[α]: only data from protocol 020/NCT00090285
[γ]: Data from protocol NCT00309166 provided for specific symptoms (pain, redness, fatigue) not included in this table.
[φ]: Data from protocol 018/NCT00092547 include males and females.
[¥]: Placebo group from protocol 018/NCT00092547 vaccinated with hepatitis B vaccine.
Sources: 1. Moreira ED, et al. Hum Vaccin. 2011;7:768-75. 2. Van Damme P, et al. Vaccine. 2016;34:4205-4212. 3. Reisinger KS, et al. Pediatr Infect Dis J. 2007;26:201-9. 4. Lehtinen M, et al. Hum Vaccin Immunother. 2016;12:3177-3185. 5. Petäjä T, et al. J Adolesc Health. 2009;44:33-40. 6. PalefskyJ M, et al. N Engl J Med. 2011;365:1576-85. 7. Castellsagué X, et al. Vaccine. 2015;33:6892-901. 8. Block SL, et al. Pediatrics. 2006;118:2135-45. 9. Van Damme P, et al. Pediatrics. 2015;136:e28-39. 10. Iversen OE, et al. JAMA. 2016;316:2411-2421.

Efficacy of HPV vaccines in females aged 25 years or above

Table A30. Evidence type for benefits: HPV vaccines in females aged 25 years or above

Outcome-related HPV type	Benefits	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
HPV types 6, 11, 16 and 18[¥]	Combined 6MPI, CIN or external genital lesions*	2vHPV and 4vHPV (2RCT) (a)	Not serious	Not serious	Not serious	Not serious	High
	Combined 6MPI or CIN1 or worse[#]		Not serious	Not serious	Not serious	Not serious	High
	6MPI		Not serious	Not serious	Not serious	Not serious	High
	CIN2/3 or worse		Not serious	Not serious	Not serious	Very serious[αβ]	Low
	Cervical cancer		Not serious	Not serious	Serious[γ]	Very serious[αβ]	Very low
	VIN2/3, VaIN2/3 or worse*		Not serious	Not serious	Not serious	Very serious[αβ]	Low
	Vulvar or vaginal cancer		Not serious	Not serious	Serious[γ]	Very serious[αβ]	Very low
	Anogenital warts*		Not serious	Not serious	Not serious	Serious[α]	Moderate
HPV types 31, 33, 45, 52 and 58	6MPI		Not evaluable with GRADE methodology. No efficacy data for 9vHPV vaccine in females aged 25-years or older.				
	CIN2/3 or worse						
	Cervical cancer						
	VIN2/3, VaIN2/3 or worse						
	Vulvar or vaginal cancer						

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
[¥]: HPV 6, 11, 16 and 18-related outcomes for 4vHPV vaccine and HPV 16 and 18-related outcomes for 2vHPV vaccine
[*]: Only data from 4vHPV vaccine trial (Protocol 019/NCT00090220).
[#]: Only data from 2vHPV vaccine trial (NCT00294047).
[α]: Downgraded by 1 for imprecision due to low event rate.
[β]: Downgraded by 1 for imprecision due to very wide 95% confidence interval.
[γ]: Downgraded by 1 for indirectness due to use of CIN2/3, VIN2/3 or VaIN2/3 or worse as surrogate marker for cervical, vulvar or vaginal cancer.
a: Efficacy data from two pivotal RCT in females (≥25-year old): 4vHPV vaccine protocol 019/NCT00090220 [1] (PICO1 Supp09) and 2vHPV vaccine NCT00294047 [2] (PICO2 Supp09); supportive immunogenicity data from protocol 019/NCT00090220 [1] (PICO1, PICO2 Supp10), NCT00294047 (PICO3, PICO4 Supp10), NCT00423046 [3,4] (PICO5,PICO6 Supp10).
Sources: 1. Castellsagué X, et al. Br J Cancer. 2011;105:28-37. 2. Wheeler CM, et al. Lancet Infect Dis. 2016;16:1154-1168. 3. Einstein MH, et al. Hum Vaccin. 2009;5:705-19. 4. Einstein MH, et al. Hum Vaccin Immunother. 2014;10:3435-45.

Table A31. Available data for females aged 25 years or above from HPV vaccine trials

Outcomes	HPV 6, 11, 16 and 18-related[¥]		HPV 31, 33, 45, 52 and 58-related	
	Direct	Indirect	Direct	Indirect
Combined 6MPI, CIN, or external genital lesions	Yes (a) [1]	Immunogenicity (a,b) [1-4]	No	No
Combined 6MPI or CIN1 or worse	Yes (b) [2]	Immunogenicity (a,b) [1-4]	No	No
6MPI	Yes (a,b) [1,2]	Immunogenicity (a,b) [1-4]	No	No
CIN2/3 or worse	Yes (a,b) [1,2]	Immunogenicity (a,b) [1-4]	No	No
Cervical cancer	No	Immunogenicity (a,b) [1-4]	No	No
VIN2/3, VaIN2/3 or worse	Yes (a) [1]	Immunogenicity (a,b) [1-4]	No	No
Vulvar or vaginal cancer	No	Immunogenicity (a,b) [1-4]	No	No
Anogenital warts	Yes (a) [1]	Immunogenicity (a,b) [1-4]	--	--

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
[¥]: HPV 6, 11, 16 and 18-related outcomes for 4vHPV vaccine and HPV 16 and 18-related outcomes for 2vHPV vaccine.
a: efficacy from 4vHPV vaccine trials (in females ≥25 years old)
b: efficacy from 2vHPV vaccine trials (in females ≥25 years old).
Sources: 1. Castellsagué X, et al. Br J Cancer. 2011;105:28-37. 2. Wheeler CM, et al. Lancet Infect Dis. 2016;16:1154-1168. 3. Einstein MH, et al. Hum Vaccin. 2009;5:705-19. 4. Einstein MH, et al. Hum Vaccin Immunother. 2014;10:3435-45.

Table A32. HPV vaccine trials used for HPV 6, 11, 16 and 18-related outcomes in females aged 25 years or above

Protocol	Intervention	Comparator	No.	Outcome	Efficicacy
019/NCT00090220 [1]	4vHPV in females 24–45 years old (per protocol population)	Placebo in females 24–45-years old	[a]	Combined 6MPI, CIN, or external genital lesions	87.7% (78.1-94.8) – PICO1 Supp09
			[a]	6MPI	89.6% (79.3-95.4) – PICO1 Supp09
			[a]	CIN2/3 or worse	83.3% (-37.6-99.6) – PICO1 Supp09
			[a]	Cervical cancer	--
			[a]	VIN2/3, VaIN2/3 or worse	--
			[a]	Vulvar or vaginal cancer	--
			[a]	Anogenital warts	100.0% (3.8-100.0) – PICO1 Supp09
			1 249	Seroconversion and geometric mean titres (by HPV)	PICO1, PICO2 Supp10
NCT00294047 [2]	2vHPV in females ≥25 years old (per protocol population)	Placebo in females ≥25 years old	3 670	Combined 6MPI or CIN1 or worse	90.5% (78.6-96.5) – PICO2 Supp09
			3 601	6MPI	91.4% (79.4-97.1) – PICO2 Supp09
			3 670	CIN2/3 or worse	83.7% (–46.5-99.7) – PICO2 Supp09
			3 670	Cervical cancer	--
			233	Seroconversion and geometric mean titres (by HPV)	PICO3, PICO4 Supp10
NCT00423046 [3,4]	2vHPV in females 27–45-years old (per protocol population)	4vHPV vaccine in females 27–45 years old	249	Seroconversion and geometric mean titres (by HPV)	PICO5, PICO6 Supp10

HPV: human papillomavirus; 6MPI: 6-month persistent infection; CIN: cervical intraepithelial neoplasia; VIN: vulvar intraepithelial neoplasia; VaIN: vaginal intraepithelial neoplasia.
[a]: Number of subjects included to assess especific outcome not provided in the paper.
Sources: 1. Castellsagué X, et al. Br J Cancer. 2011;105:28-37. 2. Wheeler CM, et al. Lancet Infect Dis. 2016;16:1154-1168. 3. Einstein MH, et al. Hum Vaccin. 2009;5:705-19. 4. Einstein MH, et al. Hum Vaccin Immunother. 2014;10:3435-45.

Safety of HPV vaccines in females aged 25 years or above

Table A33. Evidence type for harms: HPV vaccines in females aged 25 years or above

Harms	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Evidence type (GRADE)
Any adverse events	2RCT (a)	Not serious	Not serious	Not serious	Not serious	High
Injection site events (days 1–15)		Not serious	Not serious	Not serious	Not serious	High
Systemic adverse events (days 1–15)		Not serious	Not serious	Not serious	Not serious	High
Serious adverse events any time		Not serious	Not serious	Not serious	Serious[α]	Moderate
Discontinuation due to adverse events		Not serious	Not serious	Not serious	Serious[α]	Moderate

HPV: human papillomavirus; RCT: randomised clinical trial.
Analysis in participants who received at least 1 study vaccine dose and for whom safety follow-up data were available
a: data from protocol 019/NCT00090220 [1] (PICO1 Supp11) and NCT00294047 [2] (PICO2 Supp11); supportive data from NCT00423046 [3] (PICO3 Supp11).
[α]: Downgraded one level for imprecision: wide 95%CI.
Sources: 1. Castellsagué X, et al. Br J Cancer. 2011;105:28-37. 2. Skinner SR, et al. Lancet. 2014;384:2213-27. 3. Einstein MH, et al. Hum Vaccin Immunother. 2014;10:3435-45.

Table A34. Available harm data for females aged 25 years or above from HPV vaccine trials

Harms	Females aged 25-years or above		
	Protocol (design)	Incidence in HPV vaccine % (n/N)	Incidence in placebo % (n/N)
Any adverse events*	019/NCT00090220 and NCT00294047 (2RCT) (a)	1 645/1 890 (87.0%)	1 535/1 888 (81.3%)
Injection site events (day 1 to 15)		3 888/4 529 (85.8%)	3 445/4 739 (72.7%)
Systemic adverse events (day 1 to 15)*		1 121/1 890 (59.3%)	1 135/1 888 (60.1%)
Serious adverse events any time		285/4 740 (6.0%)	267/4 855 (5.5)
Discontinuation due to adverse events*		7/1 890 (0.4%)	2/1 888 (0.1%)

HPV: human papillomavirus; RCT: randomised clinical trial.
Analysis in participants who received at least 1 study vaccine dose and for whom safety follow-up data were available.
[*]: only data from 4vHPV vaccine trial (Protocol 019/NCT00090220)
a: data from protocol 019/NCT00090220 [1] (PICO1 Supp11) and NCT00294047 [2] (PICO2 Supp11); supportive data from NCT00423046 [3] (PICO3 Supp11).
Sources: 1. Castellsagué X, et al. Br J Cancer. 2011;105:28-37. 2. Skinner SR, et al. Lancet. 2014;384:2213-27. 3. Einstein MH, et al. Hum Vaccin Immunother. 2014;10:3435-

Table A35. Main characteristics of 21 studies that include cost-effectiveness analysis of universal vaccination

Author	Publication year	Country	Currency	Analysis year	Horizon	Perspective	Vaccine used	Vaccine schedule	Health outcome unit	CEA threshold defined
Taira	2004	US	USD	2001	38 y	3PP	2-valent	3 doses	QALYg	50 000–100 000
Elbasha	2007	US	USD	2005	100 y	3PP	4-valent	3 doses	QALYg	No
Kulasingam	2007	Australia	AUD	2005	73 y	3PP	2-valent	3 doses	QALYg	No
Jit	2008	UK	GBP	2006	100 y	3PP	4-valent	3 doses	QALYg	30 000
Kim	2009	US	USD	2006	100 y	SP	4-valent	3 doses	QALYg	50 000
Zechmeister	2009	Austria	EUR	2007	52 y (80 y)	3PP & SP	2-valent	3 doses	LYg	No
Olsen	2010	Denmark	EUR	2007	62 y	3PP	4-valent	3 doses	QALYg	No
Elbasha	2010	US	USD	2008	100 y	3PP	4-valent	3 doses	QALYg	50 000–100 000
Chesson	2011	US	USD	2008	100 y	SP	4-valent	3 doses	QALYg	100 000
Burger	2014	Norway	USD	2010	100 y	SP	4-valent	3 & 2 doses	QALYg	83 000
Laprise	2014	Canada	CAD	2010	70 y	3PP	4-valent	3 & 2 doses	QALYg	40 000
Pearson	2014	New Zealand	NZD	2011	98 y	3PP	4-valent	3 doses	QALYg	45 000
Bresse	2014	Austria	EUR	2012	100 y	3PP	4-valent	3 doses	QALYg	No
Blakely	2014	New Zealand	NZD	2011	98 y	3PP	4-valent	3 doses	QALYg	No
Haeussler	2015	Italy	EUR	2015	Long-term	3PP	4-valent	3 doses	QALYg	25 000–40 000
Jiménez	2015	Norway	NOK	2014	100 y	3PP & SP	4-valent & 2-valent	3 doses	QALYg	215 000
Olsen	2015	Denmark	EUR	2008	62 y (40 y)	3PP	4-valent	3 & 2 doses	QALYg	No
Qendri	2017	Netherlands	EUR	2011	Lifetime	3PP	2-valent	2 doses	LYsg	40 000
Damm	2017	Germany	EUR	2010	100 y	3PP & SP	4-valent & 2-valent	3 & 2 doses	QALYg	50 000
Largeron	2017	Germany	EUR	2014	100 y	3PP	4-valent vs 9-valent	2 doses	QALYg	40 000
Mennini	2017	Italy	EUR	2014	100 y	3PP	4-valent vs 9-valent	2 doses	QALYg	25 000–40 000

CEA: Cost Effectiveness Analysis
y: years
3PP: third-party payer or heath care system perspective
SP: societal perspective
QALYg: quality-adjusted life years gained.

Table A36. Incremental cost-effectiveness ratios (ICERs) in local currency from societal perspective and critical parameters

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy*	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
Kim 2009	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F100%/M90%	Lifelong	360	F12	FM12	114 510 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F100%/M50%	Lifelong	360	F12	FM12	164 580 (USD/QALY)
	CIN, CC, VA, VU, ANA (W), ORPH (W)	75%	F100%/M90%	Lifelong	360	F12	FM12	208 110 (USD/QALY)
	CIN, CC, VA, VU, ANA (W), ORPH (W)	75%	F100%/M50%	Lifelong	360	F12	FM12	242 520 (USD/QALY)
	CIN, CC	75%	F100%/M90%	Lifelong	360	F12	FM12	290 290 (USD/QALY)
	CIN, CC	75%	F100%/M75%	Lifelong	360	F12	FM12	382 860 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F100%/M90%	Lifelong	360	F12	FM12	90 870 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F100%/M75%	Lifelong	360	F12	FM12	123 940 (USD/QALY)
	CIN, CC	50%	F100%/M85%	Lifelong	360	F12	FM12	>220 000 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	50%	F100%/M85%	Lifelong	360	F12	FM12	62 070 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	50%	50%	Lifelong	360	F12	FM12	92 000 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F100%/M85%	Lifelong	261	F12	FM12	63 000 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	50%	Lifelong	261	F12	FM12	<100 000 (USD/QALY)
Zechmeister 2009	CIN, CC (time horizon 80y)	65%	90%	10 y+booster	330+110	F12 + B22F	FM12 + B22FM	25 000 (EUR/LY)
	CIN, CC	65%	90%	10 y+booster	330+110	F12 + B22F	FM12 + B22FM	299 000 (EUR/LY)
Chesson 2011	CIN, CC,VA, VU, ANA, PEN, ORPH, GW, RRP	75% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	184 300 (USD/QALY)
	CIN, CC,VA, VU, ANA, PEN, ORPH, GW, RRP	20% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	23 600 (USD/QALY)
	CIN, CC,VA, VU, ANA, PEN, ORPH, GW, RRP	30% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	41 400 (USD/QALY)
	CIN, CC	75% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	741 300 (USD/QALY)
	CIN, CC	20% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	69 600 (USD/QALY)
	CIN, CC	30% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	121 700 (USD/QALY)
	CIN, CC, GW	75% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	436 000 (USD/QALY)
	CIN, CC, GW	20% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	52 100 (US$/QALY)
	CIN, CC, GW	30% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	89 100 (USD/QALY)
	CIN, CC,VA, VU, ANA, PEN, ORPH	75% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	229 600 (USD/QALY)
	CIN, CC,VA, VU, ANA, PEN, ORPH	20% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	29 700 (USD/QALY)
	CIN, CC,VA, VU, ANA, PEN, ORPH	30% @ age 12	F 95%/M 90%	Lifelong	500	F12+CU13–26F	FM12+CU13–26F	50 800 (USD/QALY)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	20% @ age 12	F 95%/M 90%	Lifelong	360	F12+CU13–26F	FM12+CU13–26F	13 100 (USD/QALY)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	20% @ age 12	F 95%/M 90%	Lifelong	600	F12+CU13–26F	FM12+CU13–26F	31 200 (USD/QALY)

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy*	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	30% @ age 12	F 95%/M 90%	Lifelong	360	F12+CU13–26F	FM12+CU13–26F	25 900 (USD/QALY)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	30% @ age 12	F 95%/M 90%	Lifelong	600	F12+CU13–26F	FM12+CU13–26F	52 500 (USD/QALY)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	75% @ age 12	F 95%/M 90%	Lifelong	360	F12+CU13–26F	FM12+CU13–26F	129 000 (USD/QALY)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	75% @ age 12	F 95%/M 90%	Lifelong	600	F12+CU13–26F	FM12+CU13–26F	223 800 (USD/QALY)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	30% @ age 12	F 95%/M 90%	Lifelong	500	F12	FM12	25 000 (USD/QALY)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	45% F vs 30% FM	F 95%/M 90%	Lifelong	500	F12	FM12	103 500 (USD/QALY)
Burger 2014	CIN, CC	71%	F 100%/M 90%	Lifelong	225	F12	FM12	145 500 (USD/QALY)
	CIN, CC, VA, VU, ANA, ORPH (only female)	71%	F1 00%/M 90%	Lifelong	225	F12	FM12	119 300 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH (all)	71%	F 100%/M 90%	Lifelong	225	F12	FM12	81 700 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F100%/M 90%	Lifelong	225	F12	FM12	60 100 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	Lifelong	150	F12	FM12	40 400 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 60%	F 100%/M 90%	Lifelong	150	F12	FM12	44 400 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 80%	F 100%/M 90%	Lifelong	150	F12	FM12	56 100 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	20 y	150	F12	FM12	38 300 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 90%/M 71%	F 100%/M 90%	Lifelong	150	F12	FM12	Dom
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	79%	F 100%/M90% (2d)	Lifelong	100	F12	FM12	27 680 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 60%	F 100%/M 90%	Lifelong	225	F12	FM12	65 800 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 80%	F 100%/M 90%	Lifelong	225	F12	FM12	82 300 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	20 y	225	F12	FM12	57 200 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 90%/M 71%	F 100%/M 90%	Lifelong	225	F12	FM12	Dom
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	79%	F 100%/M 90% (2d)	Lifelong	150	F12	FM12	42 320 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	Lifelong	450	F12	FM12	116 700 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 60%	F 100%/M 90%	Lifelong	450	F12	FM12	127 200 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 80%	F 100%/M 90%	Lifelong	450	F12	FM12	157 400 (USD/QALY)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	20 y	450	F12	FM12	111 400 (USD/QALY)

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy*	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 90%/M 71%	F 100%/M 90%	Lifelong	450	F12	FM12	Dom
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	79%	F 100%/M 90% (2d)	Lifelong	300	F12	FM12	84 330 (USD/QALY)
Jiménez 2015	CIN, CC, VU, GW	82%		Lifelong	3340	F12	FM12	1 626 261 (NOK/DALY)
Damm 2017	CIN, CC, GW	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	111 386 (EUR/QALY)
	CIN, CC, GW	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	68 118 (EUR/QALY)
	CIN, CC (2-valent)	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	124 453 (EUR/QALY)
	CIN, CC (2-valent)	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	77 607 (EUR/QALY)
	CIN, CC, GW	F 20%/M 50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	41 104 (EUR/QALY)
Damm 2017	CIN, CC, GW	F20%/M 50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	20 617 (EUR/QALY)
	CIN, CC (2-valent)	F 20%/M 50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	54 574 (EUR/QALY)
	CIN, CC (2-valent)	F 20%/M 50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	30 959 (EUR/QALY)
	CIN, CC, GW	F 20%/M 80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	55 158 (EUR/QALY)
	CIN, CC, GW	F 20%/M 80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	30 164 (EUR/QALY)
	CIN, CC (2-valent)	F 20%/M 80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	68 758 (EUR/QALY)

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy*	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
	CIN, CC (2-valent)	F 20%/M 80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	40 440 (EUR/QALY)

**: Vaccination coverage and efficacy separated by / means two different coverages used in study referring to two separate populations. When numbers are separated by 'vs', two different coverages were compared in different scenarios.*

***: 'Vaccine cost' separated by + means cost of initial vaccination (three) doses plus cost of booster dose.*

Abbreviations

Health outcomes: Cervical cancer (CC), cervical intraepithelial neoplasia (CIN), genital warts (GW), vaginal cancer (VA), vulvar cancer (VU), anal cancer (ANA), penile cancer (PEN), oropharingeal cancer (ORPH), recurrent respiratory papillomatosis (RRP)

Sex: females (F), women (W), males (M)

Other: years (y), at (@), dose (d), catch-up (CU), booster (B), quality-adjusted life years (QALY), life years (LY), dominant (Dom).

Table A37. Incremental cost-effectiveness ratios (ICERs) converted to EUR from societal perspective and critical parameters

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
Kim 2009	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F 100%/M 90%	Lifelong	286	F12	FM12	90 881
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F 100%/M 50%	Lifelong	286	F12	FM12	130 619
	CIN, CC, VA, VU, ANA (W), ORPH (W)	75%	F 100%/M 90%	Lifelong	286	F12	FM12	165 167
	CIN, CC, VA, VU, ANA (W), ORPH (W)	75%	F 100%/M 50%	Lifelong	286	F12	FM12	192 476
	CIN, CC	75%	F 100%/M 90%	Lifelong	286	F12	FM12	230 389
	CIN, CC	75%	F 100%/M 75%	Lifelong	286	F12	FM12	303 857
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F100%/M90%	Lifelong	286	F12	FM12	72 119
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F 100%/M 75%	Lifelong	286	F12	FM12	98 365
	CIN, CC	50%	F 100%/M 85%	Lifelong	286	F12	FM12	>174 603
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	50%	F 100%/M 85%	Lifelong	286	F12	FM12	49 262
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	50%	50%	Lifelong	286	F12	FM12	73 016
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	F 100%/M 85%	Lifelong	207	F12	FM12	50 000
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	75%	50%	Lifelong	207	F12	FM12	<79 365
Zechmeister 2009	CIN, CC (time horizon 80 y)	65%	90%	10 y+booster	330+110	F12 + B22F	FM12+B22FM	25 000
	CIN, CC	65%	90%	10 y+booster	330+110	F12 + B22F	FM12+B22FM	299 000
Chesson 2011	CIN, CC,VA, VU, ANA, PEN, ORPH, GW, RRP	75% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	125 374
	CIN, CC,VA, VU, ANA, PEN, ORPH, GW, RRP	20% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	16 054
	CIN, CC,VA, VU, ANA, PEN, ORPH, GW, RRP	30% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	28 163
	CIN, CC	75% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	504 286
	CIN, CC	20% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	47 347
	CIN, CC	30% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	82 789
	CIN, CC, GW	75% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	296 599
	CIN, CC, GW	20% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	35 442
	CIN, CC, GW	30% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	60 612
	CIN, CC,VA, VU, ANA, PEN, ORPH	75% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	156 190
	CIN, CC,VA, VU, ANA, PEN, ORPH	20% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	20 204
	CIN, CC,VA, VU, ANA, PEN, ORPH	30% @ age 12	F 95%/M 90%	Lifelong	340	F12+CU13–26F	FM12+CU13–26F	34 558

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	20% @ age 12	F 95%/M 90%	Lifelong	245	F12+CU13–26F	FM12+CU13–26F	8 912
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	20% @ age 12	F 95%/M 90%	Lifelong	408	F12+CU13–26F	FM12+CU13–26F	21 224
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	30% @ age 12	F 95%/M 90%	Lifelong	245	F12+CU13–26F	FM12+CU13–26F	17 619
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	30% @ age 12	F 95%/M 90%	Lifelong	408	F12+CU13–26F	FM12+CU13–26F	35 714
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	75% @ age 12	F 95%/M 90%	Lifelong	245	F12+CU13–26F	FM12+CU13–26F	87 755
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	75% @ age 12	F 95%/M 90%	Lifelong	408	F12+CU13–-26F	FM12+CU13–26F	152 245
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	30% @ age 12	F 95%/M 90%	Lifelong	340	F12	FM12	17 007
	CIN, CC, VA, VU, ANA, PEN, ORPH, GW, RRP	45% F vs 30% FM	F 95%/M 90%	Lifelong	340	F12	FM12	70 408
Burger 2014	CIN, CC	71%	F 100%/M 90%	Lifelong	169	F12	FM12	109 398
	CIN, CC, VA, VU, ANA, ORPH (only female)	71%	F 100%/M 90%	Lifelong	169	F12	FM12	89 699
	CIN, CC, VA, VU, PEN, ANA, ORPH (all)	71%	F 100%/M 90%	Lifelong	169	F12	FM12	61 429
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	Lifelong	169	F12	FM12	45 188
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	Lifelong	113	F12	FM12	30 376
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 60%	F 100%/M 90%	Lifelong	113	F12	FM12	33 383
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 80%	F 100%/M 90%	Lifelong	113	F12	FM12	42 180
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	20 y	113	F12	FM12	28 797
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 90%/M 71%	F 100%/M 90%	Lifelong	113	F12	FM12	
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	79%	F 100%/M 90% (2d)	Lifelong	75	F12	FM12	20 812
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 60%	F 100%/M 90%	Lifelong	169	F12	FM12	49 474
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 80%	F 100%/M 90%	Lifelong	169	F12	FM12	61 880
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	20 y	169	F12	FM12	43 008
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 90%/M 71%	F 100%/M 90%	Lifelong	169	F12	FM12	
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	79%	F100%/M 90% (2d)	Lifelong	113	F12	FM12	31 820

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	Lifelong	338	F12	FM12	87 744
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 60%	F 100%/M 90%	Lifelong	338	F12	FM12	95 639
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 71%/M 80%	F 100%/M 90%	Lifelong	338	F12	FM12	118 346
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	71%	F 100%/M 90%	20 y	338	F12	FM12	83 759
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	F 90%/M 71%	F 100%/M 90%	Lifelong	338	F12	FM12	
	CIN, CC, VA, VU, PEN, ANA, ORPH, GW, RRP	79%	F 100%/M 90% (2d)	Lifelong	226	F12	FM12	63 406
Jiménez 2015	CIN, CC, VU, GW	82%		Lifelong	400	F12	FM12	194 529
Damm 2017	CIN, CC, GW	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	111 386
	CIN, CC, GW	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	68 118
	CIN, CC (2-valent)	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	124 453
	CIN, CC (2-valent)	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	77 607
	CIN, CC, GW	F 20%/M 50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	41 104
	CIN, CC, GW	F 20%/M 50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	20 617
	CIN, CC (2-valent)	F 20%/M 50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	54 574
Damm 2017	CIN, CC (2-valent)	F 20%/M 50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	30 959

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
	CIN, CC, GW	F 20%/M 80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	55 158
	CIN, CC, GW	F 20%/M 80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	30 164
	CIN, CC (2-valent)	F 20%/M 80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	68 758
	CIN, CC (2-valent)	F 20%/M 80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	40 440

**: Vaccination coverages separated by / means two different coverages were used in study referring to two separate populations. When the numbers are separated by 'vs', two different coverages were compared in different scenarios.*

***: 'Vaccine cost' separated by + means cost of initial vaccination (three) doses plus cost of booster dose.*

Abbreviations

Health outcomes: cervical cancer (CC), cervical intraepithelial neoplasia (CIN), genital warts (GW), vaginal cancer (VA), vulvar cancer (VU), anal cancer (ANA), penile cancer (PEN), oropharingeal cancer (ORPH), recurrent respiratory papillomatosis (RRP)

Sex: females (F), women (W), males (M)

Other: years (y), at (@), dose (d), catch-up (CU), booster (B).

Table A38. Incremental cost-effectiveness ratios (ICERs) in local currency from third-party payer or healthcare system perspective and critical parameters

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
Taira 2004	CC	70%	90%	10 y post booster	300+100	F12 + B22F	FM12 + B22FM	442 039 (USD/QALY)
	CC	30%	90%	10 y post booster	300+100	F12 + B22F	FM12 + B22FM	40 865 (USD/QALY)
	CC	70%	90%	10 y	300	F12	FM12	51 646 (USD/QALY)
	CC	70%	90%	10 y post booster	300+200	F12+2B(5/5)	FM12+2B(5/5)	388 368 (USD/QALY)
	CC	70%	90%	10y	300	F12	FM18	57 795 (USD/QALY)
	CC	Highest risk girls 30%	90%	10 y post booster	300+100	F12 + B22F	FM12 + B22FM	116 413 (USD/QALY)
Elbasha 2007	CIN, CC, GW	70%	90%	Lifelong	360	F12	FM12	Dom
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	360	F12+CU1224F	FM12+CU12–24F	41 803 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	360	F18+CU18–24F	FM18+CU18–24FM	Dom
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	360	F18+CU18–24F	FM15+CU15–24FM	Dom
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	360	F12+CU12–24F	FM12+CU12–24FM	42 697 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	300	F12+CU12–24F	FM12+CU12–24F	33 469 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	500	F12+CU12–24F	FM12+CU12–24F	61 250 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	90%	10y	360	F12+CU12–24F	FM12+CU12–24F	54 755 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	100%	Lifelong	360	F12+CU12–24F	FM12+CU12–24F	Dom
	CIN, CC, GW	70% (50%CU)	74%	Lifelong	360	F12+CU12–24F	FM12+CU12–24F	39 990 (USD/QALY)
	CIN, CC, GW	50%	90%	Lifelong	360	F12+CU12–24F	FM12+CU12–24F	23 862 (USD/QALY)
	CIN, CC, GW	90%	90%	Lifelong	360	F12+CU12–24F	FM12+CU12–24F	Dom
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	360	FM12+CU12–24F	FM12+CU12–24FM	45 056 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	300	FM12+CU12–24F	FM12+CU12–24FM	36 161 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	500	FM12+CU12–24F	FM12+CU12–24FM	65 810 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	90%	10 y	360	FM12+CU12–24F	FM12+CU12–24FM	54 928 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	100%	Lifelong	360	F12+CU12–24F	FM12+CU12–24F	Dom
	CIN, CC, GW	70% (50%CU)	100%	Lifelong	360	FM12+CU12–24F	FM12+CU12–24FM	51 436 (USD/QALY)
	CIN, CC, GW	70% (50%CU)	74%	Lifelong	360	FM12+CU12–24F	FM12+CU12–24FM	43 930 (USD/QALY)
	CIN, CC, GW	50%	90%	Lifelong	360	FM12+CU12–24F	FM12+CU12–24FM	36 235 (USD/QALY)
	CIN, CC, GW	90%	90%	Lifelong	360	FM12+CU12–24F	FM12+CU12–24FM	100 418 (USD/QALY)

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
Kulasingam 2007	CIN, CC	80%	100%	Lifelong	345	No vaccination	FM12	33 644 (AUD/QALY)
	CIN, CC	80%	84%	Lifelong	345	No vaccination	FM12	36 920 (AUD/QALY)
	CIN, CC	80%	100%	10 y	345	No vaccination	FM12	104 669 (AUD/QALY)
	CIN, CC	80%	84%	10 y	345	No vaccination	FM12	107 776 (AUD/QALY)
	CIN, CC	70%	100%	Lifelong	345	No vaccination	FM12	29 278 (AUD/QALY)
	CIN, CC	70%	84%	Lifelong	345	No vaccination	FM12	34 380 (AUD/QALY)
	CIN, CC	90%	100%	Lifelong	345	No vaccination	FM12	38 503 (AUD/QALY)
	CIN, CC	90%	84%	Lifelong	345	No vaccination	FM12	40 018 (AUD/QALY)
Jit 2008	CIN, CC, GW	80%	100%	Lifelong	211	F12	FM12	520 255 (GBP/QALY)
	CIN, CC, GW	80%	100%	10 y	211	F12	FM12	113 846 (GBP/QALY)
	CIN, CC, GW	80%	100%	20 y	211	F12	FM12	172 892 (GBP/QALY)
Zechmeister 2009	CIN, CC	65%	90%	10 y+booster	330+110	F12 + B22F	FM12 + B22FM	311 000 (EUR/LY)
Olsen 2010	CIN, CC, GW	70%	100%	-	415	No vaccination	FM12	18 677 (EUR/QALY)
Elbasha 2010	CIN, CC, VA, VU, GW, PEN, H&N, ANA, RRP	90% @ age 26	90%	Lifelong	400	F9-26	FM9-26	25 664 (USD/QALY)
	CIN, CC, VA, VU, GW, H&N, ANA, RRP	90% @ age 26	90%	Lifelong	400	F9-26	FM9-26	27 511 (USD/QALY)
	CIN, CC, VA, VU, GW, ANA, RRP	90% @age26	90%	Lifelong	400	F9-26	FM9-26	46 978 (USD/QALY)
	CIN, CC, VA, VU, GW, RRP	90% @age26	90%	Lifelong	400	F9-26	FM9-26	62 293 (USD/QALY)
	CIN, CC, VA, VU, GW	90% @age26	90%	Lifelong	400	F9-26	FM9-26	69 038 (USD/QALY)
	CIN, CC, VA, VU	90% @age26	90%	Lifelong	400	F9-26	FM9-26	178 908 (USD/QALY)
	CIN, CC	90% @age26	90%	Lifelong	400	F9-26	FM9-26	195 322 (USD/QALY)
Laprise 2014	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95%	Lifelong	255	F9+CU14F	FM9+CU14F	167 100 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95%	Lifelong	255	F9+CU14F	FM9+CU14F	68 911 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95%	20 y	255	F9+CU14F	FM9+CU14F	119 000 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95%	25 y	255	F9+CU14F	FM9+CU14F	170 300 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95%	25 y	255	F9+CU14F	FM9+CU14F	70 941 (CAD/QALY)

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95%	35 y	255	F9+CU14F	FM9+CU14F	184 400 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95% (2d)	20 y	170	F9+CU14F	FM9+CU14F	86 200 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95% (2d)	20 y	170	F9+CU14F	FM9+CU14F	55 411 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95% (2d)	25 y	170	F9+CU14F	FM9+CU14F	68 017 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95% (2d)	30 y	170	F9+CU14F	FM9+CU14F	52 676 (CAD/QALY)
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95% (2d)	30 y	170	F9+CU14F	FM9+CU14F	135 450 (CAD/QALY)
Pearson 2014	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	20 y	339	No vaccination	FM12	41 100 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	20 y	339	No vaccination	FM12	54 600 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	20 y	339	F12	FM12	118 000 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	56%/45% vs 73%	99%	20 y	339	F12 (56%/45%)	FM12 (73%)	148 000 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	20 y	339	F12	FM12	247 000 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	Lifelong	339	F12	FM12	111 000 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	Lifelong	339	F12	FM12	234 000 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	Lifelong	168	F12	FM12	81 300 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	Lifelong	168	F12	FM12	173 000 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	Lifelong	22	F12	FM12	55 300 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	Lifelong	22	F12	FM12	121 000 (NZD/QALY)
Bresse 2014	CIN, CC	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	26 701 (EURQALY)
	CIN, CC, VA	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	26 279 (EUR/QALY)
	CIN, CC, VA, VU	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	25 567 (EUR/QALY)
	CIN, CC, VA, VU, GW	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	15 820 (EUR/QALY)
	CIN, CC, VU, VA, GW, ANA	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	13 850 (EUR/QALY)
	CIN, CC, VU, VA, GW, ANA, ORPH	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	10 136 (EUR/QALY)
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	10 033 (EUR/QALY)
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	65%	F 76-100%/M 41-96%	20 y	330	No vaccination	FM9	19 590 (EUR/QALY)

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	65%	F 76-100%/M 41-96%	Lifelong	281	No vaccination	FM9	8 202 (EUR/QALY)
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	65%	F 76-100%/M 41-96%	Lifelong	380	No vaccination	FM9	11 787 (EUR/QALY)
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	80%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	9 982 (EUR/QALY)
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	50%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	11 351 (EUR/QALY)
Blakely 2014	CIN, CC, VU, ANA, ORPH, GW	56%/45%	100%	Lifelong	339	No vaccination	FM12	18 800 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	73%	100%	Lifelong	339	No vaccination	FM12	22 600 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	93%	100%	Lifelong	339	No vaccination	FM12	31 000 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	56%/45% vs 73%	100%	Lifelong	339	FM12 (56%/45%)	FM12 (73%)	34 700 (NZD/QALY)
	CIN, CC, VU, ANA, ORPH, GW	73% vs 93%	100%	Lifelong	339	FM12 (73%)	FM12 (93%)	122 500 (NZD/QALY)
Haeussler 2015	CIN, CC, VA, VaIN, VU, VIN, ANA, PEN, PeIN, H&N, GW	90%	CC 78%/ANA 70%/H&N 50%	Lifelong	168	F12	FM12	11 600 (EUR/QALY)
Jiménez 2015	CIN, CC, VU, GW	82%		Lifelong	3340	F12	FM12	1 789 463 (NOK/QALY)
	CIN, CC, VU, GW	82%		Lifelong	750	F12	FM12	351 975 (NOK/QALY)
	CIN, CC, VU, GW	82%		Lifelong	1 500	F12	FM12	765 909 (NOK/QALY)
	CIN, CC, VU, GW	82%		Lifelong	2 250	F12	FM12	1 186 606 (NOK/QALY)
	CIN, CC, VU (2-valent)	82%		Lifelong	3 340	F12	FM12	3 754 854 (NOK/QALY)
	CIN, CC, VU, GW	F92%/M82%		Lifelong	3 340	F12 (92%)	F(82%)M(82%)12	3 815 093 (NOK/QALY)
	CIN, CC, VU, GW, VA, ANA	82%		Lifelong	3 340	F12	FM12	1 538 578 (NOK/QALY)
Olsen 2015	CIN, CC, VA, VU, ANA, PEN, H&N, GW	85%	100%	Lifelong	369	F12	FM12	41 636 (EUR/QALY)
	CIN, CC, VA, VU, ANA, PEN, H&N, GW	85%	100%	Lifelong	277	F12	FM12	31 432 (EUR/QALY)
	CIN, CC, VA, VU, ANA, PEN, H&N, GW	85%	100% (2d)	Lifelong	246	F12	FM12	28 031 (EUR/QALY)
	CIN, CC, VA, VU, ANA, PEN, H&N, GW (time horizon 40y)	85%	100%	Lifelong	369	F12	FM12	47 342 (EUR/QALY)
	CIN, CC, VA, VU, ANA, PEN, H&N, GW	70%	100%	Lifelong	369	F12	FM12	31 615 (EUR/QALY)
	CIN, CC, VA, VU, ANA, PEN, GW	85%	100%	Lifelong	369	F12	FM12	276 642 (EUR/QALY)
Qendri 2017	CC, VU, VA, ANA, PEN, ORPH	F60%/40%M	98% (2d)	Lifelong	34	F12	FM12	9,134 (EUR/LY)

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
	CC, VU, VA, ANA, PEN, ORPH	F70%/40%M	98% (2d)	Lifelong	34	F12	FM12	13 083 (EURLY)
	CC, VU, VA, ANA, PEN, ORPH	F80%/40%M	98% (2d)	Lifelong	34	F12	FM12	20 631 (EUR/LY)
	CC, VU, VA, ANA, PEN, ORPH	F90%/40%M	98% (2d)	Lifelong	34	F12	FM12	36 363 (EUR/LY)
	CC, VU, VA, ANA, PEN, ORPH	F60%/50%M	98% (2d)	Lifelong	34	F12	FM12	9 935 (EUR/LY)
	CC, VU, VA, ANA, PEN, ORPH	F60%/60%M	98% (2d)	Lifelong	34	F12	FM12	9 412 (EUR/LY)
Damm 2017	CIN, CC, GW	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20y	450	F12	FM12	117 240 (EUR/QALY)
	CIN, CC, GW	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20y	300	F12	FM12	73 973 (EUR/QALY)
	CIN, CC (2-valent)	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20y	450	F12	FM12	130 449 (EUR/QALY)
	CIN, CC (2-valent)	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20y	300	F12	FM12	83 602 (EUR/QALY)
	CIN, CC, GW	F20%/M50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20y	450	F12	FM12	46 965 (EUR/QALY)
	CIN, CC, GW	F20%/M50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20y	300	F12	FM12	26 478 (EUR/QALY)
	CIN, CC (2-valent)	F20%/M50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20y	450	F12	FM12	60 682 (EUR/QALY)
	CIN, CC (2-valent)	F20%/M50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20y	300	F12	FM12	37 066 (EUR/QALY)
	CIN, CC, GW	F20%/M80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20y	450	F12	FM12	61 027 (EUR/QALY)
	CIN, CC, GW	F20%/M80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20y	300	F12	FM12	36 033 (EUR/QALY)

Author, year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (local currency)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (local currency)
	CIN, CC (2-valent)	F20%/M80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20y	450	F12	FM12	74 844 (EUR/QALY)
	CIN, CC (2-valent)	F20%/M80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20y	300	F12	FM12	46 525 (EUR/QALY)
Largeron 2017	CIN, CC, VA, VU, ANA, GW	55.6%	F 76-100%/M 41-96% (2d)	Lifelong	280 vs 293	F9-14+CU15–17 (4v)	FM9-14+CU15–17 (9v)	22 987 (EUR/QALY)
	CIN, CC, VA, VU, ANA, GW	55.6%	F 76-100%/M 41-96% (2d)	20 y	280 vs 293	F9-14+CU15–17 (4v)	FM9-14+CU15–17 (9v)	14 827 (EUR/QALY)
	CIN, CC, VA, VU, ANA, GW	70%	F 76-100%/M 41-96% (2d)	Lifelong	280 vs 293	F9-14+CU15–17 (4v)	FM9-14+CU15–17 (9v)	27 986 (EUR/QALY)
	CIN, CC, VA, VU, ANA, GW, PEN, H&N, RRP	55.6%	F 76-100%/M 41-96% (2d)	Lifelong	280 vs 293	F9-14+CU15–17 (4v)	FM9-14+CU15–17 (9v)	14 286 (EUR/QALY)
Mennini 2017	CIN, CC, VaIN, VA, VU, ANA, GW	71%	F 76-100%/M 41-96% (2d)	Lifelong	208 vs 240	F12 (4v)	FM12 (9v)	13 541 (EUR/QALY)
	CIN, CC, VaIN, VA, VU, ANA, GW	60%	F 76-100%/M 41-96% (2d)	Lifelong	208 vs 240	F12 (4v)	FM12 (9v)	11 376 (EUR/QALY)
	CIN, CC, VaIN, VA, VU, ANA, GW	71%	F 76-100%/M 41-96% (2d)	20 y	208 vs 240	F12 (4v)	FM12 (9v)	20 845 (EUR/QALY)
	CIN, CC, VaIN, VA, VU, ANA, GW, PEN, H&N, RRP	71%	F 76-100%/M 41-96% (2d)	Lifelong	208 vs 240	F12 (4v)	FM12 (9v)	7 165 (EUR/QALY)

**: Vaccination coverages separated by / means two different coverages were used in study referring to two separate populations. When numbers are separated by 'vs', two different coverages were compared in different scenarios.*

***: 'Vaccine cost' separated by + means cost of initial vaccination (three) doses plus cost of booster dose.*

Abbreviations

Health outcomes: cervical cancer (CC), cervical intraepithelial neoplasia (CIN), genital warts (GW), vaginal cancer (VA), vulvar cancer (VU), anal cancer (ANA), penile cancer (PEN), oropharingeal cancer (ORPH), head and neck cancer (H&N), recurrent respiratory papillomatosis (RRP)

Sex: females (F), women (W), males (M)

Other: years (y), at (@), dose (d), catch-up (CU), booster (B).

Table A39. Incremental cost-effectiveness ratios (ICERs) converted to EUR from third-party payer or healthcare system perspective and critical parameters

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
Taira 2004	CC	70%	90%	10 y post booster	333+111	F12 + B22F	FM12 + B22FM	491 154
	CC	30%	90%	10 yrpost booster	333+111	F12 + B22F	FM12 + B22FM	45 406
	CC	70%	90%	10 y	333	F12	FM12	57 384
	CC	70%	90%	10 y post booster	333+222	F12+2B(5/5)	FM12+2B(5/5)	431 520
	CC	70%	90%	10 y	333	F12	FM18	64 217
	CC	Highest risk girls 30%	90%	10 yr post booster	333+111	F12 + B22F	FM12 + B22FM	129 348
Elbasha 2007	CIN, CC, GW	70%	90%	Lifelong	290	F12	FM12	Dom
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	290	F12+CU12–24F	FM12+CU12–24F	33 712
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	290	F18+CU18–24F	FM18+CU18–24FM	Dom
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	290	F18+CU18–24F	FM15+CU15–24FM	Dom
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	290	F12+CU12–24F	FM12+CU12–24FM	34 433
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	242	F12+CU12–24F	FM12+CU12–24F	26 991
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	403	F12+CU12–24F	FM12+CU12–24F	49 395
	CIN, CC, GW	70% (50%CU)	90%	10 y	290	F12+CU12–24F	FM12+CU12–24F	44 157
	CIN, CC, GW	70% (50%CU)	100%	Lifelong	290	F12+CU12–24F	FM12+CU12–24F	Dom
	CIN, CC, GW	70% (50%CU)	74%	Lifelong	290	F12+CU12–24F	FM12+CU12–24F	32 250
	CIN, CC, GW	50%	90%	Lifelong	290	F12+CU12–24F	FM12+CU12–24F	19 244
	CIN, CC, GW	90%	90%	Lifelong	290	F12+CU12–24F	FM12+CU12–24F	Dom
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	290	FM12+CU12–24F	FM12+CU12–24FM	36 335
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	242	FM12+CU12–24F	FM12+CU12–24FM	29 162
	CIN, CC, GW	70% (50%CU)	90%	Lifelong	403	FM12+CU12–24F	FM12+CU12–24FM	53 073
	CIN, CC, GW	70% (50%CU)	90%	10 y	290	FM12+CU12–24F	FM12+CU12–24FM	44 297
	CIN, CC, GW	70% (50%CU)	100%	Lifelong	290	F12+CU12–24F	FM12+CU12–24F	Dom
	CIN, CC, GW	70% (50%CU)	100%	Lifelong	290	FM12+CU12–24F	FM12+CU12–24FM	41 481
	CIN, CC, GW	70% (50%CU)	74%	Lifelong	290	FM12+CU12–24F	FM12+CU12–24FM	35 427
	CIN, CC, GW	50%	90%	Lifelong	290	FM12+CU12–24F	FM12+CU12–24FM	29 222
	CIN, CC, GW	90%	90%	Lifelong	290	FM12+CU12–24F	FM12+CU12–24FM	80 982
Kulasingam 2007	CIN, CC	80%	100%	Lifelong	212	No vaccination	FM12	20 640
	CIN, CC	80%	84%	Lifelong	212	No vaccination	FM12	22 650
	CIN, CC	80%	100%	10 y	212	No vaccination	FM12	64 214
	CIN, CC	80%	84%	10 y	212	No vaccination	FM12	66 120
	CIN, CC	70%	100%	Lifelong	212	No vaccination	FM12	17 962
	CIN, CC	70%	84%	Lifelong	212	No vaccination	FM12	21 092
	CIN, CC	90%	100%	Lifelong	212	No vaccination	FM12	23 621
	CIN, CC	90%	84%	Lifelong	212	No vaccination	FM12	24 551
Jit 2008	CIN, CC, GW	80%	100%	Lifelong	310	F12	FM12	765 081
	CIN, CC, GW	80%	100%	10 y	310	F12	FM12	167 421
	CIN, CC, GW	80%	100%	20 y	310	F12	FM12	254 253
Zechmeister 2009	CIN, CC	65%	90%	10 y+booster	330+110	F12+B22F	FM12+B22FM	311 000
Olsen 2010	CIN, CC, GW	70%	100%	-	415	no vaccination	FM12	18 677

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
Elbasha 2010	CIN, CC, VA, VU, GW, PEN, H&N, ANA, RRP	90% @age26	90%	Lifelong	272	F9–26	FM9–26	17 459
	CIN, CC, VA, VU, GW, H&N, ANA, RRP	90% @age26	90%	Lifelong	272	F9–26	FM9–26	18 715
	CIN, CC, VA, VU, GW, ANA, RRP	90% @age26	90%	Lifelong	272	F9–26	FM9–26	31 958
	CIN, CC, VA, VU, GW, RRP	90% @age26	90%	Lifelong	272	F9–26	FM9–26	42 376
	CIN, CC, VA, VU, GW	90% @age26	90%	Lifelong	272	F9–26	FM9–26	46 965
	CIN, CC, VA, VU	90% @age26	90%	Lifelong	272	F9–26	FM9–26	121 706
	CIN, CC	90% @age26	90%	Lifelong	272	F9–26	FM9–26	13 ,872
Laprise 2014	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95%	Lifelong	186	F9+CU14F	FM9+CU14F	121 971
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95%	Lifelong	186	F9+CU14F	FM9+CU14F	50 300
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95%	20 y	186	F9+CU14F	FM9+CU14F	86 861
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95%	25 y	186	F9+CU14F	FM9+CU14F	124 307
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95%	25 y	186	F9+CU14F	FM9+CU14F	51 782
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95%	35 y	186	F9+CU14F	FM9+CU14F	134 599
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95% (2d)	20 y	124	F9+CU14F	FM9+CU14F	62 920
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95% (2d)	20 y	124	F9+CU14F	FM9+CU14F	40 446
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95% (2d)	25 y	124	F9+CU14F	FM9+CU14F	49 647
	CC, VU, VA, ANA, PEN, ORPH, GW	50%	95% (2d)	30 y	124	F9+CU14F	FM9+CU14F	38 450
	CC, VU, VA, ANA, PEN, ORPH, GW	80%	95% (2d)	30 y	124	F9+CU14F	FM9+CU14F	98 869
Pearson 2014	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	20 y	193	No vaccination	FM12	23 352
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	20 y	193	No vaccination	FM12	31 023
	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	20 y	193	F12	FM12	67 045
	CIN, CC, VU, ANA, ORPH, GW	56%/45% vs 73%	99%	20 y	193	F12 (56%/45%)	FM12 (73%)	84 091
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	20 y	193	F12	FM12	140 341
	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	Lifelong	193	F12	FM12	63 068
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	Lifelong	193	F12	FM12	132 955
	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	Lifelong	95	F12	FM12	46 193
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	Lifelong	95	F12	FM12	98 295
	CIN, CC, VU, ANA, ORPH, GW	56%/45%	99%	Lifelong	13	F12	FM12	31 420
	CIN, CC, VU, ANA, ORPH, GW	73%	99%	Lifelong	13	F12	FM12	68 750

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
Bresse 2014	CIN, CC	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	26 701
	CIN, CC, VA	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	26 279
	CIN, CC, VA, VU	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	25 567
	CIN, CC, VA, VU, GW	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	15 820
	CIN, CC, VU, VA, GW, ANA	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	13 850
	CIN, CC, VU, VA, GW, ANA, ORPH	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	10 136
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	65%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	10 033
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	65%	F 76-100%/M 41-96%	20y	330	No vaccination	FM9	19 590
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	65%	F 76-100%/M 41-96%	Lifelong	281	No vaccination	FM9	8 202
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	65%	F 76-100%/M 41-96%	Lifelong	380	No vaccination	FM9	11 787
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	80%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	9 982
	CIN, CC, VU, VA, GW, ANA, ORPH, PEN	50%	F 76-100%/M 41-96%	Lifelong	330	No vaccination	FM9	11 351
Blakely 2014	CIN, CC, VU, ANA, ORPH, GW	56%/45%	100%	Lifelong	193	No vaccination	FM12	10 682
	CIN, CC, VU, ANA, ORPH, GW	73%	100%	Lifelong	193	No vaccination	FM12	12 841
	CIN, CC, VU, ANA, ORPH, GW	93%	100%	Lifelong	193	No vaccination	FM12	17 614
	CIN, CC, VU, ANA, ORPH, GW	56%/45% vs 73%	100%	Lifelong	193	FM12 (56%/45%)	FM12 (73%)	19 716
	CIN, CC, VU, ANA, ORPH, GW	73% vs 93%	100%	Lifelong	193	FM12 (73%)	FM12 (93%)	69 602
Haeussler 2015	CIN, CC, VA, VaIN, VU, VIN, ANA, PEN, PeIN, H&N, GW	90%	CC 78%/ANA 70%/H&N 50%	Lifelong	168	F12	FM12	11 600
Jiménez 2015	CIN, CC, VU, GW	82%		Lifelong	400	F12	FM12	214 051
	CIN, CC, VU, GW	82%		Lifelong	90	F12	FM12	42 102
	CIN, CC, VU, GW	82%		Lifelong	179	F12	FM12	91 616
	CIN, CC, VU, GW	82%		Lifelong	269	F12	FM12	141 939
	CIN, CC, VU (2-valent)	82%		Lifelong	400	F12	FM12	449 145
	CIN, CC, VU, GW	F92%/M82%		Lifelong	400	F12 (92%)	F (82%) M (82%) 12	456 351
	CIN, CC, VU, GW, VA, ANA	82%		Lifelong	400	F12	FM12	184 040
Olsen 2015	CIN, CC, VA, VU, ANA, PEN, H&N, GW	85%	100%	Lifelong	369	F12	FM12	41 636
	CIN, CC, VA, VU, ANA, PEN, H&N, GW	85%	100%	Lifelong	277	F12	FM12	31 432
	CIN, CC, VA, VU, ANA, PEN, H&N, GW	85%	100% (2d)	Lifelong	246	F12	FM12	28 031

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
	CIN, CC, VA, VU, ANA, PEN, H&N, GW (time horizon 40 y)	85%	100%	Lifelong	369	F12	FM12	47 342
	CIN, CC, VA, VU, ANA, PEN, H&N, GW	70%	100%	Lifelong	369	F12	FM12	31 615
	CIN, CC, VA, VU, ANA, PEN, GW	85%	100%	Lifelong	369	F12	FM12	276 642
Qendri 2017	CC, VU, VA, ANA, PEN, ORPH	F60%/40%M	98% (2d)	Lifelong	34	F12	FM12	9 134
	CC, VU, VA, ANA, PEN, ORPH	F70%/40%M	98% (2d)	Lifelong	34	F12	FM12	13 083
	CC, VU, VA, ANA, PEN, ORPH	F80%/40%M	98% (2d)	Lifelong	34	F12	FM12	20 631
	CC, VU, VA, ANA, PEN, ORPH	F90%/40%M	98% (2d)	Lifelong	34	F12	FM12	36 363
	CC, VU, VA, ANA, PEN, ORPH	F60%/50%M	98% (2d)	Lifelong	34	F12	FM12	9 935
	CC, VU, VA, ANA, PEN, ORPH	F60%/60%M	98% (2d)	Lifelong	34	F12	FM12	9 412
Damm 2017	CIN, CC, GW	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	117 240
	CIN, CC, GW	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	73 973
	CIN, CC (2-valent)	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4	20 y	450	F12	FM12	130 449
	CIN, CC (2-valent)	50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	83 602
	CIN, CC, GW	F20%/M50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	46 965
	CIN, CC, GW	F20%/M50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	26 478
	CIN, CC (2-valent)	F20%/M50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	60 682
	CIN, CC (2-valent)	F20%/M50%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	37 066
	CIN, CC, GW	F20%/M80%	HPV16/18 F 98% HPV6/11 F 100%	20 y	450	F12	FM12	61 027

Author year	Health outcomes	Vaccination coverage*	Vaccine efficacy	Duration of protection	Vaccine cost (EUR)**	Base strategy (sex, age)	Comparator strategy (sex, age)	ICER (EUR)
			HPV16/18/6/11 M 90.4%					
	CIN, CC, GW	F20%/M80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	36 033
	CIN, CC (2-valent)	F20%/M80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4%	20 y	450	F12	FM12	74 844
	CIN, CC (2-valent)	F20%/M80%	HPV16/18 F 98% HPV6/11 F 100% HPV16/18/6/11 M 90.4% (2d)	20 y	300	F12	FM12	46 525
Largeron 2017	CIN, CC, VA, VU, ANA, GW	55.6%	F 76-100%/M 41-96% (2d)	Lifelong	280 vs 293	F9-14+CU15-17 (4v)	FM9-14+CU15-17 (9v)	22 987
	CIN, CC, VA, VU, ANA, GW	55.6%	F 76-100%/M 41-96% (2d)	20 y	280 vs 293	F9-14+CU15-17 (4v)	FM9-14+CU15-17 (9v)	14 827
	CIN, CC, VA, VU, ANA, GW	70%	F 76-100%/M 41-96% (2d)	Lifelong	280 vs 293	F9-14+CU15-17 (4v)	FM9-14+CU15-17 (9v)	27 986
	CIN, CC, VA, VU, ANA, GW, PEN, H&N, RRP	55.6%	F 76-100%/M 41-96% (2d)	Lifelong	280 vs 293	F9-14+CU15-17 (4v)	FM9-14+CU15-17 (9v)	14 286
Mennini 2017	CIN, CC, VaIN, VA, VU, ANA, GW	71%	F 76-100%/M 41-96% (2d)	Lifelong	208 vs 240	F12 (4v)	FM12 (9v)	13 541
	CIN, CC, VaIN, VA, VU, ANA, GW	60%	F 76-100%/M 41-96% (2d)	Lifelong	208 vs 240	F12 (4v)	FM12 (9v)	11 376
	CIN, CC, VaIN, VA, VU, ANA, GW	71%	F 76-100%/M 41-96% (2d)	20 y	208 vs 240	F12 (4v)	FM12 (9v)	20 845
	CIN, CC, VaIN, VA, VU, ANA, GW, PEN, H&N, RRP	71%	F 76-100%/M 41-96% (2d)	Lifelong	208 vs 240	F12 (4v)	FM12 (9v)	7 165

**: Vaccination coverages separated by / means two different coverages where used in the study referring to two separate populations. When numbers are separated by 'vs', two different coverages were compared in different scenarios.*

***: Vaccine cost separated by '+' means cost of initial vaccination (three) doses plus cost of booster dose.*

Abbreviations

Health outcomes: cervical cancer (CC), cervical intraepithelial neoplasia (CIN), genital warts (GW), vaginal cancer (VA), vulvar cancer (VU), anal cancer (ANA), penile cancer (PEN), oropharingeal cancer (ORPH), head and neck cancer (H&N), recurrent respiratory papillomatosis (RRP)

Sex: females (F), women (W), males (M)

Other: years (y), at (@), dose/s (d), catch-up (CU), booster (B), dominant (Dom).

Annex 2. Supplementary material

Code	File	Description
Supp01	Supp01_PICOs_males_efficacy.xlsx	Efficacy of HPV vaccines in males PICO1: Three doses of 4-valent HPV vaccine in 16–23-year-old males versus three doses of placebo in 16–26-year-old males – efficacy outcomes (for HPV 6, 11, 16, 18) PICO2: Three doses of 4-valent HPV vaccine in 16–26-year-old MSM versus three doses of placebo in 16–26-year-old MSM – efficacy outcomes (for HPV 6, 11, 16, 18) PICO3: Three doses of 4-valent HPV vaccine in >=27-year-old HIV-negative MSM versus no treatment in >=27-year-old HIV-negative MSM – efficacy outcomes (any HPV)
Supp02	Supp02_PICOs_males_immunogenicity.xlsx	Immunogenicity of HPV vaccines for boys/men PICO1: Three doses of 9-valent HPV vaccine in 9–15-year-old males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7) PICO2: Two doses (0, 6 months) of 9-valent HPV vaccine in 9–14-year-old males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7 or 4 weeks after last dose of vaccine) PICO3: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 16–26-year-old males -iImmunogenicity outcomes (month 7) PICO4: Three doses of 9-valent HPV vaccine in 16–26-year-old males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7) PICO5: Three doses of 4-valent HPV vaccine in 10 to 15-year-old males versus three doses of 4-valent HPV vaccine in 16–23-year-old females – immunogenicity outcomes (month 7) PICO6: Three doses of 4-valent HPV vaccine in –915-year-old males versus three doses of 4-valent HPV in 9–15-year-old females – immunogenicity outcomes (month 7) PICO7: Three doses of 4-valent HPV vaccine in 9–15-year-old males versus three doses of 4-valent HPV in 9–15-year-old females – immunogenicity outcomes (month 18) PICO8: Three doses of 4-valent HPV vaccine in 9–15-year-old males versus three doses of 4-valent HPV in 9–15-year-old females – immunogenicity outcomes (month 96) PICO9: Three doses (0, 2, 12 months) of 4-valent HPV vaccine versus three doses (0, 2, 6 months) of 4-valent HPV vaccine in 18–25-year-old males – immunogenicity outcomes (month 7) PICO10: Three doses of 4-valent HPV vaccine in 2745-year-old males – immunogenicity outcomes (month 7) PICO11: Three doses of 2-valent HPV vaccine in 12–15-year-old males – immunogenicity outcomes (months 7 and 42) PICO12: Three doses of 9-valent HPV vaccine in 16–26-year-old MSM versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7) PICO13: Three doses of 9-valent HPV vaccine in 16–26-year-old MSM versus three doses of 9-valent HPV vaccine in 16–26-year-old heterosexual males – immunogenicity outcomes (month 7) PICO14: Three doses of 4-valent HPV vaccine in 16–26-year-old MSM versus three doses of 4-valent HPV vaccine in 16–23-year-old heterosexual males – immunogenicity outcomes (month 7) PICO15: Three doses of 4-valent HPV vaccine in 16–26-year-old MSM versus three doses of 4-valent HPV vaccine in 16–23-year-old heterosexual males – immunogenicity outcomes (month 36) PICO16: Three doses of 2-valent HPV vaccine in 10–18-year-old males versus three doses of 2-valent HPV vaccine in 15–25-year-old females – immunogenicity outcomes (month 7)
Supp03	Supp03_PICOs_males_safety.xlsx	Safety and tolerability of the HPV vaccines in males PICO1: Three doses of 9-valent HPV vaccine in 9–1year-old males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – safety outcomes PICO2: Two doses (0, 6 months) of 9-valent HPV vaccine in 9–14-year-old males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – safety outcomes PICO3: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 16–26-year-old males - safety outcomes

Code	File	Description
		PICO4: Three doses of 9-valent HPV vaccine in 16–26-year-old males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – safety outcomes PICO5: Three doses of 4-valent HPV vaccine in 10–15-year-old males versus three doses of 4-valent HPV vaccine (3 doses) in 16–23-year-old females – safety outcomes PICO6: Three doses of 4-valent HPV vaccine versus placebo in 9–15-year-old females and males – safety outcomes PICO7: Three doses of 4-valent HPV vaccine versus three doses of placebo vaccine in 16–26-year-old males – safety outcomes PICO8: Three doses of 4-valent HPV vaccine in 27–45-year-old males – safety outcomes PICO9: Three doses of 2-valent HPV vaccine in 12–15-year-old males versus three doses of HBV vaccine in 12–15-year-old males – safety outcomes PICO10: Three doses of 4-valent HPV vaccine in 16–26-year-old MSM versus three doses of placebo vaccine in 16–26-year-old MSM – Safety outcomes PICO11: Three doses of 2-valent HPV vaccine versus three doses of HBV vaccine in 10–18-year-old males – safety outcomes
Supp04	Supp04_PICOs_9vHPV_efficacy.xlsx	Efficacy of the 9-valent HPV vaccine PICO1: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 16–26-year-old females - efficacy outcomes (for HPV types 31, 33, 45, 52, 58) PICO2: Three doses of 9-valent HPV vaccine versus three doses of placebo in 16–26-year-old females - efficacy outcomes (for HPV types 6, 11, 16, 18)
Supp05	Supp05_PICOs_9vHPV_immunogenicity.xlsx	Immunogenicity of the 9-valent HPV vaccine PICO1: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 9–15-year-old females - immunogenicity outcomes (month 7) PICO2: Three doses of 9-valent HPV vaccine in 9 to 15-year old females versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7) PICO3: Two doses (0, 6 months) of 9-valent HPV vaccine in 9–14-year-old females versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7 or 4 weeks after last dose of vaccine) PICO4: Two doses (0, 12 months) of 9-valent HPV vaccine in 9–14-year-old females and males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7 or 4 weeks after last dose of vaccine) PICO5: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7) PICO6: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in females 16–26 years – immunogenicity outcomes (month 42) PICO7: Three doses of 9-valent HPV vaccine versus placebo in 12–26-year-old females previously vaccinated with 4-valent HPV (3 doses) - immunogenicity outcomes (month 7) PICO8: Three doses of 9-valent HPV vaccine in males 9–15 years versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7) PICO9: Two doses (0, 6 months) of 9-valent HPV vaccine in 9–14-year-old males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7 or 4 weeks after last dose of vaccine) PICO10: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 16–26-year-old males - immunogenicity outcomes (month 7) PICO11: Three doses of 9-valent HPV vaccine in 16–26-year-old heterosexual males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – immunogenicity outcomes (month 7)
Supp06	Supp06_PICOs_9vHPV_safety.xlsx	Safety and tolerability of the 9-valent HPV vaccine PICO1: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 9–15-year-old females – safety outcomes PICO2: Three doses of 9-valent HPV vaccine in 9–15-year-old females versus three doses of 9-valent HPV vaccine in 16–26-year-old females – safety outcomes PICO3: Two doses (0, 6 months) of 9-valent HPV vaccine in 9– 14-year-old females versus three doses of 9-valent HPV vaccine in 16–26-year-old females – safety outcomes

Code	File	Description
		PICO4: Two doses (0, 12 months) of 9-valent HPV vaccine in 9 to 14-year old females and males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – safety outcomesPICO5: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 16–26-year-old females – safety outcomes PICO6: Three doses of 9-valent HPV vaccine versus placebo in 12–26-year-old females previously vaccinated with 4-valent HPV (3 doses) – safety outcomes PICO7: Three doses of 9-valent HPV vaccine in males 9–15 years versus three doses of 9-valent HPV vaccine in females 16–26 years – safety outcomes PICO8: Two doses (0, 6 months) of 9-valent HPV vaccine in 9– 14-year-old males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – safety outcomes PICO9: Three doses of 9-valent HPV vaccine versus three doses of 4-valent HPV vaccine in 16–26-year-old males - safety outcomes PICO10: Three doses of 9-valent HPV vaccine in 16–26 years heterosexual males versus three doses of 9-valent HPV vaccine in 16–26-year-old females – safety outcomes
Supp07	Supp07_PICOs_HIV_immunogenicity.xlsx	Immunogenicity of the HPV vaccine in HIV-infected men and women PICO1: Three doses of 4-valent HPV vaccine versus placebo in 7– 12-year-old HIV-infected children - immunogenicity outcomes (months 7–24) PICO2: Three doses of 2-valent HPV vaccine in 18– 25-year-old HIV infected females versus three doses of 2-valent HPV vaccine in 18–25-year-old females – immunogenicity outcomes (month 7) PICO3: Three doses of 2-valent HPV vaccine in HIV infected adults (>=18 years old) versus three doses of 4-valent HPV vaccine in HIV infected adults (>=18 years old) – immunogenicity outcomes (months 7–12) PICO4: Three doses of 4-valent HPV vaccine in HIV infected males >18 years old – immunogenicity outcomes (month 7)
Supp08	Supp08_PICOs_HIV_safety.xlsx	Safety of the HPV vaccine in HIV-infected men and women PICO1: Three doses of 4-valent HPV vaccine versus placebo vaccine in 7–12year-old HIV-infected children - safety outcomes PICO2: Three doses of 2-valent HPV vaccine in 18–25-year-old HIV-infected females versus placebo (3 doses) in HIV infected females 18–25-year-old– Safety outcomes PICO3: Three doses of 2-valent HPV vaccine in HIV infected adults (>=18 years old) versus three doses of 4-valent HPV vaccine in HIV infected adults (>=18 years old) – safety outcomes PICO4: Three doses of 4-valent HPV vaccine in HIV infected 16–23-yearld HIV infected females – safety outcomes PICO5: Three doses of 4-valent HPV vaccine in HIV infected males >18 years old – safety outcomes

PDF TQ-01-20-171-EN-N

European Centre for Disease Prevention and Control (ECDC)

Gustav III:s Boulevard 40, 16973 Solna, Sweden

Tel. +46 858601000
Fax +46 858601001
www.ecdc.europa.eu

An agency of the European Union
www.europa.eu

Subscribe to our publications
www.ecdc.europa.eu/en/publications

Contact us
publications@ecdc.europa.eu

Follow us on Twitter
@ECDC_EU

Like our Facebook page
www.facebook.com/ECDC.EU

Publications Office of the European Union

ISBN 978-92-9498-459-3
DOI 10.2900/71487